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Chromatin, a polymer formed from DNA, histones, and associated
proteins, is the physiological form of genetic information in all eukaryotic
cells. Posttranslational modification of histones, such as acetylation,
methylation, and phosphorylation, regulates various DNA-dependent
processes, ranging from transcription to replication, DNA repair, and
apoptosis. A key mechanism by which histone modifications exert these
effects is by recruitment of specific binding partners (effector proteins),
that in turn direct downstream functions. Insight into the underlying
mechanisms are of great importance for a full understanding of chromatin
structure and function.
One of these effector proteins, Heterochromatin Protein 1 (HP1), plays
important roles in heterochromatin formation. It is recruited to chromatin
by interaction with methylated lysine 9 of histone H3 (H3K9me). However,
it has remained enigmatic how HP1 reversibly dissociates from chromatin
during mitosis, while the histone mark that recruits the protein, H3K9me,
persists.
In the first part of my thesis, my collaborators and I show through a
combination of in vitro and in vivo experiments that this release depends on
a novel mechanism, “methyl-phos switching”, in which two nearby histone
marks collaborate to accomplish the dynamic regulation of effector protein
binding. Phosphorylation of histone H3 at serine 10, immediately adjacent
to HP1’s binding site at H3K9me, at the onset of mitosis interferes with
HP1 binding to H3K9me, resulting in the release of the effector protein.

In the second part of my thesis, I investigate to what extent
posttranslational modification of HP1 itself is involved in the regulation of
the effector protein. I identify ten novel phosphorylation sites for the three
human HP1 isoforms (α, β, γ), most of which map to the HP1 “hinge region”
and are specifically phosphorylated in mitosis. For one highly conserved
site, HP1α serine 92 phosphorylation, I identify Aurora B as the responsible
kinase in vivo. In vitro data suggest that mitotic phosphorylation of the
HP1α hinge may play a role in the regulation of HP1 association with
RNA.
My thesis work indicates that HP1’s behavior and interactions in
mitosis are regulated by posttranslational modifications on two levels:
phosphorylation of histone H3 as well as phosphorylation of HP1 itself.
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Chapter 1

General Introduction

Posttranslational modifications of histone proteins control chromatin
structure and function, thereby playing a regulatory role in many
fundamental cellular processes. An important mechanism how histone
modifications accomplish their biological function is by recruiting specific
binding proteins (effectors) to chromatin, that then in turn induce
downstream functions.
Insight into the mechanisms for how these effectors are recruited
and how their downstream functions are controlled lies at the heart of a
deeper understanding of chromatin function. In my Ph.D. project, I studied
how an important chromatin effector protein, Heterochromatin Protein 1
(HP1) is regulated by posttranslational modifications, both of the histone
and of the effector protein itself.
In this introductory chapter, I will review relevant literature to
provide a framework for describing my research course. The first part of the
chapter will give a general overview of what is known about chromatin, its
molecular components and the mechanisms that guide its functions. In the
second part, I summarize the current knowledge about Heterochromatin
Protein 1, highlight important findings already reported, point out open
questions, and put the research of my Ph.D. into context.
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Chromatin
The genetic information of eukaryotic cells is stored in the form of DNA in
the cell nucleus (Avery et al., 1944). In order to fit 2 meters worth of DNA
(in human cells) into a cell nucleus only a few micrometers in diameter, the
DNA ‘fibers’ must be significantly condensed. This enormous compaction
is achieved by association of the DNA with a set of nuclear proteins,
resulting in the formation of chromatin (Figure 1.1), which constitutes the
physiological form of all genetic and inheritable information (Felsenfeld
and Groudine, 2003).

Figure 1.1: Chromatin and the organization of DNA within
the cell.
1.1
At regular intervals, the double helix of DNA is wrapped around complexes of
histone molecules, forming nucleosomes that are arranged like beads on a string.
By mechanisms that are currently not well understood, the nucleosome units
are then folded into a fiber 30 nm in diameter and further into higher-order
structures. The overall compaction of DNA by this organization is more than
10,000-fold (adapted from Felsenfeld and Groudine, 2003).

2

Early cytological studies established the existence of two different
forms of chromatin (Heitz, 1928): euchromatin has an open, accessible
conformation, replicates early in S-phase, and contains the majority of
active genes; heterochromatin, in contrast, is tightly compacted, replicates
late in the cell cycle, and contains very few active genes. Some regions of
the genome, such as centromeres, pericentric regions and telomeres, are
heterochromatic in all types of cells and at all times, and have therefore
been called constitutive heterochromatin. Other heterochromatic regions of
the genome can change their status during development or differentiation
and are therefore referred to as facultative heterochromatin.

Nucleosomes and histones
The fundamental repeating unit of chromatin is the nucleosome (Kornberg,
1974; Olins and Olins, 1974), which is formed by wrapping a stretch of
147 bp of DNA around a protein core of eight histone proteins – two copies
each of the histones H2A, H2B, H3 and H4 (Figure 1.2) (Luger et al., 1997).
An additional histone, linker histone H1 (and, in some organisms, H5),
interacts with the nucleosomal core as well as with the adjoining linker
DNA, forming higher levels of chromatin organization and architecture
(Thomas, 1999).
Histones are a family of small basic proteins with remarkable
conservation among distantly related species. Structurally, they consist of
two parts (Arents et al., 1991): The C-terminal domain is mainly α-helical;
by forming histone-histone and histone-DNA interactions these histonefold domains are critical for the formation of the nucleosome core. The
N-terminal tails of histones, on the other hand, are far less structured.
Because of their accessibility to proteases, histone tails are thought to
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protrude outwards from the core nucleosome (Luger and Richmond, 1998).
This exposed localization makes them available for contacts with adjacent
nucleosomes and with other chromatin-associated proteins (Ausio et al.,
1989; Hansen et al., 1998; Shogren-Knaak et al., 2006; Whitlock and
Simpson, 1977).

A

B

DNA double helix

Histone proteins

Histone tail

H2A

H2B

H3

H4

Figure 1.2: Composition of the nucleosome.
1.2
(A) Cartoon depiction and (B) crystal structure of the nucleosome
(solved with

Xenopus laevis histones (Davey et al., 2002); view down the DNA superhelical
axis shown). The nucleosome core is formed by an octamer of histone proteins,
two copies each of the four core histones H2A, H2B, H3 and H4. Around this
protein core of mostly α-helical structure (shown as cylinders), the DNA is wound
in roughly two superhelical turns (147 bp). Binding of the linker histone H1
to this assembly (not shown) confers additional stability and compaction. The
N-terminal histone tails protrude outwards from the nucleosome core.
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Regulatory role of chromatin
For a long time it was believed that the only function of chromatin was to
serve as a protective and static scaffold for storage of the genetic information
encoded in the DNA sequence. However, in the last decade it has become
clear that dynamic changes in chromatin actively regulate numerous
genomic processes. Every nuclear process that requires access to DNA has
to function in the context of chromatin, and thus all template-dependent
processes, such as transcription, replication, mitotic chromosome
condensation, and recombination as well as apoptosis and DNA repair are
impacted and controlled by structural changes in chromatin.
Chromatin function is regulated by two general and overlapping
mechanisms:

(A)

through

changes

in

chromatin

structure

("cis"

mechanisms) and (B) through the recruitment of specific effector proteins
("trans" mechanisms).
A. Changes in chromatin structure
Structural changes of chromatin result in the adoption of more open
or condensed conformations of chromatin. Such structural changes
significantly affect the accessibility of DNA and thus can control various
processes that require access to the DNA template (Hansen, 2002). On
a molecular level, changes in chromatin structure are achieved in three
different ways: 1) through chromatin remodelling complexes, 2) through
the incorporation of histone variants, and 3) through the addition or
subtraction of posttranslational modifications of histone proteins (Allis
et al., 2007). Each will be briefly discussed below as follows:
1. Chromatin remodeling complexes are ATP-hydrolyzing machines
that modify DNA-histone contacts, facilitate nucleosome sliding,
relocate nucleosomes, or even actively remove core histone dimers,
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thus modulating the exposure of DNA within chromatin (Cairns,
2007; Johnson et al., 2005). Based on their composition and
activities, several families (such as the Swi/Snf, ISWI or NuRD
families) with various members have been delineated. Their
mechanisms of action are not yet completely understood (Cairns,
2007), but it is clear that they mediate chromatin rearrangements to
facilitate processes such as transcription, DNA repair, replication,
chromatin assembly, and homologous recombination (Becker and
Horz, 2002; Georgel et al., 1997; Lee et al., 2001).
2. Chromatin structure and function can be altered through the
incorporation of histone variants (Kamakaka and Biggins, 2005).
These variants differ from the corresponding major histones in their
primary sequence, in some cases by very subtle differences of a few
amino acids, in others dramatically by the presence of specialized
domains (Bernstein and Hake, 2006). In several cases, histone
variants are localized to specific regions of the genome: macroH2A,
e.g., is found at the inactive X chromosome of female mammals
(Costanzi and Pehrson, 1998), CENP-A at centromeric chromatin
(Black and Bassett, 2008), or H3.3 at actively transcribed genes
(Ahmad and Henikoff, 2002). For the deposition of some of these
histone variants specialized chromatin remodeling complexes have
been identified (Mizuguchi et al., 2004; Tagami et al., 2004). It is
believed that the sequence differences amongst histone variants
gives them distinct biophysical characteristics that alter the
properties of the nucleosome. In addition, the sequence variation
allows them to acquire specific patterns of histone modifications
(such as the phosphorylation of H2A.X on a serine unique to this
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variant at DNA repair sites; Fernandez-Capetillo et al., 2004;
Rogakou et al., 1998) and to undergo specific and distinct molecular
interactions.
3. Changes in chromatin structure are also brought about by covalent
posttranslational modifications of histone proteins, especially of the
N-terminal tails of the core histones. Many histone modifications
change the electrostatic charge of the histone tails, thereby
strengthening or weakening histone-DNA and histone-histone
contacts ("cis" mechanism). This, in turn, is thought to modulate
higher-order chromatin structure (Kouzarides, 2007; ShogrenKnaak et al., 2006; Workman and Kingston, 1998; see below
Section "Mechanism of histone modifications").
B. Recruitment of effector proteins
Besides direct changes in chromatin structure, the function of chromatin
can also be modulated in an indirect fashion: Distinct patterns of
covalent modifications within histones act as "signaling platforms",
recruiting specific nuclear factors that in turn mediate downstream
functions (Seet et al., 2006; Strahl and Allis, 2000; Taverna et al., 2007;
see below, Section "Mechanism of histone modifications").
These mechanisms to regulate chromatin structure and function
are also evident in the molecular characteristics of euchromatin and
heterochromatin. The two forms of chromatin show differences in the
patterns of their histone modifications as well as in their non-histone
protein constituents (Dillon and Festenstein, 2002; see Table 1.1).

Since my thesis work focuses on a specific effector protein, Heterochromatin
Protein 1, which is recruited to chromatin by a histone modification
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("trans" mechanism), I will in the following section provide a more detailed
background on histone modifications, the enzymes that establish them,
and the mechanisms underlying their functions.
Table 1.1: Molecular characteristics of euchromatin and heterochromatin
Euchromatin

Heterochromatin

Conformation
during interphase

decondensed

condensed

Gene density

high

low

Replication

mainly early

late

Levels of H3 and H4
acetylation

high

low

Other specific
modifications

H3K4me

H3K9me, H3K27me,
H4K16Ac

Effector proteins

e.g. BPTF, WDR5

e.g. HP1, Pc

Histone variants

H3.3, H2A.Z

Levels of DNA
methylation

low

high

Histone modifications – histone marks
As early as the 1960s Vincent Allfrey and collegues discovered that histones
can be extensively post-translationally modified (Allfrey, 1966). In fact,
some types of post-translational protein modifications (like acetylation and
phosphorylation) were actually first discovered on histone proteins.
Over the last decades, an enormous number of distinct posttranslational modification types and sites have been identified on histones
(so-called "marks") have been unveiled, especially since the introduction
of mass spectrometric approaches to histone biology a few years ago. In
particular the histone tails have been found to be subject to a great variety
and high density of posttranslational modifications (Figure 1.3). Lysine
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residues in histones can be modified by acetylation, (mono-, di-, or tri‑)
methylation, ubiquitylation and sumoylation; arginine residues can be
(mono-, and symmetrically/asymmetrically di-) methylated, serine and
threonine residues can be phosphorylated, and glutamate residues can be
ADP-ribosylated (Kouzarides, 2007; Peterson and Laniel, 2004). All in all,
close to a hundred individual histone marks have been identified to date,
about half of which have been confirmed by independent experimental
methods (i.e. detected by mass spectrometry and immunological/enzymatic
methods).

Figure 1.3: Posttranslational modifications of histone molecules.
Histone proteins, in particular their N-terminal tails, are subject to a great
diversity and extreme density of posttranslational modifications. Depiction of a
1.3
half nucleosome (one copy of each of the core histones), DNA shown in turquois.
Ac: acetylation. M: methylation. P: phosphorylation. Ub: ubiquitylation. Note that
lysine residues can be mono-, di-, or tri-methylated and arginine residues can be
mono- and di-methylated. In addition, other classes of modifications have been
found, such as sumoylation or ADP-ribosylation. Figure courtesy of Dr. Wolfgang
Fischle.
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Correlation of histone modifications with biological effects
The idea that histone modifications may play important regulatory roles
within the cell was raised by Allfrey and colleagues more than thirty years
ago, when they described a positive correlation between the levels of
histone acetylation and gene expression (Allfrey, 1966; Allfrey et al., 1964;
Pogo et al., 1968). Since then, it has been possible to directly correlate
many histone marks with defined cellular events. For example, besides
H3 and H4 acetylation (reviewed in Kurdistani and Grunstein, 2003), gene
activation also correlates with methylation of H3 at K4 (Honda et al., 1975;
Ruthenburg et al., 2007a). Gene repression correlates with hypoacetylation
of H3 and H4 (Allfrey et al., 1964; Green, 2005; Peterson, 2002), with
methylation of H3 at K9 (Grewal and Jia, 2007; Peters et al., 2001) and
with methylation of H3 at K27 (Schuettengruber et al., 2007). And mitotic
chromosome condensation correlates with the phosphorylation of H3 at
S10 and S28 (Gurley et al., 1973; Hendzel et al., 1997; Nowak and Corces,
2004) (for more examples see Table 1.2).

"Histone Code"
Understanding how an ever-increasing number of post-translational
histone modifications can work together to bring about specific biological
outcomes has been a challenge for the field. As solution to this problem,
the existence of a "histone code" has been proposed. According to this
concept, different combinations of post-translational histone modifications
are established and maintained in particular regions of chromatin,
and function in a sequential or combinatorial fashion to specify unique
downstream biological functions (Jenuwein and Allis, 2001; Strahl and
Allis, 2000; Turner, 2000).
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Table 1.2: Examples of histone marks, functions they correlate with and
the responsible enzymes (Homo sapiens, Mus musculus)
Mark

Function

Enzyme(s)

Polycomb silencing,

H2A

K119ub1

H2B

S14ph

Apoptosis, Somatic hypermutation
and class switch recombination

K120ub

Cell cycle progression, meiosis

R2me

Gene Expression

CARM1 (me2a)

Transcriptional activation

SET7/SET9 (me1)

Trithorax activation

MLL1/MLL2/MLL3 (me3)

Nuclear receptor coactivator

SRC1

K4me
K9ac

K9me

RING1B

UV damage response

Transcriptional
printing

repression,

Im-

Pericentric heterochromatin,

S10ph

Transcriptional activation
mediate early genes

G9a (me1, me2)
SUV39H1/2 (me3)

Rb-mediated silencing

H3

Mst1/krs2

of

im-

MSK1/2, RSK2

Mitotic chromosome condensation

Aurora B

K14ac

Transcriptional activation

Gcn5,
P300,
TAFII230, TAFII250

K18ac

Transcriptional activation

P300, CBP

K23Ac

Transcriptional activation

CBP

PCAF,

Polycomb repression
K27me

Early B cell development

EZH2 (me3)

X chromosome inactivation
S28ph
K79me
R3me

MSK1

Mitotic chromosome condensation

Aurora B

Telomeric silencing,

DOT1L (me2)

pachytene checkpoint
Transcriptional activation

PRMT1

Histone deposition

Hat1

Transcriptional activation

p300

K8ac

Transcriptional activation

PCAF/p300

K12ac

Excluded from Xi, Histone deposition

Hat1

K16ac

Sequence-specifc TF

ATF2

K5ac

H4

UVB induced phosphorylation

K20me

Transcriptional silencing,
mitotic condensation

Pr-SET7/Set8 (me1)

Adapted from Allis et al., 2007. For references and a more complete list, see
there.
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Enzymes that establish histone marks
In 1996, it was discovered that certain transcriptional coactivators and
corepressors had histone acetyltransferase (HAT) and deacetylase (HDAC)
activity, respectively (Brownell et al., 1996; Taunton et al., 1996). These
findings provided the first real functional link between histone acetylation
and transcription, and therefore precipitated a significant wave of interest
in the role of histone modifications in the regulation of DNA-dependent
processes. As a consequence, over the last decade a remarkable number of
enzymes that establish histone marks ("writers") has been identified. Among
these are histone acetyltransferases (HATs; Sterner and Berger, 2000),
histone kinases (Nowak and Corces, 2004), histone methyltransferases
(HMTases; Qian and Zhou, 2006; Zhang and Reinberg, 2001), and
enzymes that mediate histone ubiquitylation (Weake and Workman, 2008),
sumoylation (Nathan et al., 2006), and ADP-ribosylation (Hassa et al.,
2006) (see Table 1.2 for specific examples).
Many histone marks have turned out to be reversible. Indeed, several
classes of enzymes have been identified that can remove specific histone
modifications ("erasers"), such as histone deacetylases (HDACs, Holbert
and Marmorstein, 2005) and phosphatases that work on histones (Nowak
and Corces, 2004). Histone methylation was for a long time considered to
be more stable than the other modifications, based on early studies looking
at the turnover of methyl groups in bulk histones (Byvoet, 1972; Duerre
and Lee, 1974). However, recently several classes of enzymes have been
identified that can reverse specific methyl marks on histones (Lan et al.,
2008; Shi et al., 2004; Tsukada et al., 2006; Wang et al., 2004; reviewed
in Lan et al., 2008).
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In addition to the removal of individual histone modifications by
specific enzymes, proteolytic clipping of histone tails (Allis et al., 1980;
Duncan et al., 2008) and histone replacement (Ahmad and Henikoff, 2002)
also result in the removal of histone marks.

Molecular mechanisms of histone modifications
As described above, correlations with distinct biological events have been
found for many histone modifications. However, the exact molecular
mechanisms how these histone marks exert their physiological functions is
in many cases not fully understood. As outlined before, histone modifications
use two general (albeit not mutually exclusive) mechanisms: They either
modulate chromatin structure in cis by directly affecting internucleosomal
contacts and histone-DNA interactions, or they act in trans by recruiting
binding partners that then induce and direct downstream functions (Figure
1.4; Allis et al., 2007).
Several mutational studies have led to observations that can best be
explained by direct or cis effects of histone marks. For example, deletions
of large regions of the histone tails of H3 and H4 in yeast have very little
effect (Ling et al., 1996; Smith and Stirling, 1988), pointing to redundancy
among lysine acetylation marks. Similarly, the effects of several lysine
residues within the H3 tail that can be acetylated have been explained in
the sense of charged patches: Only the number of charged residues/lysines
was important for transcriptional activation in S. cerevisiae, whereas their
exact position was irrelevant (Kristjuhan et al., 2002).
Published reports have repeatedly confirmed the importance of
histone tails for the regulation of higher-order chromatin structure
(reviewed in Hansen, 2002). The extensive involvement of the histone
13
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histone-histone and
binding modules
histone-DNA
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Figure 1.4: Molecular mechanisms
of histone modifications.

Histone modifications fulfill their function by two general mechanisms. They either
change the net charge of the histone tail, which affects inter/intranucleosomal
contacts and results in structural changes of the chromatin
fiber ("cis"
1.4
mechanisms, left). Or they recruit proteins with specific binding modules, such as
bromodomains (acetyl-lysine binders), chromo domains (methyl-lysine binders),
or BRCT domains (phospho-serine/threonine binders). Upon recruitment, theses
effector proteins mediate downstream functions ("trans" mechanisms, right).
Ac: acetylation. M: methylation. P: phosphorylation. BD: bromodomain. CD:
chromodomain.

BRCT:

Breast-cancer-susceptibility

protein-1

C-terminal

domain.

tails in folding of the chromatin fiber suggests that at least some histone
marks may have an effect on chromatin fiber dynamics, and in specific
cases there is already experimental evidence that strongly supports such
a conclusion (e.g. for H4K16ac; Shogren-Knaak et al., 2006). However, at
this point biophysical and structural studies of mononucleosomes and
nucleosomal arrays containing modified histones have not yet succeeded
in demonstrating a significant difference to their corresponding less or unmodified counterparts.
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The trans mechanism has attracted even more interest in recent
years, and several histone modification-specific effector modules (some of
which had been observed in other context before, Seet et al., 2006) and a
number of specific binding proteins ("readers") have been identified over
the last years: Bromodomains, e.g., are binding modules that recognize
acetylated lysines (Dhalluin et al., 1999). They are found in several
transcription factors (Gcn5, TAFII250, PCAF) and chromatin remodeling
complexes (Swi/Snf, RSC) and recruit these proteins to sites of active
transcription (Zeng and Zhou, 2002). In fact, successive recruitment of
multiple bromodomain containing proteins to promoter regions during
the course of transcriptional activation has been demonstrated in several
model systems (Agalioti et al., 2002; Agalioti et al., 2000; Cosma et al.,
1999).
Chromo domains, in contrast, act as binding modules for methylated
lysines. The list of chromo domain-containing proteins includes HP1
(Heterochromatin Protein 1), which recognizes histone H3 methylated at
lysine 9 and mediates gene silencing and heterochromatinization (Jacobs
et al., 2001; Lachner et al., 2001), and Polycomb, a repressive protein
complex in Drosophila with important functions in development (Fischle et
al., 2003c). In addition, several other binding modules have been identified,
including domains recognizing methyl-arginine and phospho-serine/
threonine residues (Seet et al., 2006; Taverna et al., 2007; see Table 1.3
for more examples).
Frequently, effector proteins carry multiple binding modules (Seet et
al., 2006), for example the chromatin remodeler BPTF (two PHD fingers) or the
methyltransferase MLL1 (bromo domain, several PHD fingers). Furthermore,
often several proteins with binding affinity for histone marks are united in a
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multisubunit complex, for example in the chromatin remodeling complexes
RSC (yeast RSC contains eight bromodomains in different subunits of the
complex) or NURF (which contains, in addition to BPTF, several complex
members with multiple WD40 repeat domains) (Ruthenburg et al., 2007b).
The observation that binding modules are often linked is mirrored by the
finding that different histone marks often seem to collaborate to achieve

Table 1.3: Examples of binding modules and effector proteins for histone
marks

Binding
module

Mark

Bromo domain

acetylated lysine

Chromo domain

di/tri-methylated lysine

PHD finger

(methylated) lysine

MBT domain

mono/di-methylated
lysine

Tudor domain

methylated arginine

WD40 repeats

di-metylated arginine

WDR5 (H3K4me2)

14-3-3

phosphorylated
serine/threonine

14-3-3 (H3S28ph)

BRCT domain

phosphorylated
serine/threonine

MDC1 (H2A.XS139ph)

Examples
PCAF (H4K16ac),
TAFII250 (H3K9ac, H3K14ac)
HP1 (H3K9me),
Polycomb (H3K27me)
BPTF (H3K4me2/3),
BHC80 (H3K4me0)
L3MBT, pocket 2 (a. o.
H4K20me1/2)
JMJD2A (H4K20me1/2)
53BP1 (H4K20me1/2)

PCAF: p300/CBP-associated factor. TAFII250: TATA-binding protein-associated
factor II 250. Chromo: Chromatin organization modifier. HP1: Heterochromatin
protein 1. PHD: Plant homeodomain. BPTF: bromodomain and PHD finger
transcription factor. BHC80: BRAF-HDAC complex 80. MBT: malignant brain
tumor. L3MBTL1: lethal-(3) malignant brain tumor repeat–like protein-1.
JMJD2A: Jumonji domain–containing protein-2A. 53BP1: p53-binding protein
1. WDR5: WD repeat domain 5. BRCT: Breast-cancer-susceptibility protein-1 Cterminal. MDC1: Mediator of DNA damage checkpoint 1. See Ruthenburg et al.,
2007; Seet et al., 2006; Taverna et al., 2007 for more details.
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specific biological effects, as illustrated by the coexistence of H3S10ph and
H3K14ac at sites of immediate early gene activation (Cheung et al., 2000),
H3K4me2/3 and H4K16ac at transcriptionally active homeotic genes (Dou
et al., 2005), or H3K27me3 and H2AK119ub1 at silent homeotic genes
(Bernstein et al., 2005; Schuettengruber et al., 2007). Linking together
multiple binding modules may lead, through thermodynamic and kinetic
effects, to dramatic increases in affinity and specificity, while keeping the
effector recruitment dynamic and susceptible to competition (Ruthenburg
et al., 2007b).
While histone modifications can this way work together to recruit
an effector protein/complex with multiple binding modules, they can
also influence each other directly in various ways ("cross-talk" of histone
modifications; Fischle et al., 2003b). For example, it has been found
that the presence of certain marks enhances or decreases others. In
the simplest case, this is just by directly blocking the site (e.g. H3K9
acetylation blocks H3K9 methylation). But there are also effects of enyzme
recruitment and substrate recognition/turnover (e.g. the activity of the
H3K79 methyltransferase Dot1 is activated by the presence of ubiquitylated
histone H2B in the same nucleosome; McGinty et al., 2008). Such
"cross-talk" between modifications (for recent reviews, see Fischle, 2009;
Suganuma and Workman, 2008) represents, together with the finding that
multivalency is important in effector recruitment, additional support for
the existence of a histone code.

Histone modifications and disease
Mutations in various factors involved in chromatin formation and regulation
have been linked to the development of disease, in particular cancer (Wang
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et al., 2007). Through diverse mechanisms, these mutations lead either to
repression of normally active genes (e.g. tumour suppressor genes) or result
in the activation of genes that are normally silent (such as oncogenes).
Connections have been found for various modifications and at
all levels of chromatin formation/regulation: for "writers" such as the
H3K27 methyltransferase EZH2 (overexpressed in metastatic prostate
cancer, Varambally et al., 2002), "readers" like the H3K9me-binder HP1
(downregulated in invasive metastatic breast cancer, Norwood et al., 2006),
for "erasers" such as HDAC1 (aberrant recruitment to promotors due to
fusion with DNA-binding proteins, Lin et al., 1998), and for chromatin
remodelers such as the NuRD complex (deletion of its ATPase subunit in
certain neuroblastomas, Bagchi et al., 2007).
The multitude and variety of these connections foreshadows the
enormous potential that intervention with these processes may have for the
treatment of cancer in the clinic. In fact, first steps to exploit the insights
of chromatin biology in the interest of the patient have already been taken:
Small molecule inhibitors of histone deacetylases have been tested with
promising results for the treatment of tumors, and many such compounds
have already entered into clinical trials (Bolden et al., 2006).
It is clear at this point, however, that a much deeper understanding
of the principle mechanisms regulating chromatin structure and function
and the specific mechanisms of chromatin-dependent tumorigenesis is
required, and much basic research will still be necessary, to achieve the
full potential of chromatin-based therapeutics. The close connections
between chromatin and cancer make such research imperative.
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Having outlined the basic principles of chromatin biology, I will in the
following give a more detailed view of one specific non-histone component
of chromatin: Heterochromatin Protein 1, the chromatin effector protein
that was at the center of my Ph.D. research.

Heterochromatin Protein 1
Identification of HP1 and its gene
As early as 1930, it had been observed in experiments with flies that
genes translocated by X-rays from euchromatic regions into the vicinity
of pericentric heterochromatin acquire a variegated pattern of expression
(Muller and Altenburg, 1930). The effect, which is caused by the repressive
properties of heterochromatin, was called Position Effect Variegation (PEV,
Figure 1.5), and it was exploited starting in the 1980s to systematically
screen for factors that positively or negatively regulate heterochromatin
formation.
One of the genes identified in such screens was the gene of
Heterochromatin protein 1 (HP1). HP1 had previously been described as a
protein that localizes to heterochromatin in immunofluorescence stainings
(James and Elgin, 1986). The HP1 mutation Su(var)2-5 turned out to be
a strong suppressor of PEV, suggesting that HP1 plays an key role in the
formation of heterochromatic structures (Eissenberg and Hartnett, 1993;
Eissenberg et al., 1990; Eissenberg et al., 1992; Wustmann et al., 1989).
Complete loss of Drosophila HP1 in homozygous Su(var)2-5 null mutants
is lethal, underlining the importance of HP1 in normal development. Flies
die at the late third instar larval stage, at the time when the maternal
supply of HP1 becomes exhausted (Eissenberg and Hartnett, 1993; Lu et
al., 2000), probably due to the failure of HP1 null cells to segregate their
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chromosomes faithfully (Fanti et al., 1998). Deletion of the HP1 homolog
Swi6 in S. pombe results in impaired silencing at the centromeres and a
significant increase in chromosome loss (Ekwall et al., 1995).

wt

W+

red eye

Heterochromatin

Inversion
partly red,
partly white

 red facet

W+ gene close to
heterochromatin

 white facet

Su(var)

E(var)

mostly white eye

mostly red eye

Figure 1.5: Position effect variegation in Drosophila melanogaster.
The white gene (W+) is essential for normal red pigmentation of the1.5
flye eye. In
wild-type flies, its gene locus (depicted in red) is located within distal euchromatin
(grey). Through X-ray-induced inversion, W+ can end up in the proximity of
pericentric heterochromatin (blue), resulting in a variegating phenotype: In some
cells, the white gene is still regularly expressed at this new location, leading
to red eye facets; in others, heterochromatic proteins spread over the break
points, condensing the relocated W+ locus and silencing the gene, leading to
white eye facets. Based on this position effect variegation, selection for secondsite mutations allows the identification of proteins that affect heterochromatic
structure: Suppressors of variegation (mutation leads to reduced silencing and
thus more red eye facets) encode proteins that contribute to heterochromatic
silencing. Enhancers of variegation (mutation results in further spreading of
heterochromatin and thus more white eye facets) encode proteins that contribute
to the active state. Similar PEV screens have been carried out in fission yeast.
(Fly depiction adapted from Grewal and Elgin, 2002.)
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Conservation of HP1 in different organisms
Heterochromatin protein 1 is a rather small, phylogenetically conserved
protein of about 200 amino acids (Singh et al., 1991). Characteristic of
all HP1 proteins in different organisms is their specific domain structure:
a highly conserved N-terminal chromo (chromatin-organization modifier)
domain is connected by a less conserved "hinge region" to a well conserved
C-terminal chromoshadow domain (see Figure 1.6A for schematic).
HP1 is found in virtually all higher eukaryotes, ranging from yeast
(S. pombe) and plants to flies, frogs, and mammals (for an overview see
Kwon and Workman, 2008). A notable exception is the budding yeast S.
cerevisiae, in which silent information regulatory (SIR) proteins likely fulfill
a similar role. In many organisms there are several different HP1 isoforms
(see Figure 1.6B for examples). While there is one HP1 protein found in
Tetrahymena thermophila (Hhp1p) and S. pombe (Swi6; recently it has been
suggested that another chromatin protein in fission yeast, Chp2, may also
be part of the HP1 family; Sadaie et al., 2008), there are two HP1 isoforms
in C. elegans (HPL-1 and HPL-2) and three in Drosophila (HP1a, HP1b,
HP1c; HP1a was the first HP1 protein identified, and the literature refers
to it often as "Drosophila HP1") and Xenopus laevis (HP1α, HP1β, HP1γ).
Mammals also have three HP1 isoforms (HP1α, HPβ, HPγ), which share an
overall sequence identity of about 50% with Drosophila HP1; my thesis will
focus on the mammalian HP1 isoforms.
The different isoforms have similarities in their amino acid sequence
(see Figure 1.7 for an alignment; ; see Appendix for human HP1 sequences
with numbered residues). To what extent there is redundancy among
isoforms is currently not completely clear. In Drosophila, deletion of one
isoform (dHP1a) is lethal (Eissenberg and Hartnett, 1993), causing cell
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Figure 1.6: Domain structure of HP1.
A: HP1 proteins comprise three domains, an N-terminal chromo domain, a hinge
region, and a C-terminal chromoshadow domain. For details on the molecular
interactions of the three domains, see section "HP1 domains and molecular
interactions".
B: Left: Schematic representation of HP1 isoforms in human, mouse, Xenopus
laevis, Drosophila melanogaster and Schizosaccharomyces pombe. Even though
there is some variation in the length and amino acid sequence of the domains,
all HP1 proteins have a chromo domain, a hinge region and a chromoshadow
domain. Especially dHP1b, dHP1c and Swi6 have extensive additional sequence
stretches. Right: Table showing the conservation (% identity) of the different
domains, compared to the most intensely studied HP1 protein, Drosophila HP1a.
The hinge region is less conserved than the CD and CSD. Table adapted from Li
et al., 2002.
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Figure 1.7: Alignment of HP1 proteins of different organisms.
Amino acid alignment of HP1 proteins from different organisms. The chromo
domain and chromoshadow domain are highly conserved, while there is less
conservation of the hinge region (for exact % identity see Table in Figure 1.6B,
right).
hHP1: human HP1. mHP1: mouse HP1. xHP1: Xenopus laevis HP1. dHP1:
Drosophila melanogaster HP1. Identical residues in red (identity threshhold 0.75),
similar residues in yellow. The CD is marked with a red line, the hinge region
with yellow and the chromoshadow domain with blue. Green astersiks indicate
amino acids of the aromatic cage. Residue numbers for human HP1α are given
above the sequence.
Alignment generated with ClustalW. The S. pombe homolog Swi6 was not included
in the alignment, because its significantly larger length and lower sequence
conservation made an inclusion in this multiple-species alignment difficult. For
dHP1b and dHP1c, not the full sequence is shown, but the last 58 aa resp. 69 aa
of their long C-terminal tails are omitted (compare to Figure 1.6B, left).
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1.7

death through chromosome fusions (Fanti et al., 1998). In mammals,
knock-down of HP1α by RNA interference does not lead to directly
observable effects, while HP1α/HP1γ double RNAi results in the formation
of micronuclei, indicative of aberrant mitotic chromosome segregation
(Obuse et al., 2004). This indicates differences between organisms in how
the multiple functions of HP1 are distributed among the isoforms, as well
as organism-specific differences in the exact functions fulfilled by HP1.
In line with such an interpretation, various differences in the molecular
interactions and cellular localization of the different isoforms have been
observed (see Sections "HP1 domains and molecular interactions" and
"Cellular localization and functions of HP1").

HP1 domains and molecular interactions
In the following, I will give a brief summary of what is known about the
three domains of HP1 and the molecular interactions they undergo.
A. Chromo domain
The chromo domain (CD) was originally described as an evolutionarily
highly conserved domain of about 40 amino acid with an obscure
biological role that was present in various proteins involved in chromatin
organization and gene regulation (Koonin et al., 1995). The CD of HP1
was actually the first chromo domain for which finally a molecular
function could be identified: A series of landmark papers published in
2001 demonstrated that the HP1 chromo domain is a binding module
for a methyl mark on the histone H3 tail, methylated lysine 9 (H3K9me,
see Figure 1.8A; Bannister et al., 2001; Jacobs et al., 2001; Lachner
et al., 2001). Subsequently, it was shown that chromo domains in
general are methyl-lysine binding domains. The chromo domain of HP1
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in particular has since developed into a highly studied paradigm for
methyl-lysine binding and the recruitment of effector proteins.

A

HP1

CSD

CD
M
M

H3 tail: NH2-A R T K Q T A R K S T G G K A...
1

9

B

Y48

Y24
W45
N
C

Figure 1.8: The chromo domain of HP1 binds methylated lysine 9 of

1.8

histone H3.

A: The HP1 CD binds methylated lysine 9, a histone mark that is part of a
sequence motif "ARKS" within the N-terminal tail of histone H3.
B: Crystal structure of the CD of Drosophila HP1a (23-76) bound to a trimethyl-K9
H3 tail peptide (1-15) (Jacobs and Khorasanizadeh, 2002). Two different views
of the same structure are shown, the view on the right is rotated by 90° to the
left around the vertical axis. The peptide (yellow, trimethyl-K9 shown) is bound
by the CD (in blue) in a weak (Kd in the lower µM), but specific interaction. No
density was seen for H3 residues 1 to 4 and 11 to 15, suggesting that they
are not directly involved in binding. Left: The peptide inserts into the chromo
domain in an extended conformation, forming a β-strand that completes the β
sandwich architecture of the CD. Right: The methylammonium group of lysine
9 is coordinated by three aromatic residues (Y24, W45, Y48; shown in purple),
the "aromatic cage". Mutation of any of these completely abolishes binding.
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Di- and trimethylation of H3 lysine 9 can be found at pericentric
heterochromatin in virtually all higher eukaryotes and is considered
a hallmark of silenced chromatin (Grewal and Jia, 2007). The enzyme
mainly responsible for this methylation is the histone methyltransferase
Su(var)3-9, as first shown with the S. pombe homolog Clr4 (Rea et
al., 2000), and then confirmed with the mammalian homolg SUV39H
(Peters et al., 2001) and the Drosophila homolog Su(var)3-9 (Schotta
et al., 2002). Like HP1, Su(var)3-9 is a suppressor of PEV, confirming
its importance in the formation of pericentric heterochromatin. By
methylating H3 at lysine 9 through its C-terminal SET domain (Rea et
al., 2000), Su(var)3-9 "writes" the histone mark that the HP1 CD then
reads.
Interestingly, the amino acid context of H3K9 ("ARKS", Figure 1.8A)
is found in identical or similar form at multiple other sites in histones
and other proteins. In several of these instances the corresponding
lysine has been found to be a methylation site as well. Moreover, even
recruitment of interaction partners with chromo domains has been
shown (e.g. H3K27: ARKmeS binds Polycomb, Fischle et al., 2003c;
H1K26: ARKmeS binds HP1, Daujat et al., 2005; G9aK165: ARKmeT
binds HP1, Sampath et al., 2007), and additional modifications such
as lysine acetylation and serine phosphorylation are known to happen
in this sequence stretch. Thus, ARKS and related sequences are typical
examples of "modification cassettes" that are found in multiple proteins
and confer the ability for the recruitment of specific binding partners
(Fischle et al., 2003a).
The crystal structure of the HP1 chromo domain bound to
a methylated H3 peptide shows that the main structural features
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of the chromo domain are an antiparallel three-stranded β-sheet
packed against an α-helix (Figure 1.8B). Of critical importance for the
interaction of the CD with the methylated lysine are three aromatic
amino acids within the chromo domain (the "aromatic cage", marked
by green asterisks in the alignment of Figure 1.7 and shown in purple
in the crystal structure of Figure 1.8B; Jacobs and Khorasanizadeh,
2002; Nielsen et al., 2002). Mutation of any of these residues results in
loss of methyl-K9 binding in vitro and functional defects in vivo (Platero
et al., 1995).
Biophysical measurements by fluorescence anisotropy have
determined dissociation constants for the binding of the CD of Drosophila
and human HP1s to methylated H3 tail peptides (Fischle et al., 2005;
Fischle et al., 2003c). The Kd values are in the low micromolar range and
little difference is observed between the chromo domains of the three
isoforms. However, there is some discrimination between the level of K9
methylation: the affinity of the HP1 CD for H3K9me3 and H3K9me2 is
about five- to tenfold higher than for H3K9me1.
Binding of the chromo domain to the modified H3 tail is essential
for recruitment of HP1 to chromatin, and disruption of this interaction
by mutations in the CD or removal of the H3K9me mark results in
mislocalization of HP1 in flies, S. pombe and mammals (Fischle et al.,
2003c; Platero et al., 1995; Stewart et al., 2005; Thiru et al., 2004).
Besides its interaction with H3K9me, the HP1 CD has been
reported to bind components involved in nuclear architecture and to
Psc3, a subunit of the mitotic cohesin complex in S. pombe (see Table
1.4 for references).
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Table 1.4: Examples of HP1 interactions
(Adapted from Kwon and Workman, 2008; Li et al., 2002; Lomberk et al., 2006.)
Chromo domain:
Interaction partner
H3K9me

Shown with
Swi6, DmHP1a,
mHP1, mHP1,
mHP1

Lamin B, LAP2beta
Psc3

mHP1
Swi6

References
Bannister et al., 2001
Lachner et al., 2001
Jacobs et al., 2001
Nakayama et al., 2001
Kourmouli et al., 2000
Nonaka et al., 2002

Chromoshadow domain:
HP1

Swi6, mHP1,
mHP1, mHP1

Su(var)3-9

DmHP1a, mHP1,
mHP1, hHP1

TIF1alpha

mHP1

KAP-1/TIF1beta

mHP1, mHP1,
mHP1, hHP1,
hHP1
mHP1, hHP1
DmHP1a

Rb
Su(var)3-7
CAF-1 (p150)
TAFII130
AF10
ORC1-6 (CD+CSD)
Ku70
ATRX
Su(z)12
Ki67
PIM1
SP100B
Lamin B receptor

mHP1, mHP1,
hHP1
hHP1, hHP1
DmHP1a
DmHP1a
hHP1
mHP1, mHP1
hHP1, hHP1
mHP1, mHP1.
mHP1
hHP1
hHP1, hHP1,
hHp1
hHP1, hHP1,
hHP1

Le Douarin et al., 1996
Brasher et al., 2000
Cowieson et al., 2000
Thiru et al., 2004
Aagaard et al., 1999
Yamamoto and Sonoda, 2003
Schotta et al., 2002
Nielsen et al., 1999
Le Douarin et al., 1996
Nielsen et al., 1999
Le Douarin et al., 1996
Lechner et al., 2000
Nielsen et al., 2001b
Cleard et al., 1997
Delattre et al., 2000
Murzina et al., 1999
Brasher et al., 2000
Vassallo and Tanese, 2002
Linder et al., 2001
Pak et al., 1997
Song et al., 2001
McDowell et al., 1999
Yamamoto et al., 2004
Scholzen et al., 2002
Koike et al., 2000
Lehming et al., 1998
Seeler et al., 1998
Polioudaki et al., 2001
Ye et al., 1997

(continued on next page)
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Hinge:
RNA
INCENP
H1b

mHP1, mHP1
hHP1, hHP1
hHP1

Muchardt et al., 2002
Ainsztein et al., 1998
Hale et al., 2006

Interacting HP1 domain not determined:
Dnmt3a/b

mHP1, mHP1,
hHP1, hHP1,

Histone H3 core

hHP1, hHP1,
hHP1
mHP1, mHP1,
mHP1

Su(var)4-20

Lehnertz et al., 2003
Bachman et al., 2001
Fuks et al., 2003
Nielsen et al., 2001a
Schotta et al., 2004

B. Chromoshadow domain
Distantly related to the chromo domain in primary amino acid sequence
(Aasland and Stewart, 1995), the chromoshadow domain (CSD) is also
highly conserved between HP1 proteins of different organisms. The
structure of the CSD bears some resemblance to the chromo domain
structure (a three-stranded β sheet packed against two α helices;
Cowieson et al., 2000). However, it does not engage a histone modification,
but rather mediates a wide array of protein interactions. More than
three dozen different molecular interactions of the HP1 chromoshadow
domain have been identified to date (see Table 1.4 for examples).
Of particular interest among the interactions of the chromoshadow
domain is the interaction with HP1 itself: as shown for Drosophila and
mammalian HP1, the HP1 CSD mediates homodimerization with the
same HP1 isoform as well as heterodimerization between different
HP1 isoforms. The finding has been observed by various independent
methods, such as two hybrid interaction assay (Gaudin et al., 2001;
Le Douarin et al., 1996), in vitro pull-downs (Cowieson et al., 2000;
Ye et al., 1997), gel filtration, equilibrium sedimentation analysis, and
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structural studies (Brasher et al., 2000; Cowieson et al., 2000; Thiru et
al., 2004). The dimer interaction is quite tight (Kd < 150 nM). Even so, it
can be disrupted by single point mutations (e.g. I161E, Y164E in HP1β;
Brasher et al., 2000).
Dimerization of HP1 through the CSD is an intriguing observation,
because it suggests a mechanism how HP1 could achieve condensation
and silencing of specific chromosomal domains. As depicted in
Figure 1.9A, HP1 may crosslink H3K9-methylated nucleosomes, thus
condensing regions of chromatin through a "handcuffing" mechanism
(Jenuwein and Allis, 2001). Direct testing of this hypothesis by point
mutations has been difficult, though, because deletions of the CSD
or mutations abolishing HP1 dimerization also affect HP1 chromatin
association in general (Thiru et al., 2004; Vogel et al., 2006).
A phage display screen carried out with the HP1 CSD identified
a pentapeptide motif PXVXL/I (X = any amino acid) that interacts
specifically with the chromo shadow domain (Smothers and Henikoff,
2000). The peptide motif was subsequently shown to be present in
many of the molecules reported to bind the HP1 CSD, for example in
KAP-1 (Brasher et al., 2000), Su(var)3-7 (Delattre et al., 2000), CAF-1
p150 (Brasher et al., 2000), the TAFII130 component of TFIID (Vassallo
and Tanese, 2002), and AF10 (Linder et al., 2001). Binding of proteins
with the PXVXL/I motif to HP1 requires dimerization of the CSD, which
generates a hydrophobic groove that the peptide motif associates with
(Thiru et al., 2004).
As described above, Su(var)3-9 functionally interacts with the
chromo domain of HP1: It methylates H3K9 and thus generates a
binding site for the HP1 CD that is essential for HP1 recruitment to
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chromatin. However, it has been found that Su(var)3-9 also interacts
physically with HP1. In co-immunoprecipitation experiments, it was
shown that mouse HP1β binds the mouse homolog of Su(var)3-9,
SUV39H1 (Aagaard et al., 1999). The interaction was mapped to the
CSD of HP1 and the extreme N-terminus of SUV39H1 (residues 1 – 42,
outside of the chromo domain of SUV39H1 as well as its SET domain;
Melcher et al., 2000).
The interaction between SUV39H1 and HP1 has potentially farreaching biological implications, because it suggests a mechanism for
the spreading and maintenance of heterochromatic structures and
epigenetic gene silencing. According to this model, SUV39H1, the histone
H3 tail and HP1 collaborate to form a self-sustaining loop: methylated
H3K9me recruits HP1, which in turn directs more SUV39H1 histone
methyltransferase to chromatin, enabling further methylation (Figure
1.9B).
Besides dimerization and the interaction with Su(var)3-9, several
transcriptional regulators have been shown to bind to the HP1 CSD,
such as the transcriptional repressors TIF1α, KAP-1/TIF1β, and Rb (Le
Douarin et al., 1996; Nielsen et al., 1999; Nielsen et al., 2001b). This
could provide means for initial recruitment of HP1 to specific regions of
chromatin. Rb, for example, has been reported in human cells to recruit
HP1β to the cyclin E promoter and induce tri-methylation of H3K9 by
SUV39H1 (Nielsen et al., 2001b). The reported interaction of the HP1
chromoshadow domain with class II HDACs (Zhang et al., 2002; reports
of HP1 interaction with HDACs also in S. pombe, Yamada et al., 2005)
may contribute to gene repression and the initiation of stable silencing
through hypoacetylation of histones H3 and H4 and deacetylation of
H3K9, which allows for K9 methylation.
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Figure 1.9: Models for HP1-mediated chromatin condensation and the
1.9
spreading of heterochromatic domains.
A: Model for chromatin condensation through nucleosome crosslinking via HP1
dimerization. According to this model, HP1 binds to the H3K9me mark (small red
dot) through its chromo domain (blue). Dimerization of HP1 molecules through the
CSD (in pale red) can bridge individual adjacent nucleosomes, thus preventing a
more open chromatin conformation of loci carrying H3K9me (left). "Discontinuous"
bridging between different chromatin fibers could even cause condensation of larger
heterochromatic domains (right). The structures may then be further stabilized by
interactions with additional heterochromatic factors.
B: Model for the spreading of heterochromatin by interplay of SUV39H1, histone
H3, and HP1. The histone mark H3K9me (small red circle "M") recruits the effector
protein HP1 via its chromo domain (CD) to chromatin, possibly with the contribution
of other stabilizing interactions. HP1 crosslinks nucleosomes and forms condensed,
heterochromatic structures. In addition, however, HP1 also recruits the HMTase
SUV39H1 (in yellow). Upon recruitment to chromatin, SUV39H1 methylates
through its SET domain adjacent unmethylated H3 tails at lysine 9, forming new
H3K9me binding sites for HP1. Thus, this three-component system could explain
spreading and maintenance of heterochromatic gene silencing.
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In addition to these, various other molecular interactions of HP1
have been described, ranging from histone chaperones over Su(var)3-7,
a PEV modifier with an unknown molecular function, to proteins
involved in replication, DNA repair and nuclear architecture. For more
examples and references see Table 1.4.
C. Hinge region
Compared to the chromo and chromoshadow domains, the hinge
region that connects them has received much less attention. The hinge
is somewhat variable in length between the different isoforms (ranging
for Drosophila, e.g., from 60 aa in HP1a to 23 aa in HP1c, Figure 1.6B).
As can be seen from the Table in 1.6B, its sequence conservation is
significantly lower than that of the CD or the CSD, with the notable
exception of a few clusters of mostly basic amino acids (see alignment
in Figure 1.7).
The sequence variation between the hinge regions of the different
HP1 isoforms has led to the suggestion that the hinge may be the
key to explain the differences that have been observed in localization
and behaviour between the isoforms. Indeed, most of the molecular
interactions that have been described for the hinge region so far have
only been observed for specific isoforms (Ainsztein et al., 1998; Hale et
al., 2006).
Despite its low level of sequence conservation, the hinge regions
of all three isoforms have a common characteristic found in various
organisms: a striking density of charged amino acids (K, E, D) and
serines. The presence of multiple serine residues has led to speculation
that this region of HP1 may be the site of phosphorylation (see below),
but no phosphorylation sites in the hinge have been unambiguously
identified so far.
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The hinge region is assumed to have no defined secondary
structure, but instead is probably unstructured, in keeping with a very
high accessibility by proteases (Ball et al., 1997). Even though much
less is known about the molecular interactions of the hinge region than
those of the CD and CSD, nevertheless several molecular interactions
of this domain of HP1 have been discovered. Since much of my Ph.D.
research focuses on the HP1 hinge, I will describe the interactions of
the hinge in a little more detail.
The HP1 hinge binds to INCENP (inner centromere protein), a
member of the chromosomal passenger complex (Ainsztein et al., 1998).
The chromosomal passenger complex (CPC) is a mitotic kinase complex
that shows very distinct localization changes during mitosis and plays an
important regulatory role in multiple steps of chromosome segregation
and cell division. After identification of human HP1α and HP1γ from
a two hybrid screen with INCENP, the interaction was reproduced for
HP1α in pull-down experiments with recombinant/in vitro translated
components and has since been confirmed by co-IP from Xenopus egg
extracts (Tseng, 2008). The interaction is not required for targeting
of INCENP to centromeres, and the exact biological function of this
interaction is currently still elusive.
An interaction of the HP1 hinge region with RNA was demonstrated
in mouse cells by Muchardt and colleagues (Muchardt et al., 2002).
Through immunofluorescence-overlay assays, it was shown that
besides the chromo domain the hinge region and an RNA component
was required for the proper localization of HP1 to regions of pericentric
heterochromatin, in keeping with observations by Maison et al. (Maison
et al., 2002). The hinge of HP1α and HP1γ directly interacts with RNA by
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EMSA (electrophoretic mobility shift assay). Competition experiments
showed that a mixture of nuclear RNA bound best, while control
sequences (AU- and GC-rich RNA oligomers, tRNA, ssDNA, dsDNA) did
not. This suggests that there may be a specific secondary structure or
sequence motif that is present in some of the nuclear RNAs and that is
specifically bound by the HP1 hinge, but to date nothing more is known
about the nature and sequence of any RNAs HP1 may bind to.
Recently, it has been reported that the hinge region of human
HP1 also interacts with the linker histone H1b, as shown by both in
vitro binding and in vivo FRET experiments (Hale et al., 2006). The
interaction, which was mapped to the C-terminal domain of H1b, is
specific for the isoform HP1α (the HP1 isoform that also has been
specifically linked to breast cancer metastasis, see below; Kirschmann
et al., 2000). Interestingly, binding of H1b to HP1α is controlled by
posttranslational modification of H1b. Phosphorylation of the histone
by CDK2/cyclin E at late G1/S abolishes the interaction, a step that is
required for efficient progression of the cell cycle, possibly because it
leads to a more relaxed structure that facilitates DNA replication.
Despite these published interactions, the HP1 hinge remains a
region about which very little is known compared to the other domains of
HP1. The identification of additional interaction partners, understanding
the contribution of the HP1 hinge to the differences observed between
isoforms, and potential phosphorylation of hinge serines remain wide
open questions in the understanding of HP1.
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Cellular localization and functions of HP1
HP1 in heterochromatin
Thorough localization studies of HP1 in Drosophila and mammals have
shown that HP1 proteins are localized primarily to regions of constitutive
heterochromatin around the centromeres and at the telomeres, which are
rich in repetitive DNA sequences. For example in polytene chromosomes of
Drosophila, mainly the chromocenter (i.e. regions of pericentric chromatin)
and the telomeres are stained with HP1 antibodies (Fanti et al., 1998;
James and Elgin, 1986; Li et al., 2002). The S. pombe homolog Swi6 is
found at silent mating-type loci, centromeres and telomeres (Ekwall et al.,
1995), and in mouse cells, colocalization of HP1 with DAPI-dense regions
of constitutive heterochromatin is observed during interphase (Figure 1.9;
Lachner et al., 2001).
As is evident from its function as a dominant suppressor of
variegation, HP1 plays an essential role in the the formation of silenced
domains of constitutive heterochromatin at pericentric regions, which in
turn is crucial for the faithful segregation of chromosomes during mitosis.
HP1 mutation also leads to defective telomere protection in Drosophila (it
is required for telomere capping, silencing and telomere length control;
Perrini et al., 2004) and loss of silencing at mating type loci in S. pombe.
But besides this role in gene silencing, HP1 also has a function in
promoting gene expression within heterochromatin. Some genes located
within pericentric heterochromatin require a heterochromatic environment
for their normal expression, as first described for the "light" and "rolled"
genes (Lu et al., 2000). These genes depend on HP1 to generate the
heterochromatic structures needed for their proper expression, and similar
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observations have by now been made for many other genes (de Wit et al.,
2007). Thus HP1 plays different, quite opposing roles within constitutive
heterochromatin, which are not understood in mechanistic terms.

HP1 in euchromatin
However, it is well documented that HP1 does not only localize to regions
of constitutive heterochromatin. A small fraction of HP1 is also found
at sites within euchromatic regions of the chromosomes. In polytene
chromosomes of Drosophila, e.g., HP1a is present at about 200 sites within
the chromosome arms (Fanti and Pimpinelli, 2008; Li et al., 2002). This
suggests that HP1 may also play a role in the repression of individual genes
within euchromatin, an interpretation supported by reports demonstrating
recruitment of HP1 by several transcriptional repressors (Le Douarin et al.,
1996; Nielsen et al., 1999; Nielsen et al., 2001b) and the observation that
some HP1-bound genes in euchromatin are upregulated upon mutation of
HP1a in Drosophila (Hwang et al., 2001).
Several experimental obervations argue that HP1 by itself can initiate
heterochromatic structures and may indeed directly induce gene silencing
within euchromatin. When HP1 is tethered to sites within euchromatic
regions of Drosophila chromosomes through an ectopic binding domain,
this is almost always sufficient to nucleate the formation of heterochromatin
and silencing of nearby reporter genes (Li et al., 2003). In mammalian cells,
targeting of HP1α through a GAL/lacR system to euchromatic regions leads
to local condensation of the higher order chromatin structure (Verschure
et al., 2005). These experiments suggest that HP1 could indeed play a role
in gene repression within euchromatic regions of chromosomes.
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However, the involvement of HP1 in the regulation of euchromatic
regions is even more complex and goes beyond its well established role in
gene silencing. Quite surprisingly, at some euchromatic loci HP1 association
clearly correlates with increased gene expression, such as in some
developmental (ecdysone-) and heat-shock induced chromosome puffs in
Drosophila (chromosome puffs are morphological features caused by strong
decondensation of chromatin due to high levels of gene expression). Upon
induction of gene expression at these sites, Drosophila HP1a is specifically
recruited to these decondensed regions of extremely active transcription
(Piacentini et al., 2003), suggesting that HP1 can indeed promote gene
expression without inducing heterochromatic structures. Support for this
interpretation comes from recent high-resolution mapping of HP1 binding
sites in Drosophila that finds HP1 at transcriptionally active loci (de Wit et
al., 2007; Johansson et al., 2007), from the observation that HP1 deletion
reduces mRNA levels of some euchromatic genes (Cryderman et al., 2005),
and from ChIP (Chromatin immunoprecipitation) experiments in mouse
cells that find HP1γ at actively transcribed regions (Vakoc et al., 2005).
Thus, despite its name, HP1 seems to have functions in euchromatin that
go beyond its role as an initiator of gene silencing and heterochromatin
formation, at least at a subset of loci.

In addition to constitutive heterochromatin and sites of repressed and
activated euchromatic genes, HP1 has also been detected at a few other
cellular structures in mammalian cells, such as in PML nuclear bodies
(discrete subnuclear structures of unknown function that are dirupted in
acute promyelocytic leukemia; Everett et al., 1999; Seeler et al., 1998) or
at the periphery of nucleoli (Minc et al., 1999).
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To further complicate the localization of HP1, in many instances
subtle differences between the three HP1 isoforms are observed. It has
repeatedly been noted, for example, that euchromatic localization and
function is more pronounced in the case of HP1γ/HP1c than in the case
of the other two isoforms (Hwang and Worman, 2002; Minc et al., 2000;
Smothers and Henikoff, 2001; Vakoc et al., 2005). High-resolution mapping
in Drosophila Kc cells confirms these findings: As opposed to HP1a, little
enrichment of HP1c at pericentric regions is observed, but rather a focal
distribution to a few "hotspots" near highly active genes, where HP1c
colocalized with many transcription factors and other regulatory proteins
(de Wit et al., 2007; Moorman et al., 2006). From a molecular point of view,
differences between the isoforms are perhaps not completely surprising,
because there is clear sequence variation between the three isoforms, in
particular in the hinge region. Differences in the molecular interactions
of the three isoforms (e.g. HP1α interacts with histone H1b, while HP1β
and HP1γ do not), and in their involvement in human disease (e.g. HP1β,
but not HP1α, is downregulated in the progression of human melanoma;
Nishimura et al., 2006) have been known for a long time.
In summary, HP1 is clearly involved in multiple, sometimes seemingly
opposing cellular events. It is a central player in the formation/maintenance
of constitutive heterochromatin at pericentric regions and telomeres, which
is crucial for the faithful segregation of chromosomes during mitosis, as
well as for the normal expression of certain genes located within pericentric
heterochromatin. Besides its function in heterochromatin, HP1 clearly also
plays a part in euchromatin, where it represses transcription at some loci,
while promoting gene expression at others. On a molecular level, little is
known how HP1 fulfills these multiple functions.
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The paradigm that the presence of HP1 always accompanies and
promotes constitutive heterochromatin is clearly not completely true,
since ample evidence exists for both euchromatic localization and positive
involvement in gene expression. However, by far the largest fraction of
cellular HP1 is indeed localized to regions of constitutive heterochromatin by
H3K9me-dependent mechanisms, where it is involved in heterochromatin
formation and gene silencing.

Changes in HP1 localization during the cell cycle
Detailed studies of HP1 in cultured cells have revealed dramatic changes
in HP1 localization during mitosis in Drosophila (Kellum et al., 1995) as
well as human cells (Hayakawa et al., 2003; Minc et al., 1999; Murzina et
al., 1999). When chromosome condensation is initiated during prophase,
all three HP1 isoforms are released from their interphase binding sites on
chromatin and become dispersed throughout the cytoplasm (see Figure
1.10). No earlier than telophase/early G1 does the bulk of HP1 isoforms
reassociate with chromatin.
Quite surprisingly, the binding site of HP1 at constitutive
heterochromatin, methylated lysine 9 (K9) of H3, is not removed during
this dissociation (Bannister et al., 2002). This is surprising, because in
most other cases where release of a recruited effector protein is observed,
this is achieved by removal of the histone mark. Before our work, the
mechanisms of the reversible ejection of HP1 from chromatin during
mitosis were thus still enigmatic.
Several studies have reported another subtlety of HP1 dynamics
during mitosis observed in human cells: A small fraction of the HP1α
isoform (and, according to some reports also of HP1β and HP1γ) reassociates
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at metaphase with centromeric regions of chromosomes (Hayakawa et al.,
2003; Minc et al., 1999; Sugimoto et al., 2001). Hayakawa and colleagues
demonstrated that this reassociation is chromo domain-independent and
rather requires the CSD and part of the hinge region (HP1α 101-180).
Recently, it has been reported that HP1 interacts with shugoshin, a factor
that is required for protection of centromeric cohesins during mitosis/
meiosis (Yamagishi et al., 2008). The interaction is conserved in both S.
pombe and humans, and shugoshin is mislocalized in the absence of HP1,
suggesting that shugoshin recruitment may be the biological funtion of the
reassociation of HP1α with centromeric regions of chromosomes during
metaphase.

DNA

anti-HP1

Overlay

Interphase

Metaphase

Figure 1.10: Cellular localization of HP1 in mammalian cells.
1.10
Localization of HP1 in interphase and metaphase. Immunofluorescence staining
of 3T3 mouse fibroblast cells. In interphase the HP1α signal colocalizes with
densely staining regions of DNA, indicating that HP1α is concentrated at
regions of pericentric heterochromatin. (Note: These striking dots of condensed
heterochromatin are specifically observed in mouse cells and not seen as clearly
in other, e.g. human, cells.) In metaphase, HP1α is dispersed throughout the
cytoplasm and for the most part excluded from the condensed DNA, which is
arranged in the metaphase plate. Similar observations are made with the other
HP1 isoforms. DNA stained with DAPI.
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The mechanism of the reversible HP1 release has not been uncovered
(or had not been uncovered at the time when I started with my thesis), and
the biological function of the striking changes in HP1 localization during
mitosis are completely unknown.

Molecular mechanism of HP1 recruitment
Essential role of CD-H3K9me interaction
Many studies have shown that the CD interaction with H3K9me is absolutely
essential for the recruitment of HP1 to chromatin. If this interaction is
abolished by point mutations or deletions of the chromo domain (e.g.
Cheutin et al., 2003; Thiru et al., 2004) or by removal of the K9-methyl mark
(Ekwall et al., 1996; Lachner et al., 2001), HP1 is not localized to pericentric
heterochromatin anymore in several in vivo systems. Point mutations that
abolish CD binding to H3K9me in flies exhibit the same phenotypic effects
as HP1 deletions (suppression of PEV, homozygous lethality) and such
constructs are incapable of rescuing the deletions (Eissenberg et al., 1990;
Eissenberg et al., 1992; Platero et al., 1995).

Contribution of other mechanisms
However, several in vivo observations suggest that CD binding to H3K9me
may not be sufficient for stable chromatin association of HP1 in the cell.
The chromo domain alone is not targeted properly to heterochromatin
in vivo and shows much lower resistance to extraction with detergents
(Cheutin et al., 2003; Smothers and Henikoff, 2001; Thiru et al., 2004).
Even certain point mutations in the chromoshadow domain are sufficient to
reduce the stability of HP1‘s association with heterochromatin significantly
(Fanti et al., 1998; Thiru et al., 2004). Moreover, the three HP1 isoforms
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have somewhat different localization patterns, even though their chromo
domains bind H3K9me equally well in vitro. This suggests that additional
molecular interactions contribute to HP1 chromatin association in vivo.
Several in vitro observations support the understanding that stable
chromatin binding of HP1 involves additional interactions besides CDH3K9me binding, especially in the context of the nucleosome (in contrast
to experiments with histone peptides). In pull-down experiments with
recombinant GST-HP1, the CD alone could not pull down native soluble
oligonucleosomes from chicken erythrocyte extracts (Meehan et al., 2003).
Binding of bacterially expressed HP1 to mononucleosomes required the fulllength protein (Zhao et al., 2000). And, as Eskeland and colleagues reported,
the association of recombinant Drosophila HP1 with highly methylated
reconstituted chromatin was much weaker than with methylated peptides
and presumably not sufficient to maintain a heterochromatic structure in
vivo (Eskeland et al., 2007).
Considering the enormous increase in affinity that can be achieved
through multivalency (Ruthenburg et al., 2007b), it seems possible that
additional interactions besides CD binding to H3K9me could be the key
to understand HP1 chromatin association in vivo. Several studies have
proposed specific factors that may stabilize HP1 binding to chromatin.
Eskeland and colleagues, e.g., found that the addition of the chromatin
remodeler ACF1 (ATP-utilizing chromatin assembly and remodeling factor
1) or the HMTase Su(var)3-9 increased binding of recombinant HP1 to
methylated reconstituted chromatin arrays. Both factors are suppressors
of variegation known to interact with the CSD of HP1, and the effect was
independent of Su(var)3-9 HMTase activity, suggesting an increase in
affinity through bimodal binding of HP1 to methylated chromatin (Eskeland
et al., 2007).
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RNA is another molecule that has been implicated in HP1 chromatin
association, based on the findings that RNase treatment of nuclei results
in the release of HP1 binding in mammalian tissue culture cells (Maison
et al., 2002), that HP1 recruitment to transcriptionally active heat-shock
puffs depends on RNA (Fanti and Pimpinelli, 2008) and that HP1 interacts
directly with RNA (Muchardt et al., 2002).
In addition, several other interactions of HP1 have been suggested
to play a role in HP1‘s association with chromatin in vivo, such as the
interactions with H1 and the histone H3 core (Meehan et al., 2003; Nielsen
et al., 2001a) or with HOAP (Heterochromatin protein 1/origin recognition
complex-associated protein; Badugu et al., 2003). However, the exact nature
of these interactions is still quite enigmatic, and it seems there may be
multiple factors among the huge number of HP1’s molecular interactions
capable of contributing to HP1’s chromatin association.

H3K9me-independent chromatin association of HP1
As discussed above, the stabilization of HP1 on chromatin is a complex
phenomenon and involves the CD-H3K9me interaction and additional
interactions mediated by factors associated with HP1. However, the reality
is actually even more complicated, because abundant observations show
that there are also mechanisms of HP1 chromatin association that are
completely independent of H3K9 methylation.
It has been noted, for example, that in Drosophila polytene chromosome
stainings there is no full overlap of HP1 and H3K9me staining, indicating
that particularly on euchromatic arms of chromosomes there are sites of
HP1 binding that do not depend on the interaction with methylated lysine
(Fanti and Pimpinelli, 2008; Li et al., 2002). In keeping with this, in chromo
46

domain point mutants that abolish K9me3 binding, association with sites
on chromosome arms is still observed (Fanti et al., 1998). HP1 association
with Drosophila telomeres is mediated by two mechanisms: One population
of HP1 binds in a chromo domain-dependent fashion and is essential for
silencing of telomeric sequences and telomere length control. The other
fraction binds independently of the chromo domain and is required for
telomere stability (Perrini et al., 2004).
While there are some hints about the mechanisms that could be
involved in such K9me3-independent recruitment to chromatin (for
example binding of the HP1 CD to H1K26me, Daujat et al., 2005); or HP1binding proteins with DNA-binding affinity, Nielsen et al., 1999), it seems
that the enigmatic multiple functions of HP1 may be related to the many
means by which the protein is targeted to its site of action. Clearly much
more careful research will be required to tease apart all of these different
mechanisms of HP1 recruitment and chromatin binding.

Dynamics of HP1 binding
Even though the overall structure of heterochromatic domains is quite
stable over time, HP1 binding to chromatin is actually highly dynamic.
As demonstrated by FRAP (fluorescence recovery after photobleaching)
experiments in mammalian cells, HP1 association with chromatin is
characterized by rapid on-off kinetics (Cheutin et al., 2003; Festenstein et
al., 2003; Schmiedeberg et al., 2004). These experiments also showed that
there are at least three different subpools of HP1 with different mobilities
in heterochromatin.
As described in more detail later in this thesis, I observed in my own
experiments with mammalian cells some differences in the fractionation/
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extraction behaviour of exogenous GFP-HP1 compared to endogenous
HP1 (see Chapter 4). Thus, these results on HP1 dynamics have to be
interpreted with caution.

HP1, heterochromatin nucleation and RNAi
According to current understanding, heterochromatin nucleation is distinct
from the subsequent steps of heterochromatin spreading and maintenance.
Two alternative mechanisms seem to be involved in the nucleation process.
One way is the recruitment of HP1 by factors with DNA-binding affinity,
such as Rb or KAP-1 (see Section "HP1 domains and molecular interactions:
Chromoshadow domain"). HP1 in turn recruits methyltransferase activity
and mediates spreading/maintenance of heterochromatic structures. This
appears to be the predominate mechanism for the repressive function of
HP1 in euchromatic regions.
Formation of constitutive heterochromatin, however, seems to be
mediated by other mechanisms. Besides DNA-binding proteins (Jia et
al., 2004; Kim et al., 2004; Yamada et al., 2005), it can be mediated by
mechanisms that require the presence of repetitive DNA elements and
involves the RNAi machinery, as suggested by observations made in genetic
experiments with S. pombe. Loss of/mutations in components of the RNA
interference pathway (Argonaute 1, Dicer, RNA-dependent RNA polymerase)
prevent heterochromatin-specific chromatin modifications (such as
H3 K9 methylation), binding of Swi6 and formation of heterochromatin
at centromeres and mating type regions (Hall et al., 2002; Volpe et al.,
2002). The result has been confirmed by similar findings in Tetrahymena
(Mochizuki et al., 2002), Drosophila (Pal-Bhadra et al., 2004) and mouse
(Kanellopoulou et al., 2005).
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Through a series of other observations, a pathway is emerging
that involves transcription of repetitive elements within centric regions
by RNA Polymerase II into double-stranded RNAs, processing of these
dsRNAs into short interfering RNAs by the RNase Dicer, and the RNAinduced transcriptional gene silencing complex (RITS). It is clear at
this point that the repetitive elements are sufficient to nucleate Swi6dependent heterochromatin at ectopic sites. However, the exact molecular
details of many steps of the pathway, and how siRNAs generated during
this process localize histone-modifying activities, in particular the Clr4
HMTase, is currently not understood (see Grewal and Jia, 2007 and Kwon
and Workman, 2008 for more details and references).

HP1 phosphorylation
In several organisms, it has been reported that HP1 is multiply
phosphorylated. These studies detected HP1 phosphorylation upon
metabolic
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P-phosphate labelling of cells, and confirmed the presence

of several differently charged isoforms by immunoblotting after 2D or
acid urea gel electrophoresis, leading to the observation of seven to eight
differently charged isoforms in Drosophila (Eissenberg et al., 1994), four
in Tetrahymena (Huang et al., 1999), and three (HP1α) and five (HP1γ) in
human tissue culture cells (HP1β was found not to be phosphorylated in
this study; Minc et al., 1999).
Changes in the phosphorylation state of HP1 correlate with specific
biological events. The number of differently charged HP1 isoforms in
Drosophila, e.g., increases at hour 1.5 – 2 of early embryonic development,
around the time when cytologically visible heterochromatin appears and HP1
concentrates in heterochromatin (Eissenberg et al., 1994). In Tetrahymena,
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HP1 hyperphosphorylation correlates with chromatin changes induced by
starvation (Huang et al., 1999). And in human HeLa cells, the number
of charged isoforms is specifically increased during mitosis (Minc et al.,
1999).
Despite these interesting correlations, an in depth analysis of HP1
phosphorylation and its role has turned out to be difficult. Due to the
lability of the modifications and the challenges in purifying a protein
that is strongly associated with heterochromatic structures, none of the
phosphorylation sites have really been mapped in vivo to date.
A few sites have been proposed based on in vitro phosphorylation:
Pim-1 kinase can phosphorylate HP1γ in the hinge region (the exact site
was not mapped) in in vitro kinase assays (Koike et al., 2000). Three sites
(one in the N-terminus at S15, two at the very C-terminus at S199 and
S202; additional phosphorylation suggested in the hinge) were found
phosphorylated in recombinant HP1a after incubation with nuclear extracts
from Drosophila embryos (Zhao and Eissenberg, 1999). While these may
indeed represent sites of in vivo phosphorylation of Drosophila HP1a, due
to the known promiscuity of kinases in the test tube these results have to
be interpreted with caution.
Naturally, the lack of knowledge about the exact sites of
phosphorylation has hindered an understanding of the biological function of
HP1 phosphorylation beyond the described correlative data. Where results
were obtained, they have often not been fully conclusive, despite some
curious observations. For example, while Eissenberg and colleagues had
found that HP1 becomes hyperphosphorylated at the stage of development
when HP1 seems to localize to heterochromatin in Drosophila embryos
(Eissenberg et al., 1994), another study reported that hyperphosphorylated
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HP1a is extracted more easily with salt from chromatin of Drosophila
embryos (Huang et al., 1998). When Zhao and Eissenberg tested mutants
of phosphorylation sites for their effect on HP1 silencing, they found
that both S to A and S to E mutation showed the same effect (reduced
silencing; Zhao et al., 2001). However, another study mutated nine serine
residues in the hinge region of Drosophila HP1a (most of these residues
not conserved in other organisms), including the same sites as Zhao et
al. In this case enhanced silencing activity for both S to G and S to E
mutants was observed (Badugu et al., 2005). In addition, Badugu et al.
reported that HP1 dimerization and binding to H3K9me were enhanced
by the mutations, while interactions with components of the Drosophila
Origin of Replication Complex were reduced. No other interactions besides
these were tested.
In summary, the sites of HP1 phosphorylation have not been
successfully mapped in any organism at this point, nor have the biological
function(s) of HP1 phosphorylation been fully understood. This is
particularly true for the human HP1 isoforms, where not a single site has
been mapped so far. Similarly, the role of HP1 phosphorylation in mitosis
has not been studied at all, despite the curious observation that HP1
becomes hyperphosphorylated at this stage of the cell cycle. Some of these
questions, I have tackled in my thesis project (see below).

Open questions
In recent years, enormous progress has been made in our understanding
of the general principles how chromatin is organized and functions within
the cell. HP1 is today one of the best-studied factors among all chromatin
components. Since its discovery in the 1980s, much has been learned
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about its multiple important roles in the cell, the molecules it binds to and
the pathways it interacts with.
However, there are still many fundamental questions in HP1 biology
that have not been answered. For example, a full understanding of the
different ways how HP1-dependent heterochromatin is nucleated, of the
different roles of the three HP1 isoforms, of the regulation of HP1’s diverse
molecular interactions, or of the exact molecular mechanism(s) of HP1mediated gene silencing will still require plenty of research. HP1 may have
additional, still undiscovered roles in the cell, as suggested by its binding
partners (e.g., structural components of the nucleus, implicating HP1 in
nuclear organization). When I began my Ph.D., little was known about
HP1’s posttranslational modifications beyond the fact that they exist.
Furthermore, the molecular mechanisms underlying the relocalization of
HP1 at the onset of mitosis and the biological reason for these striking
localization changes remained exciting, but still unaddressed questions.
In the past few years, several studies have implicated genetic
alteration of HP1 in the development of several types of human cancer. In
highly invasive/metastatic breast cancer cells, HP1α (not HP1β or HP1γ)
is down-regulated compared to poorly invasive/nonmetastatic breast
cancer cells (Kirschmann et al., 2000). Similarly, HP1β downregulation
correlates with the invasivess of several melanoma cell lines (Nishimura
et al., 2006). The involvement of HP1 in human disease underlines the
importance of learning more about this important chromatin protein. A
better understanding of the multiple roles that HP1 plays in the cell and
the molecular mechanisms underlying its functions will not only contribute
hugely to our understanding of chromatin and its functions in the cell,
but may also lead to insights that could one day be used for the benefit of
human patients in the clinic.
52

The research of my Ph.D. thesis focused on understanding the remarkable
changes that HP1 undergoes during mitosis, both with respect to its
localization and to its posttranslational modification profile.
Fascinated by the question of how reversible dissociation of HP1
could be achieved without any changes to the histone mark that recruits the
effector, in the first part of my thesis I sought to understand the molecular
mechanisms of the mitotic chromatin dissociation of HP1. Through the
combination of in vitro and in vivo experiments presented in this thesis, I
show that the transient release of HP1 during mitosis is achieved by a novel
mechanism, methyl-phos switching, in which two histone marks cooperate
to bring about dynamic release of an effector protein: Phosphorylation of
H3 at serine 10 at the onset of mitosis interferes with HP1 binding to
methylated lysine 9 and thus ejects the effector protein from its binding
site at chromatin. In vivo inhibition experiments show that methyl-phos
switching is a necessary step for the mitotic release of HP1.
Prompted by observations made during the study of methyl-phos
switching, in the second part of my thesis I set out to learn more about the
dramatic changes in HP1’s posttranslational modification profile during
mitosis. This led to purification/mass spectrometry identification of
almost a dozen phosphorylations on the three human HP1 isoforms, most
of which map to the HP1 hinge region and are upregulated in mitosis.
For one particularly conserved site, I was able to identify Aurora B as
the responsible kinase. In various attempts, no substantial evidence for a
connection between mitotic HP1 phosphorylation and the mitotic release
of HP1 or the reassociation of a subpool of HP1 to centromeres could
be established. I conclude with in vitro data that suggests that mitotic
phosphorylation of the HP1α hinge may play a role in the regulation of HP1
association with RNA.
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In sum, my thesis has revealed that HP1's behavior and interactions
in mitosis are regulated by posttranslational modifications on two levels:
phosphorylation of histone H3 as well as phosphorylation of HP1 itself.
Some of the mechanistic findings presented in this thesis may have
implications even beyond the realm of chromatin biology.
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CHAPTER 2
MATERIALS AND METHODS
Reagents
Chemicals, media and recombinant proteins
Nocodazole, MG132, Microcystin LR, and Thymidine were purchased
from Sigma, β-glycerolphosphate from Calbiochem, and propidium
iodide from Molecular Probes. Calyculin A was from LC Laboratories.
Hesperadin was received as a gift from Boehringer Ingelheim, Austria.
Radiolabelled nucleotides were obtained from Amersham/GE Healthcare,
and IPTG was from Acros Organics. Normal goat serum was from Jackson
Immunoresearch. All tissue culture media and G-418 were purchased
from Gibco. Recombinant MSK1, RSK2, and IKKalpha were from Upstate
Biotechnology.

Immunoprecipitated

Xenopus

laevis

Chromosomal

Passenger Complex was a kind gift of Boo Shan Tseng (Funabiki lab,
Rockefeller University). All other reagents that were not generated by
ourselves were from Fisher Scientific.

Peptides and peptide modification
Unmodified and posttranslationally modified peptides of the histone H3tail (residues 1-15 and 1-20) and of the HP1α hinge region (residues 83101) were synthesized either at the Baylor College of Medicine Protein
Chemistry Core Laboratory or the Rockefeller University Proteomics
Resource Center. For H3 peptides, a non-native tyrosine residue was added
at the C-terminus (for concentration determination by UV absorption
measurements). For pull-down experiments, an artificial biotin group was
added to the C-terminus (H3 peptides) or N-terminus (HP1α peptides)
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during synthesis. Peptides were purified by RP-HPLC (reversed-phase
high-performance liquid chromatography) and characterized by MALDIMS (Matrix-assisted laser desorption/ionization mass spectrometry) by
the Proteomics Resource Center.
For fluorescence anisotropy measurements, peptides were labelled
using fluorescein-5-EX succinimidyl ester (Molecular Probes) according
to manufacturer's instructions and then purified by gel filtration (column:
0.5 ml G10 Sephadex, Pharmacia; buffer: 100 mM KPO4 (pH 7.5)) and RPHPLC.
Bacterial media
Bacteria were grown in LB medium (1% tryptone, 0.5% yeast extract,
1% NaCl), usually at 37° C. For selection, the following antibiotics were
included in the media: ampicillin (100 µg/ml), kanamycin (50 µg/ml), or
chloramphenicol (25 µg/ml).
Cell lines and tissue culture media
Human HeLa, HeLa S3, HEK293, HeP2, mouse NIH3T3, and 10T1/2 cell
lines were all from ATCC. Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, with 4.5 g/l D-Glucose, L-Glutamine and 110 mg/l
Sodium pyruvate; Gibco) supplemented with 10% fetal bovine serum (FBS,
PAA Laboratories) and penicillin−streptomycin (10 000 U/ml and 10 000
µg/ml, respectively; Invitrogen), at 37 °C in a humidified atmosphere with
5% CO2. Cell monolayers were detached by one wash with PBS (phosphate
buffered saline) followed by incubation in 0.05% trypsin/0.5 mM EDTA
(Gibco).
Antibodies
For primary and secondary antibodies used, including dilutions, see Table
2.1 and Table 2.2, respectively.
56

Table 2.1: Primary antibodies
Antibody

Source

HP1S92ph1

gift of R. Urrutia (Mayo

("Phos-HP1")

Clinic, Rochester, MN)

Anti-HP1

MAB3446 (Chemicon)

Western

IF

1:2 000

1:200

1:7 500

---

1:2 000

---

#05-689 (Upstate)
Anti-HP1
(cl15.19s2)
Anti-HP1

MAB3584 (Chemicon)

---

1:5 000

Anti-HP1

MAB3448 (Chemicon)

1:10 000

1:7 500

Anti-HP1

MAB3450 (Chemicon)

1:40 000

1:15 000

Anti-H3K9me3

#07-442 (Upstate)

1:1 000

1:1 000

Anti-H3S10ph

#05-598 (Upstate)

0.5 μg/ml

---

Anti-H3S10ph

#06-570 (Upstate)

1:5 000

---

Anti-H3S10ph

#05-806 (Upstate)

---

1:4 000

Anti-H3K9me3S10ph

#05-809 (Upstate)

1:1 000

1:1 000

Anti-H3

Ab1791 (Abcam)

0.5 μg/ml

---

Anti-H3

#06-755(Upstate)

1:1 000

---

1:10 000

---

---

1:750

1:250

---

Anti-GFP

Anti-Aurora B

Anti-Aurora B

#11814460001
(Roche)
gift of S. Taylor
(Ditchfield et al., 2003)
#611082
(BD Biosciences)

Anti-Aurora A

#603301(Biolegend)

1:500

---

Anti-Flag M2

F1804 (Sigma)

1:2 000

1:1 500

MMS-101P (Covance)

1:1 000

1:1 500

#05-373 (Upstate)

1:1 000

---

Anti-HA (HA.11)
Anti-Cyclin B1
1

purified rabbit IgG against HP1 peptide 85-98 (SESNKRKSphNFSNSA)
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Table 2.2: Secondary antibodies
Antibody
Anti-rabbit(IgG)-HRP

Source

Western

IF

1:2 500

---

1:2 500

---

1:2 000

---

Molecular Probes

---

1:2 000

Invitrogen

---

1:2 500

---

1:1 500

Amersham/GE
Healthcare
#PO399,

Anti-rabbit(IgG)-HRP
Dakocytomation
Anti-mouse(IgG)-HRP
Goat-anti-rabbit
AlexaFluor488
Donkey-anti-rabbit
AlexaFluor488

Amersham/GE
Healthcare

Sheep-anti-mouse-

Jackson

Rhodamine Red X

ImmunoResearch

Molecular Biology
Plasmids
Constructs were generated by standard techiques of DNA cloning
(Sambrook and Russel, 2001 ; for a brief description see next section),
using the commercially available vectors pET11a (Novagen) for His-tagged
constructs, pEGFP-N and pEGFP-C (Clontech) for GFP-tagged constructs,
and pGEX (Amersham/GE Life Science) for GST-tagged constructs.
To generate His6-tagged full-length or chromo domain constructs
of the three HP1 isoforms, the full sequence of human HP1α (GenBank
BC006821; residues 1-191), HP1β (GenBank BC002609; residues 1-185)
and HP1γ (GenBank BC000954; residues 1-183), or regions encompassing
the chromodomains (HP1α: 15-71, HP1β: 15-72, HP1γ: 24-81) were fused
to His6-tags by PCR with EST (expressed sequence tag) clones as templates
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(HP1α I.M.A.G.E. Consortium Clone ID 3448801; HP1β: I.M.A.G.E.

Consortium Clone ID 5013102; HP1γ: I.M.A.G.E. Consortium Clone
ID 3450099). PCR products were then cloned into the pET11a vector
via the Nde I and BamH I restriction sites.
The vector pHD-N (N-terminal Flag-HA-Flag tag for expression
in mammalian cells) for ligation-independent cloning (see below) was
constructed by inserting an oligonucleotide cassette into the vector
pIRESneo (Clontech) via the Nhe I and BamH I sites, pHD-C (C-terminal
Flag-HA-Flag tag for expresion in mammalian cells) was generated by
inserting a cassette into pIRESneo (Clontech) via the EcoR V and BamH I
sites.
The GST-Aurora B plasmid (in pGEX, Amersham/GE Healthcare)
was a gift of Ciaran Morrision (National University of Ireland, Galway). The
His6-H1.4 plasmid (in pET16, Novagen) was a gift from Szabolcs Sörös
(MPI for Biophysical Chemistry, Göttingen)

General DNA manipulation
For cloning and plasmid amplification, recombinase-deficient TOP10
and XL1-Blue E. coli strains were used (see Table 2.3). Plasmid DNA
was purified with the Quagen Mini and Midi prep kits (Qiagen). DNA
digestions were carried out with restriction enzymes from NEB according
to manufacturer’s instructions. DNA fragments were isolated with the
QIAquick Gel extraction kit (Qiagen). Cut vectors were treated with calf
intestine phosphatase (NEB) and then purified using the QIAquick PCR
purification kit (Qiagen). Ligation of DNA was carried out with T4 DNA
ligase (NEB) for 3 h at RT. Bacterial transformations were carried out by
42° C heat shock according to standard protocols (Sambrook and Russel,
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2001). All plasmid DNA constructs were fully sequenced, and sequencing
was carried out by Genewiz Inc. Synthesized DNA and oligonucleotides for
cloning and introducing mutations were purchased from Operon, Sigma
Genosys, and GenScript.
Table 2.3: Bacterial strains
Strain

Genotype

Source

TOP10

F- mcrA (mrr-hsdRMS-mcrBC) 80lacZM15
lacX74 deoR recA1 araD139 (ara-leu)7697 galU
galK rpsL (StrR) endA1 nupG

Invitrogen

XL1-Blue

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA
lac[F’ proAB lacIqZM15 Tn10 (Tetr)]

Stratagene

BL21

F- ompT hsdSB(rB- mB-) gal dcm

Stratagene

RosettaBlue

endA1 hsdR17(rK12-mK12+) supE44 thi-1 recA1
gyrA96 relA1 lac pRARE (CmR) [F’ proA+B+
lacIqZDM15 ::Tn10(TcR)]

Stratagene

endA1 hsdR17(rK12-mK12+) supE44 thi-1 recA1
Rosetta(DE3)
gyrA96 relA1 lac pLacIRARE (CmR) [F’ proA+B+
pLacI
lacIqZDM15 ::Tn10(TcR)] (DE3)

Stratagene

PCR and mutation of plasmids
PCR to amplify DNA was carried out with Pfu polymerase (dPromega)
according to manufacturer’s instructions. Typically, 50 µl reactions were
set up with 10 ng template, 400 nM of each primer, 0.2 mM of each dNTP,
5 µl 10X Pfu buffer, and 1 U of Pfu polymerase. A typical cycling program
was 95°C/3:00min–[92/0:45–48/0:30–72/1:00]6x – [95/0:45–56/0:30–
72/1:00]26x–72/2:00–4/pause. PCR products were purified with the
QIAquick PCR purification kit (Qiagen).
Mutations were introduced into plasmids with a protocol based on
the "QuickChange Site-Directed Mutagenesis" procedure (Stratagene). Two
primers of complementary sequence with the mutated bases in the middle
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and about annealing 15-20 bases up- and downstream were designed
with the QuikChange Primer Design software (at www.stratagene.com).
The PCR product was purified with the QIAquick PCR purification kit
(Qiagen), digested for 1 h at 37° C with Dpn I (NEB) and an aliquot used to
transformed bacterial cells.

Ligation-independent cloning
Vectors were linearized with the blunt-end cutter BsaB I (NEB) and PCR
purified (QIAquick PCR purification kit, Qiagen). Inserts were generated by
PCR. Single-stranded ends for annealing ("sticky ends") are generated in
this protocol through a T4 polymerase reaction in the presence of only one
dNTP, which by its 3’→5' exonuclease activity removes the second strand
to the first position where this nucleotide is in the sequence. The vector
and the insert are constructed in a way that their resulting annealing
sequences match and can be annealed. Because the annealing sequence
is much longer than in standard ligations, the annealed sequences are
so stable that no ligation enzyme is required. Vector "sticky ends" were
generated by carrying out a T4 polymerase reaction (NEB) in the presence
of dGTP, insert "sticky ends" in the presence of dCTP. The resulting vector
and insert products were mixed (molar ratio or about 1:3), after 5 min of
incubation at room temperatur EDTA was added to a final concentration
of 10 mM. The annealing reaction was incubated for another 10 min at RT
and then transformed into competent E. coli cells.

Cell-based methods
Mitotic arrest
To arrest HeLa cells in mitotis, 200 ng/ml nocodazole (Sigma) was added
to culture media at 40-60% cell confluence. Cells were processed after
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a 12 to 16 h incubation. Typical enrichment rates were about 70-80%
mitotic cells.

Transfection of tissue culture cells and selection for stable cell lines
Transfection of DNA into HeLa cells was performed using Fugene 6 reagent
(Roche) in accordance with the instructions of the manufacturer, typically
using 3 µl Fugene reagent and 1 µg of DNA per 6-well. HEK293 cells
were transfected by CaPO4 precipitation following established protocols
(Sambrook and Russel, 2001).
Selection was started 5 days after transfection. HeLa cells were
selected for four weeks with 0.5 µg/ml geneticin (G-418 sulfate; Gibco),
HEK293 cells with 1 µg/ml. Untransfected cells were treated at the side
as a control to verify that the treatment was working. No clonal selection
was carried out and no clonal cells were used in this study (because this
might have been a bias towards cells expressing the transgene at higher/
lower levels). For storage of cell lines, cells were frozen in fetal calf serum
containing 10% DMSO (Sigma) and stored in a liquid nitrogen tank.

siRNA-mediated gene silencing
For a list of the siRNAs used, see Table 2.4. siRNA duplices (20 µM or
100 µM) were stored at –80° C. For transfection with siRNAs, HeLa cells
were grown for one day in DMEM/FBS without antibiotics/antimycotics.
Transfection was carried out at 30-50% confluency in 24-well plates
with Oligofectamine (Invitrogen), using 60 pmol siRNA duplices and 3
µl Oligofectamine reagent per well. To optimize transfection efficiencies,
BLOCK-iT fluorescent oligos (Invitrogen) were used and transfected cells
analyzed by flow cytometry. Knock-down was analyzed by SDS-PAGE of
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whole-cell extracts and subsequent immunoblotting. Pilot experiments were
carried out to determine which time span of incubation after transfection
resulted in maximal knock-down (for HP1 protein: 3.5 d).

Table 2.4: siRNA oligos
Name

Sequence

Source

5’-AACGCGGCACUUCACAAUUGA-3’

Dharmacon
(Lampson and
Kapoor, 2005)

HP1 (5'-UTR)

5’-GGGACCUGGUGGCCUUAGUCUUUCA-3’

Dr. W. Fischle
(MPI Göttingen,
Germany)

HP1

5’-UGACACCAUAGAGGUGGCUUGAGAA-3’

Dr. W. Fischle

HP1

5’-GGUUACUUUGAACAAAUAA-3’

Qiagen

Aurora B

Cell synchronization by double thymidine block
To obtain a highly synchronized culture of HeLa cells, thymidine (2 mM
final concentration was added to the medium of cultures grown to 2030% confluency (first block). After 15 h, cells were washed with PBS,
fresh thymidine-free medium added and the cells grown for 9 h. Thymidin
was re-added 2 mM f.c.) for another 15 h (second block). To release the
second block, cells were washed in PBS and fresh thymidine-free medium
was added. Cell synchrony was checked by light microscopy, by western
blotting with mitotic markers, and by cell cycle flow cytometry.
Harvesting tissue culture cells
Cell were harvested commonly by scraping them off the plate with a cell
scraper. For highly enriched mitotic cells, mitotic shake-off was carried
out (i.e. rounded-up and detached mitotic cells were selectively pipetted
off the plate). If cells were to be analyzed for phosphorylation, phosphatase
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inhibitors (10 mM NaF, 2 mM Orthovanadate, 10 nM Calyculin A) were
added, then cells were collected by centrifugation (500 g/5 min). Cells were
washed once with PBS (including phosphatase inhibitors) and then flash
frozen in liquid nitrogen and stored at –80° C until further processing.
Whole cell extracts were generated by resuspending the cells in protein
sample buffer, heating the mixture for 5 min to 95° C, and subsequent
shearing the the DNA by sonication in a BioRuptor (Diagenode) for 5 min
at setting High.

Immunofluorescence staining and confocal microscopy
For analysis by immunofluorescence microscopy, tissue culture cells were
grown on cover slips in 24-well plates. Where indicated, cells were treated
with hesperadin (200 nM, in DMSO) for 1 h prior to fixation. Cells were
fixed with 3.7 % parafomaldehyde in PBS for 15 min and permabilized
with 0.2% Triton X-100/0.2% NP-40 in PBS. Where mentioned, the order
was reversed, and the cells were first extracted with 0.2% NP-40 for 5 min
and then fixed. Cells were blocked for 30 min in Blocking solution (PBS
with 2.5% bovine serum albumine, 10% normal goat serum, and 0.1%
Tween-20). Primary and fluorescently labelled secondary antibodies were
applied in Blocking solution for 1 h at RT/over night at 4° C (primary
antibodies) or for 30 min at RT (secondary antibodies), followed by three
washing steps with PBS containing 0.1% Triton X-100. DNA was stained
with DAPI (1 µg/ml in PBS; Sigma) for 30 seconds. The cover slips were
mounted onto microscope slides with Prolong Gold Antifade (Molecular
Probes). All steps were carried out at RT unless noted otherwise.
Stainings were analyzed on an inverted LSM 510 laser scanning confocal
microscope (Zeiss Axiovert 200) with a 63x/1.4 N.A. oil immersion lens
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using a pinhole diameter of 1 Airy Unit. Image capture and processing was
performed with the LSM 510 confocal software (Zeiss).

Cell cycle analysis and flow cytometry
Staining for cell cycle analysis was carried out following standard protocols
(Darzynkiewicz et al., 1999). Cells were detached by trypsinization, collected
by centrifugation (200 x g, 5 min), washed in PBS and resuspended to
about 106 cells per 0.5 ml PBS. Ice-cold 70% ethanol was added under
vortexing (to achieve a single cell suspension) and the cells were kept in
fixative for at least 2 h on ice. Cells were centrifuged (500 x g, 5 min), the
ethanol removed, and the cells washed in PBS. For staining of DNA, cells
were resuspended in Propidium iodide staining solution, consisting of
0.1% Triton X-100 in PBS with 0.2 mg/ml DNase free RNAse A (prepared
by boiling RNase A for 5 min; Sigma) and 20 µg/ml of propidium iodide
(Molecular Probes). After 30 min incubation at RT, the cells were analyzed
on a FACSCalibur Flow Cytometry System (Becton-Dickinson). Cell cycle
modelling was carried out with the software package FloJo (Tree Star)
using the Watson Pragmatic Model.

Biochemical methods
Gel electrophoresis
SDS-PAGE was carried out according to the protocol by Laemmli (Laemmli,
1970) with adaptions. Usually 12% or 15% Tris-glycine gels were used,
for peptides 15% Tris-tricine gels (Schagger and von Jagow, 1987; Strom
et al., 1993). Gel pouring and running was carried out with the Bio-Rad
minigel system. For samples intended for mass spectrometry, the Novex
precast system (Novagen) was used.
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Samples were boiled for 5 min in protein sample buffer (60 mM
Tris (pH 6.8) 10% glycerol, 2% SDS, 140 mM β-mercaptoethanol, 0.03%
bromophenol blue). Gels were run typically for 40 min at 200 V in SDSPAGE running buffer (25 mM tris base, 200 mM glycine, 0.1% SDS). Novex
gels were run according to manufacturer's instructions in the provided
MOPS or MES buffer systems. Gels were stained with Coomassie (10%
acetic acid, 50% methanol, 0.05% Coomassie R-250) and destained with
40% methanol/10% acetic acid.

Transfer of proteins to membrane and western blotting
Proteins separated by SDS-PAGE were transferred to PVDF membranes
(Immobilon-P Millipore) in a semi-dry system (Hoefer) using Towbin
buffer (192 mM glycine, 25 mM Tris-Cl, 0.1% SDS, 20% methanol, pH
8.0). Alternatively, proteins were transferred to PVDF or nitrocellulose
membranes by slot blotting, using the Bio-Dot SF microfiltration apparatus
(Bio-Rad) following the manufacturer’s instructions.
Transferred proteins were visualized by Amido black staining (0.1
% (w/v) amido Black, 40% methanol, 10% acetic acid). Membranes were
blocked for 1 h at room temperature TBS-milk, which is 5% non-fat dry
milk in TBS (20 mM Tris (pH7.6), 137 mM NaCl, 0.0015% phenol red).
After incubation with primary antibody (dilutions see Table 2.1) for 1 h
at RT, the membrane was washed three times for 5 min with TBS. The
membrane was incubated with the HRP-coupled secondary antibody (see
Table 2.2) in TBS-milk for 45 min at RT, and afterwards washed three
times with TBS. Blot were developed with the ECL plus chemiluminescence
detection system (Amersham Biosciences) and exposures were carried out
with BioMax film (Kodak).
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Peptide competitions
For peptide competition experiments in western blotting, antibodies were
preincubated in TBS-milk (20 mM Tris (pH7.6), 137 mM NaCl, 0.0015%
phenol red, 5% non-fat dry milk) with 2 µg/ml peptide, tumbling for 1 h
at room temperature. For peptide competitions in immunofluorescence
stainings, antibodies were preincubated with 2 µg/ml peptide in Blocking
solution (PBS with 2.5% bovine serum albumine, 10% normal goat serum,
and 0.1% Tween-20) for 1 h rotating at RT. Afterwards, the preincubated
antibodies were used for western blotting or immunofluorescence stainings,
respectively, following the usual procedure.

Expression of recombinant proteins in E.coli
For expression of recombinant proteins, the recombination-deficient
(and codon-optimized) E. coli strains BL21, RosettaBlue, and RosettaBlue(DE3)pLacI were used (see Table 2.3). A single colony from a plate was
used to inoculate a 50 ml culture of the respective bacterial strain in LB
including the respective antibiotic for selection, and the culture was grown
over night in a shaker-incubator (37° C, 250 rpm). The next morning, the
overnight culture was used to inoculate a 2 l culture of LB (37° C, 250
rpm). At an OD600 of about 0.6, the cells were induced with 1 mM IPTG
final concentration. After induction, cells were usually grown for another 3
to 5 h at 37° C. After harvesting the cells (6 000 rpm/10 min/4º C in SLA1500), the pellet was immediately frozen at –80° C.

Ni-NTA purification of His6-tagged proteins
The bacterial cell pellet was resuspended in 30 ml Lysis buffer (20 mM Tris
(pH 8.0), 300 mM NaCl, 0.1 mM MgCl2, 0.1 % Triton X-100, 2 mM imidazol,
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5 mM β-Mercaptoethanol, Complete EDTA-free protease inhibitor (Roche),
1 mM PMSF), and the cells were lysed on ice with an Emulsiflex-C5 cell
disrupter (10 000 psi, three passages). Insoluble cell debris was pelleted
(15 500 rpm/15 min/ 4º C in SS34), meanwhile Ni-NTA beads (nickel
nitrilotriacetic acid, Qiagen; 1 ml per 5 mg of expressed recombinant
protein) were equilibrated with 50 ml Lysis buffer. The soluble supernatant
of the disrupted cells was applied to the Ni-NTA beads and incubated
rotating for 20 min at 4º C. After three washes "in batch" with Lysis buffer
, the beads were transferred to a plastic chromatography column, washed
with 4 column volumes of Column Wash buffer (20 mM Tris (pH 8.0),
1 M NaCl, 0.1 % Triton X-100, 0.1 mM MgCl2, 30 mM Imidazol, 5 mM
β-Mercaptoethanol). The recombinant protein was eluted with 6 column
volumes of Elution buffer (20 mM Tris (pH 8.0), 300 mM NaCl, 0.1 mM MgCl2,
150 mM Imidazol, 5 mM β-mercaptoethanol), dialyzed against Dialysis
buffer (25 mM Tris (pH 8.0), 150 mM NaCl, 1 mM DTT) and concentrated
with Centricon centrifugal filter units (Millipore). Protein concentrations
were determined by absorbance spectroscopy using predicted extinction
coefficients. Proteins were stored at 4º C or shock frozen and stored at
–80° C.

Column chromatography
All protein purification chromatography with the exception of NiNTA purification was carried out on ÄKTA Purifier fast protein liquid
chromatography (FPLC) instruments (Amersham/GE Healthcare). Gel
filtration as a second purification step for GST-Aurora B was performed
with a Superdex 75 (Pharmacia; 20 mM imidazole (pH 8.0), 25 mM NaCl, 2
mM DTT). Separation of RNA from the recombinant HP1 hinge was carried
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out on a MonoS column (Amersham/GE Healthcare) with a linear gradient
from 50 mM KCl to 1 M KCl. Purity was routinely confirmed by SDS-PAGE
and Coomassie staining.

GST purification of Aurora B
GST-tagged recombinant Aurora B was prepared by GST purification
according to the protocol from Dr. Ciaran Morrison, National University
of Ireland, Galway. All steps of the procedure were carried out at 4° C.
Briefly, bacterial cells were lysed in Lysis buffer (50 mM Tris (pH 8.0), 150
mM NaCl, 50 mM EDTA, 1 mM DTT, 10% glyerol, 1 mM PMSF) with an
Avestin EmulsiFlex C5 cell disruptor (three passages). Insoluble cellular
debris was removed by centrifugation (15 500 rpm, 15 min, SS34 rotor).
The supernatant was applied to Glutathione Sepharose (Fast flow 4B,
Amersham/GE) and incubated on a rotator for 1.5 h. Unbound proteins
were washed off (four washes with Lysis buffer), transferred into a plastic
column (Bio-Rad) and eluted with Elution buffer (50 mM Tris (pH 8.0), 150
mM NaCl, 10 mM EDTA, 1 mM DTT, 10% glycerol, 25 mM GSH (reduced
glutathione), 1 mM PMSF). The eluate was eluted over night against 50%
glycerol/50% XBE2 (10 mM K-HEPES (pH 7.7), 50 mM sucrose, 100 mM
KCl, 2 mM MgCl2, 0.1 mM CaCl2, 2 mM K-EGTA, pH adjusted to 7.9). After
protein concentration with a Centricon centrifugal filter units (Millipore),
aliquots were flash frozen in liquid nitrogen and stored at –80° C.

Acid extraction
Cells were lysed by resuspending them directly in 0.2 M H2SO4 and agitated
on a rotator for 1 h at 4° C. Insoluble matter was pelleted by centrifugation
and the soluble proteins were precipitated by adding trichloroacetic acid
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(TCA) to a final concentration of 25%. After 1 h incubation on ice, proteins
were collected by centrifugation, washed once with acetone containing
0.1% HCl, a second time with pure acetone, and dissolved in a buffer for
further processing or dried and stored at –80° C.

Preparation of Dignam extracts
Nuclear extracts for peptide pull-downs with the HP1α (83-101) S92ph
peptide were prepared following the procedure by Dignam and colleagues
(Dignam et al., 1983). All steps were carried out at 4° C and protease
inhibitors (Complete protease inhibitor cocktail, Roche) and phosphatase
inhibitors (10 mM NaF, 5 mM Orthovanadate, Calbiochem Phosphatase
Inhibitor Cocktail Set I [final concentrations

25 µM Bromotetramisole

oxalate, 5 µM Cantharidin, 5 nM Microcystin-LF]) were used in all
buffers.
The cell pellet was resuspended in 5 PV (pellet volumes) of buffer
A (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, pH 7.9) and
incubated on ice for 5 min to swell the cells. Then the cells were collected
by centrifugation (750 rpm, 10 min), the supernatant was removed and
the cells resuspended in 2 PV buffer A. Cell lysis was carried out with
a Dounce homogenisator (pestle B) with 15 to 20 strokes. Nuclei were
collected by centrifugation (1500 rpm, 7 min), and the supernatant flash
frozen in liquid nitrogen (cytosolic fraction). The nuclei were resuspended
in 4 ml buffer B (20 mM HEPES, 25 % (v/v) glycerol, 45 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, pH 7.9) and broken by another round
of douncing in this buffer. The suspension was centrifuged at 25000 x g
for 30 min. The supernatant was dialyzed against buffer C (50 mM TrisCl, 120 mM NaCl, 0.5 mM EDTA, 0.1% NP-40, 0.5 mM DTT, 1 mM PMSF,
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pH 7.5) for 5 h. Aliquots were flash frozen in liquid nitrogen and stored at
–80° C until further use.
Alternative biochemical fractionation of cells
As an alternative to the Dignam protocol, the procedure of Mendez and
Stillman was used to fractionate cells (Mendez and Stillman, 2000). All
steps were carried out on ice and phosphatase inhibitors were included
in all buffers (10 nM Calyculin A, 10 mM NaF, 5 mM Orthovanadate,
Calbiochem Phosphatase Inhibitor Cocktail Set I [final concentrations 25
µM Bromotetramisole oxalate, 5 µM Cantharidin, 5 nM Microcystin-LF]).
HeLa cells (5⋅108 cells) were resuspended in 25 ml of Buffer A (10 mM
HEPES (7.9), 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol)
including 0.2% NP-40 and incubated for 7 min on ice to lyse the cells.
Cell nuclei were pelleted with a low-speed spin (1500 rpm, 5 min, in
Eppendorf 5810R table-top centrifuge). While the supernatant (Cytosolic
fraction) was transferred to a new tube and the salt concentration was
adjusted to 250 mM NaCl, the nuclei were washed once with Buffer A
(without NP-40) and then disrupted by resuspending them in 25 ml NoSalt
buffer (3 mM EDTA, 0.2 mM EGTA). The nuclei were incubated for 30
min on ice, interrupted by occasional vortexing. By centrifugation (3000
rpm, 5 min, in Eppendorf 5810R), chromatin was collected as the pellet.
The supernatant (soluble nuclear fraction and proteins stripped off the
chromatin with NoSalt buffer) was adjusted to 250 mM NaCl. To solubilize
most chromatin-bound proteins, the chromatin pellet was extracted with 5
ml HighSalt solubilization buffer (50 mM Tris (8.0), 2.5 M NaCl), vortexed,
and chromatin sheared with a BioRuptor sonicator (Diagenode) for 10 min
at setting High. Unsolubilized material was pelleted (4000 rpm, 5 min) and
the supernatant (solubilized chromatin proteins) diluted down to 250 mM
NaCl.
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Peptide pull-down
Peptide pull-downs were carried out as previously described (Wysocka,
2006; Wysocka et al., 2005). Typically, 100 µg of biotinylated peptide
in PBS were prebound to 400 µl of avidin-coated beads (Pierce) for 5 h
at 4° C with rotation. Unbound peptide was removed by three washes
with PBS/0.1% Triton X-100. Immobilized peptides were incubated with
cellular extracts for 3 h at 4° C. Beads were washed (six washes with
Washing buffer (20 mM HEPES (pH 7.9), 150 mM KCl, 20% v/v glycerol,
0.2 mM EDTA, 0.1% Triton X-100). For more or less stringent washing, 3
washes with 300 mM or 50 mM KCl were carried out, respectively. In case
phosphorylated peptides were used, phosphatase inhibitors (10 mM NaF, 5
mM Orthovanadate, Calbiochem Phosphatase Inhibitor Cocktail Set I [final
concentrations

25 µM Bromotetramisole oxalate, 5 µM Cantharidin, 5

nM Microcystin-LF]) were included at all steps,. Protease inhibitors (Roche
Protease inhibitor cocktail and 1 mM PMSF) were included from the point
of adding the cellular extract. Peptides and bound proteins were eluted
by boiling the beads in protein sample buffer. Samples were run on SDSPAGE gels and stained with Coomassie or by silver staining (SilverSnap
Staining Kit, Pierce).

Anti-FLAG immunoprecipitation of tagged HP1 constructs /
Immuno-precipitation of endogenous HP1
Immunoprecipitation of exogenous, Flag-tagged HP1 proteins expressed in
HeLa cells was carried out with anti-Flag M2 beads (Sigma). Phosphatase
inhibitors were included in all buffers (10 mM NaF, 2 mM Orthovanadate,
10 nM Calyculin A). Beads were washed twice in Wash buffer (50 mM TrisCl,pH 8.0, 150 mM NaCl, 0.05% NP-40), then the beads were incubated
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with the extracts (Cytosolic, NoSalt-soluble and HighSalt-soluble) for
45 min at 4° C. Beads were washed three times with 1M-Wash buffer
(50 mM Tris-Cl, pH 8.0, 1 M NaCl, 0.1% NP-40), brought down in Wash
buffer to a volume of 1 ml, spun down again and resuspended in Storage
buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl). Aliquots were taken during
the whole procedure and the different steps subsequently analyzed by
western blotting. Samples were shock frozen in liquid nitrogen, stored at
–80° C, shipped to the Hunt lab on dry ice and analyzed there by mass
spectrometry.
Immunoprecipitation of endogenous HP1 isoforms was carried
out essentially by the same procedure, with a few minor differences:
monoclonal HP1 antibodies (HP1α: MAB3584, HP1β: MAB3448, HP1γ:
MAB3450 (Chemicon)) were immobilized on magnetic sheep-anti-mouse
beads (M280 Sheep-anti-mouse IgG, Dynal Biotech). During washes, beads
were collected not by centrifugation, but with a magnet.

RP-HPLC
Separation of acid extracted proteins was carried out by RP-HPLC
(reversed-phase HPLC) on a C8 column (220 x 4.6 mm Aquapore RP-300
(PerkinElmer) or Vydac 208TP510). A linear gradient of 35-60% solvent
B (solvent A: 5% acetonitrile, 0.1% trifluoroacetic acid; solvent B: 90%
acetonitrile, 0.1% trifluoroacetic acid) was applied over 75 min at 1.0 ml/
min flow-rate on a Beckman Coulter System Gold 126 Pump Module and
166/168 Detector. Peptides were purified by a similar procedure on a C18
column. Fractions were subsequently lyophilized and stored at –80° C.

73

In vitro kinase reactions and analysis
Kinase reaction with H3 peptides (1-5 µM) or recombinant HP1 proteins
(500 ng) were typically carried out in a 50 µl volume of Kinase Buffer (15 mM
MOPS (pH 7.2), 30 mM MgCl2, 25 mM NaCl, 10 mM β-glycerolphosphate,
2 mM EGTA, 1 mM DTT) with 150 µM ATP and 2-3 μCi [γ-32P]-ATP. 5
µl of immunoprecipitated chromosomal passenger complex (CPC) (kindly
provided by Boo Shan Tseng, Funabiki Laboratory, Rockefeller University),
100 ng of commercial recombinant kinases (MSK1, RSK2, IKKα; UBI/
Millipore), or 2 µg of recombinant Aurora B kinase (own preparation) were
used. Where indicated, hesperadin was added at a final concentration of 4
µM. Reactions were stopped after 60-90 min by adding acetic acid to 30%
(v/v) and then either run on 15% Tris-Glycine or 20% Tris-Tricine gels for
analysis by autoradiography or analyzed by filter binding assay.
For filter binding assays, the reaction mixture was spotted onto P81 filter
paper (Whatman). The filter paper was washed three times with 0.75%
phosphoric acid, once with acetone, dried and then analyzed by scintillation
counting on the 3H-channel [sic] in a Beckman LS6000IC scintillation
counter.
For non-radioactive kinase reactions with fluorescinated peptides, 100 nM
peptide, 1 mM ATP and 10 μl CPC were used. The reactions were stopped
with a final concentration of 0.5% (v/v) trifluoro acetic acid and peptides
were analysed by MALDI-TOF mass spectrometry.

"Bioinformatics" methods
Alignments were generated with ClustalW (at www.ebi.ac.uk/ Tools/
clustalw2), graphic depictions of alignments with Boxshade (at http://
mobyle.pasteur.fr).
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Kinase predictions were carried out with the Group Based Prediction
System (Xue et al., 2008). Depiction of crystal structures were generated
with PyMol (DeLano, 2008). Extinction coefficients for recombinant proteins
were calculated from their amino acid sequence using the ProtParam tool
(ExPASy, http://ca.expasy.org).

Other methods
Fluorescence anisotropy binding measurements
Fluorescence anisotropy binding assays were typically performed in a 100
µl volume of 20 mM imidazole (pH 8.0), 25 mM NaCl, 2 mM DTT, and 100
nM fluorescein-labelled peptide (Jacobs et al., 2004). Measurements were
made on a Plate Chameleon multilabel counter (Hidex), and fluorescence
polarization (P) values were converted to anisotropy (A) values by the
equation A = 2P / (3-P). For the analysis of binding curves, non-linear leastsquares fitting of the data was carried out with the software KaleidaGraph
(Synergy Software) using the equation A = [Af - (Ab-Af)]⋅[protein] / (Kd +
[protein]) where Af and Ab are the anisotropy values of the free and bound
peptides, respectively.

Mass spectrometry
Mass spectrometry analysis of HP1 proteins was carried out by Hillary
Montgomery (Hunt lab, University of Virginia). Analysis of peptides was
carried out by MALDI-TOF mass spectrometry on a Voyager RP STR
instrument (ABI) in linear mode using hydroxy cinnamic acid as matrix.

Phage display screen
The phage display screen for proteins binding to HP1α in a manner
dependent on HP1α S92 phosphorylation was carried out with the T7Select
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system (Novagen). This screen was carried out by myself in the laboratory
of Dr. Wolfgang Fischle (Goettingen, Germany).
Two commercially available cDNA phage libraries (T7Select Human
Liver cDNA Library and T7Select Human Brain cDNA Library, Novagen)
were used. Upon amplification of the libraries, an aliquot of the liver
library was supplemented with a T7 phage with the HP1α gene cloned into
it (kindly provided by Henriette Franz, Fischle lab) in a 1:106 dilution, to
serve as a positive control in the screen. For amplification of T7 phages,
BLT5403 E. coli cells grown in TB (12 g bacto tryptone, 24 g yeast extract,
4 ml glycerol, 2.31 g KH2PO4 and 12.54g K2HPO4 per 1000 ml) were used.
Phage concentration was determined by plaque assay (a diluted aliquot of
the phage-containing solution was mixed with uninfected E. coli bacteria,
plated, and incubated over night at 37° C; plaques of killed bacteria were
counted the next day and phage titers calculated).
Biotinylated HP1α peptides (83-101, unmodified and phosphorylated
at serine 92) and histone H3 peptides (1-20, unmodified and tri-methylated
at lysine 9) were immobilized on avidin beads (Pierce). For the biopanning
selection procedure, the phage mixture was incubated with the beads for
2 h rotating at 4° C. Unbound phage was washed off (three washes with
PBS including 0.05% Tween-20). During all these steps, buffers included
25 mM NaF and 25 mM β-glycerolphosphate as phosphatase inhibitors.
Phages selected in the pull-down were amplified by adding the beads with
bound phages to a 50 ml culture of BLT5403 bacteria and growing the
culture over night at 37° C. Phages obtained from this amplification were
used for the next round of biopanning selection. Five rounds of biopanning
were carried out.

76

For a qualitative analysis of the selection procedure, a PCR reaction
was carried out with (template: aliquots from the phage solution taken at
each round of selection; primers" specifically designed to anneal at the 5’and 3’-ends of the phage insert).

Electrophoretic mobility-shift assay (EMSA)
Electrophoretic mobility-shift assays (EMSA) were carried out as
described (Akhtar et al., 2000). Briefly, single-stranded probe RNA was
in vitro transcribed with the MEGAscript T7 Kit (Ambion) using a 500
nucleotide fragment of the human cyclin E gene as template. The RNA
was radioactively labeled by 5’-end-labeling with T4 Polynucleotide kinase
(NEB) and [γ-32P]ATP and purified with the RNeasy kit (Qiagen). Binding
reactions were carried out in 20 µl of Binding Buffer (20 mM HEPES (pH
7.6), 100 mM KCl, 2 mM EDTA, 0.01% NP-40, 1 mM DTT) including 20 U
RNasin Ribonuclease inhibitor (Promega), 10,000 cpm labelled RNA (about
1 pmol). Reactions were incubated for 30 min on ice, and then run on a
4% native 0.5x Tris-borate-EDTA gel (prerun for 30 min at 100V at RT) for
3 h at 250 V at 4° C. Data was imaged with a FLA-5000 phosphorimager
(Fujifilm).
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Chapter 3
Regulation of the chromatin association
of HP1 through phosphorylation of
histone H3: "Methyl-phos switching"
Introduction
In recent years, it has become increasingly clear that dynamic changes in
chromatin structure actively regulate all kinds of DNA-dependent processes,
ranging from transcription and mitotic chromosome condensation to
DNA-repair and apoptosis (Felsenfeld and Groudine, 2003). Functions
of chromatin are controlled, among other ways, by posttranslational
modifications of N-terminal histone tails (Kouzarides, 2007; Peterson
and Laniel, 2004). These modifications can serve as binding sites for the
recruitment of modification-specific binding proteins (effectors), which
then direct downstream functions (de la Cruz et al., 2005; Strahl and Allis,
2000).
Recruitment of binding partners to chromatin is often dynamic, and
the ability to release effector proteins from their binding site enables the cell
to react to changes in environmental cues (Felsenfeld and Groudine, 2003).
In many cases, reversibility is achieved efficiently by the enzymatic removal
of relatively short-lived posttranslational modifications. For example,
removal of histone acetylation can be achieved by histone deacetylases
(Keogh et al., 2006; Sterner and Berger, 2000). Alternatively, histone tails
can be clipped proteolytically (Allis et al., 1980; Duncan et al., 2008) or even
the complete histone can be replaced (Ahmad and Henikoff, 2002). What
all these mechanisms have in common is that they result in elimination of
the posttranslational modification that recruits the effector.
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However, there are also situations where a histone modification
appears to be more stable, yet dynamic behaviour of an effector protein is
nevertheless observed. This suggests the existence of other, so far unknown
mechanisms to control the release of effector proteins from their binding
sites at chromatin.
One such case where an effector protein dissociates from its binding
site at chromatin, while the histone mark persists, is the mitotic release of
Heterochromatin protein 1 (HP1).
HP1, an effector protein with important functions in heterochromatin
formation and gene silencing, is recruited to chromatin by histone H3
methylation at lysine 9 (H3K9me) (Bannister et al., 2001; Lachner et al.,
2001). In interphase cells, HP1 is tightly associated with chromatin. At
the onset of mitosis, however, the protein is released from its binding site
at H3K9me (see Introduction, Figure 1.10; Hayakawa et al., 2003; Minc
et al., 1999; Schmiedeberg et al., 2004), even though the methyl-mark it
binds to is not reduced. Although this phenomenon has been observed
for years (Bannister et al., 2002), the mechanism of this dissociation was
completely unknown.
In this chapter, I describe experiments that I carried out in
collaboration with a postdoctoral fellow in the Allis laboratory, Dr. Wolfgang
Fischle, to elucidate the mechanism of HP1 release from chromatin during
mitosis. Other key experiments, using the Xenopus cell-free system, were
carried out in collaboration with the laboratory of Dr. Hironori Funabiki
(data not presented in this thesis). In a combination of biophysical in vitro
and in vivo immunofluorescence experiments, we show that the mitotic
release of HP1 from chromatin is mediated by histone H3 phosphorylation,
thus implicating histone H3 phosphorylation in the regulation of HP1
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chromatin association. Our findings define a novel mechanism to regulate
binding of an effector protein, "methyl-phos switching", in which two
modifications work together to bring about dynamic control of binding to a
histone mark, with far-reaching implications, inside as well as outside of
the realm of chromatin.

Results
HP1 is released during mitosis, even though the H3K9me3 mark
persists
We began our investigation into HP1’s chromatin association by reproducing
the observation that HP1 is released from chromatin, while the H3K9me3
mark persists (Bannister et al., 2002; Kellum et al., 1995; Minc et al., 1999).
Immunofluorescence microscopy (IF) of mouse fibroblast cells (Figure 3.1A)
clearly shows that HP1 dissociates from chromatin in mitosis, while the
H3K9me3 signal is still observed at the DNA.
To analyze the levels of the H3K9me3 mark throughout the cell-cycle
in a more quantitative way, we carried out western blotting experiments.
Comparison of asynchronously growing HeLa cells with cells arrested in
mitosis by nocodazole treatment clearly shows that the overall level of
H3K9me3 in the cell does not change at the different stages of the cell
cycle (Figure 3.1B).
Taken together, the IF and immunoblotting experiments confirm
that HP1 is released during mitosis from chromatin, even though the
mark that is largely responsible for its recruitment, H3K9me3, remains
unchanged. Naturally, this finding raises the puzzling question of how an
effector protein like HP1 can be released, when the histone mark mainly
responsible for its recruitment is stable.
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Figure 3.1: HP1 dissociates from chromatin during mitosis, even though the
H3K9me3 mark persists (in collaboration with Dr. Wolfgang Fischle).
3.1
A: Immunofluorescence microscopy of mouse 10T1/2 fibroblast cells. In
interphase, HP1β localizes to dot-like structures throughout the cell nucleus that
coincide with H3K9me3 and DAPI-dense regions, indicating HP1's association
with pericentric heterochromatin Maison and Almouzni, 2004. In mitosis, HP1β
is dispersed throughout the cytoplasm, while the H3K9me3 signal still overlaps
with the DNA aligned in the metaphase plate. Similar observations were made
for HP1α and HP1γ. Overlay generated from HP1β and H3K9me3 channels. Scale
bar, 10 µm.
B: Immunoblotting of extracts obtained from asynchronously growing (Interphase)
or nocodazole-arrested (Mitosis) HeLa cells. Acid-extracted histones (H3K9me3,
H3S10ph and H3 blots) or total cell extracts (HP1β blot) were treated with or without
alkaline phosphatase and then analyzed by western blotting. The H3S10ph signal
confirms the enrichment for mitotic cells upon nocodazole arrest. No significant
changes in the global H3K9me3 levels or in the expression of HP1β through the
cell cycle are observed (similar results obtained for HP1α and HP1γ).
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The Binary Switching Hypothesis
To explain this enigma of effector protein release from a stable histone
mark, Drs. Fischle and Allis proposed a novel mechanism for how
cells might control binding of effector proteins to posttranslational
modifications. According to their "Binary Switching" hypothesis (Fischle
et al., 2003a), dynamic regulation of the read-out of a stable histone mark
can be achieved through an adjacent reversible modification. Addition of
the reversible modification would interfere with the binding of the effector
protein and thus releases the effector from its binding site. Removal of the
reversible modification, on the other hand, would allow the effector protein
to reassociate (Figure 3.2).
How could such a binary switch be constructed in the specific case
of H3K9me3 and HP1? H3K9me3 might form a "methyl-phos switch"
by collaborating with the adjacent phosphorylation of H3 at serine 10
(H3S10ph), a mitotically robust histone mark that has been known for
years (Hendzel et al., 1997).
H3S10 phosphorylation is a very prominent mark in all eukaryotic
cells during mitosis, when it is observed globally and on all chromosomes
(Hsu et al., 2000; Kaszas and Cande, 2000; Van Hooser et al., 1998; Wei
et al., 1998; Wei et al., 1999). In fact, due to its abundance serine 10
phosphorylation has been used widely as a general marker for mitosis.
However, although this mark and the enzymes responsible for its steadystate balance have been characterized quite well, the biological role of this
modification is still elusive (Hsu et al., 2000; Prigent and Dimitrov, 2003;
Wei et al., 1999). According to the binary switching theory, at least one of
the biological functions of serine 10 phosphorylation in mitosis might be
to regulate binding of the effector protein HP1 to H3K9me, a process that
we refer to as "methyl-phos switching".
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Figure 3.2: The Binary Switching Hypothesis.
According to the Binary Switching Hypothesis Fischle et al., 2003, dynamic readout of a stable histone mark can be achieved through an3.2
adjacent reversible
modification. A stable modification S (blue circle) serves as a binding site to recruit the effector protein X. Addition of the reversible modification R (pink pentagon) immediately adjacent to the stable modification sterically interferes with
the binding of X to the stable modification and therefore causes the release of
the effector protein. Upon removal of the reversible modification, the effector X
can reassociate with its binding site. Together the two modifications work like a
switch for the recruitment and release of a specific binding protein. Such switches are possible for various combinations of modifications, such as "methyl-phos",
"acetyl-phos", or "methyl-acetyl" switches.

Several observations suggested to us that this might indeed be the
case. Firstly, we had evidence for the existence of the dual modification mark
H3K9meS10ph in vivo through mass spectrometry. In collaboration with
the laboratory of Dr. Donald Hunt (University of Virginia, Charlottesville),
Dr. Fischle had examined the modification profile of histones obtained
from mitotic HeLa cells. This had led to the identification of a novel
dual modification mark, where lysine 9 methylation and serine 10
phosphorylation are present at the same time on one and the same H3 tail
(H3K9me1S10ph, H3K9me2S10ph, and H3K9me3S10ph).
Secondly, Dr. Fischle had validated the identification of this novel dual
histone mark through an independent method. After raising an antiserum
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that specifically recognizes the dually-modified H3K9me3S10ph epitope,
western blotting confirmed that the dual-mark epitope is specifically
detected on histones of mitotic cells, while it is not found in histones
purified from asynchronously growing cells.

(W55)

E56

N

C

S10

Figure 3.3: Binding of the HP1 chromo domain to H3K9me3 is likely to be
impaired by the presence of H3S10ph.

3.3

Crystal structure of the Drosophila melanogaster HP1 chromo domain (23-76)
interacting with the H3 tail tri-methylated at K9 (Jacobs and Khorasanizadeh,
2002). Peptide in yellow, K9me3 and S10 shown in detail, Cβ of serine 10 in green.
Left: Electrostatic surface charge rendering of the HP1 CD (negative charge in
red, positive charge in blue) interacting with an H3K9me3 tail peptide. H3 serine
10 is close to a negative patch of the CD. From this depiction it is evident that
phosphorylation of serine 10 will lead to steric interference with the CD, as well
as repulsion between the negative charge of the phosphate and the negative patch
of the CD. Right: Ribbon depiction of the HP1 CD interacting with an H3K9me3
tail peptide. The three caging residues of HP1 that coordinate trimethyl-K9 of H3
are shown in purple. H3 serine 10 undergoes multiple hydrogen bonds with glutamate 56 and a carbonyl group of the HP1 backbone (W55). Phosphorylation of
S10 would prevent formation of this network of hydrogen bonds. The sum of these
effects (steric hindrance, electrostatic repulsion, and loss of hydrogen bonds) is
likely to abolish the interaction between the H3 tail and the HP1 chromo domain
upon phosphorylation of H3 serine 10.
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Thirdly, a close examination of the co-crystal structure of the HP1
chromodomain bound to a methylated H3 tail peptide (Fischle et al.,
2003b; Jacobs and Khorasanizadeh, 2002; Nielsen et al., 2002) revealed
that serine 10 phosphorylation was likely to interfere with chromodomain
binding by effects of steric hindrance, electrostatic repulsion, and loss of
hydrogen bonds (see Figure 3.3).
Taken together, these observations all pointed in the direction
that dissociation of HP1 from chromatin during mitosis might indeed be
achieved by a binary switching mechanism involving the H3K9me3S10ph
dual mark.

Reduced binding affinity of HP1 to H3K9me3S10ph peptides in vitro
As a first test of this hypothesis, we attempted to verify the prediction from
the co-crystal structure that HP1 binding to H3K9me3 would be affected
by the presence of adjacent serine 10 phosphorylation. In in vitro binding
experiments by fluorescence anisotropy, we compared HP1 binding to
a singly modified H3K9me3 peptide with binding to a peptide carrying
the dual modification (H3K9me3S10ph). These experiments revealed
that binding of HP1β to a dually modified H3K9me3S10ph peptide is
significantly weaker than binding to a H3K9me3 peptide (Figure 3.4).
Similar measurements were also made for the chromo domains of the
other human HP1 isoforms and for full-length HP1 proteins (Table 3.1),
therefore confirming that binding of HP1 to methylated lysine 9 is indeed
impaired by phosphorylated serine 10.
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Figure 3.4: The binding affinity of the HP1β chromo domain to methylated
H3 peptides is significantly reduced by the presence of serine 10 phosphorylation.
Binding curves determined by fluorescence anisotropy for interaction of the HP1β
chromo domain with the indicated peptides. The HP1β chromo domain binds to
a H3 (1-20) K9me3 peptide with the expected binding affinity in the low micromolar range (red plot). The interaction with a dually modified peptide H3 (1-20)
K9me3S10ph was significantly weaker (> 500 µM; blue plot). (The Kd can be estimated from this graph as the concentration of HP1β CD for which the Fraction
bound is 0.5.)
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Table 3.1: Dissociation constants (Kd) for the binding of human HP1
chromo domains to different H3 peptides (data generated by Dr. Wolfgang
Fischle)
H3 unmodified

H3K9me3

H3K9me3S10ph

HP1 CD

> 500

13 ± 3

> 500

HP1 CD

> 500

3±1

360 ± 60

HP1 CD

> 500

7±2

500 ± 100

FL-HP1

> 500

18 ± 4

> 500

FL-HP1

> 500

6±1

450 ± 80

FL-HP1

> 500

7±2

> 500
(values in μM ± s.d.)

Even though Kd values for the interaction of HP1 proteins with H3K9me3S10ph
are not quite as low as for the unmodified H3 peptide, they are two orders of
magnitude lower than for H3K9me3. Note that dissociation constants greater
than 500 μM cannot be determined by this assay. H3 peptides: residues 1-20.
CD: chromo domain. FL: full-length.

Reconstitution of the release mechanism in the test tube
While these results were encouraging, simple measurement of binding
affinities does of course not at all reproduce the dynamic environment
within the cell. Here, serine 10 would have to be phosphorylated by a
kinase, while the neighboring H3K9me3 is engaged by HP1, and this
phosphorylation would subsequently result in the release of the effector
protein.
We realized that it would be almost impossible to tease apart the
molecular mechanism of mitotic HP1 release directly by in vivo experiments.
Redundancy among H3 genes (about a dozen in human cells, Marzluff
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et al., 2002) and the enormous complexity of the cellular events during
mitosis makes it very difficult to obtain more than correlative data in this
question from the tissue culture system. Therefore, we decided to pursue
an extreme reductionist approach, trying to reconstitute the complete
release mechanism of HP1 with purified components in the test tube.

Identification of kinases capable of phosphorylating H3S10 in the
presence of H3K9 methylation
As a first step towards this reconstitution, I sought to identify conditions
for efficient and specific in vitro phosphorylation of H3 peptides. The
mammalian kinase responsible for mitotic phosphorylation of histone H3 at
serine 10 is Aurora B kinase, a component of the Chromosomal Passenger
Complex (CPC) (Hsu et al., 2000; Vagnarelli and Earnshaw, 2004). However,
it had been reported that Ipl1, the homolog of Aurora B in S. cerevisiae, is
not capable of phosphorylating H3 in vitro, if lysine 9 is methylated (Rea
et al., 2000). I therefore tested not only recombinant Aurora B kinase for
its ability to phosphorylate H3 serine 10 in vitro, but also several other H3
kinases, such as IKKα (IκB kinase α), MSK1 (Mitogen- and stress-activated
kinase 1), and RSK2 (Ribosomal S6 kinase 2), that have been reported to
phosphorylate serine 10 at specific genomic loci upon immediate early
gene activiation (Anest et al., 2003; Sassone-Corsi et al., 1999; Strelkov
and Davie, 2002).
To my surprise, all these kinases were capable of phosphorylating
H3 peptides methylated at lysine 9 in radioactive in vitro kinase assays
(Figure 3.5). Phosphorylation by recombinant Aurora B (even though
with a rather low specific activity) was rather unexpected in light of the
published findings on Ipl1 (Rea et al., 2000). We therefore compared the
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activity of Aurora B on unmodified and methylated H3 peptides directly.
Both peptides were phosphorylated by recombinant Aurora B with almost

103 cpm

identical efficiency (Figure 3.6A).

Figure 3.5: Phosphorylation activity of different H3 serine 10 kinases on
methylated H3 peptides (In vitro kinase assays).

3.5

Radioactive in vitro kinase assay with different recombinant kinases. Phosphorylation of H3 peptides methylated at K9 (residues 1-15, 3 µM) was determined in
filter binding assays by scintillation counting.
All four kinases tested were able to phosphorylate the positive control, recombinant H3 (2 µg; the high levels of phosphorylation observed for Aurora B are
probably caused by Aurora B's ability to phosphorylate full-length H3 on multiple
sites). The specific activity of recombinant Aurora B kinase is much lower than
that of MSK1 and RSK2 (amounts of enzyme used in this experiment: 3 µg of
Aurora B, 100 ng of IKKα, MSK1, RSK2). Aurora B, MSK1 and RSK2 also show
significant activity on H3K9me3 peptides (in other experiments, a weak activity
of IKKα on H3K9me3 peptides was detected as well). The H3K9me3S10A control
proves that the phosphorylation of the peptides is specific for serine 10. Recombinant IKKα, MSK1, RSK2 from UBI, recombinant Aurora B from own purification.

89

B

rec. Aurora B

%

103 cpm

A

C



Unmod
K9me3

Xenopus CPC

%

103 cpm

D

Time [min]

Figure 3.6: In vitro phosphorylation of methylated H3 peptides.
3.6
A: Radioactive in vitro kinase assay to determine the activity of recombinant
Aurora B on unmodified and K9me3 H3 peptides (1-15). The methylated H3 peptide
is phosphorylated almost as well as the unmodified peptide. Comparison of the
K9me3S10A reaction with the No peptide control (---) reveals exquisite specificity
of the peptide phosphorylation for serine 10; the low levels of background phosphorylation are mostly caused by autophosphorylation of the kinase.
B: Quantitative comparison of in vitro phosphorylation of different H3 peptides
(1-15) by recombinant Aurora B (n=3; error bars indicate s.d.). Reactions were
evaluated by filter binding assay and scintillation counting. Counts were corrected
for background and exact peptide concentration (quantitative mass spectrometry),
and normalized to the unmodified H3 peptide (100%). Unmodified H3 peptides and
peptides mono-, di-, and tri-methylated at K9 are all phosphorylated by Aurora B
with similar efficiencies in vitro. Phosphorylation of H3 serine 10 by the CPC is thus
not inhibited by K9 methylation.
C: Reaction kinetics (radioactive filter binding assay) of the phosphorylation of unmodified and K9-methylated H3 peptides (1-15) by Aurora B. Values corrected for
autophosphorylation of the kinase and background peptide phosphorylation. The
unmodified (blue) and H3K9me3 (red) peptide are phosphorylated with very similar
kinetics (n=3, error bars show s.d.).
D: Similar experiment as in panel B carried out with the Chromosomal Passenger
Complex immunoprecipitated from Xenopus egg extracts (provided by Boo Shan
Tseng, Funabiki laboratory, Rockefeller University). Again, unmodified and mono/
di/tri-methylated H3 peptides are phosphorylated with very similar efficiencies.
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Rea and colleagues had used dimethylated H3 peptides (Rea et
al., 2000), while I used trimethylated peptides. Although an effect of this
difference would be unexpected, I directly compared the phosphorylation
of H3 peptides with different stages of K9 methylation. To make sure my
measurements of peptide concentration were not affect by degraded peptide
(photometric measurement through a tyrosin added to the C-terminal end
of the peptides), the exact peptide concentrations was determined in these
experiments by quantitative mass spectrometry. Once again, my results
showed that peptides of all methylation stages are phosphorylated by
Aurora B about equally well (Figure 3.6B).
The discrepancy between my findings with mammalian Aurora B
and the published observations with the yeast homolog could be explained
by an effect of reaction kinetics: If phosphorylation of unmodified and
methylated H3 peptides proceeds at a very different rate, then samples
taken at an early time-point will show quite different phosphorylation
levels; the end point of the reaction, however, would in both cases be a
fully phosphorylated peptide. I therefore carried out an experiment that
followed the kinetics of the peptide phosphorylation by Aurora B kinase
(Figure 3.6C). Unmodified H3 peptide and H3K9me3 peptide were found to
be phosphorylated with almost identical kinetics.
Aurora B phosphorylates peptides of all methylation stages equally
well, and no differences were observed in the phosphorylation kinetics
of unmodified and K9me3 H3 peptides. Thus, it seems that the observed
differences between mammalian Aurora B and its yeast homolog Ipl1 in
their ability to phosphorylate serine 10 in the presence of K9-methylation
are probably a real distinction between these enzymes rather than an
artifact of the experimental conditions. It should be noted that S. cerevisiae
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chromatin does not have H3K9 methylation (Briggs et al., 2001). Thus, it is
possible that the mammalian kinase or the complex that it resides in (see
below) has acquired the ability to phosphorylate serine 10 in the presence
of K9 methylation, while its yeast homolog has not.
While recombinant Aurora B kinase was capable of phosphorylating
H3 peptides, the specific activity was extremely low. In particular
recombinant MSK1 showed similar site specificity and phosphorylated
all methylation stages equally well, but with a much (about 100-fold)
higher specific activity, making MSK1 the most efficient serine 10 kinase
for H3K9me3 peptides among all enzymes tested. Since an in vitro test of
the "methyl-phos switching" mechanism of course represents an artificial
system anyway and the higher activity of MSK1 might be quite helpful for
a principal test of the feasibility of binary switching, we decided to also
proceed with this kinase.
We subsequently found that the Chromosomal Passenger Complex
immunoprecipitated from Xenopus egg extracts (kindly provided by Boo
Shan Tseng, Funabiki lab, Rockefeller University) had a several-fold
higher specific activity on H3 peptides than recombinant Aurora B. It is
unclear whether this increased activity is due to the presence of other
complex members or reduced activity of bacterially expressed Aurora B.
Like recombinant Aurora B, Xenopus CPC phosphorylated H3 peptides
irrespective of their methylation status (Figure 3.6D). Moreover, the complex
could be easily removed after kinase reactions, due to its immobilization
on beads from the immunoprecipitation. We therefore decided to use the
immunoprecipitated Xenopus CPC rather than recombinant Aurora B
for our attempt to reconstitute the release mechanism of HP1 in the test
tube.
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Reconstitution of the "methyl-phos switching" mechanism in the
test tube
In contrast to the situation in these in vitro kinase experiments on methylated
peptides, operation of a "methyl-phos switching" mechanism inside of the
cell involves an additional level of complexity: The phosphorylation site at
serine 10 may often not be freely accessible to the CPC, since methyl-K9
recruits HP1 which in turn might prevent access to serine 10. Thus, to
complete the in vitro reconstitution of "methyl-phos switching", HP1 was
included in the reaction.
The activity of the CPC on H3K9me3 peptides in the presence of the
effector protein was again measured by radioactive kinase assay. In these
experiments, the kinase complex was able to efficiently phosphorylate
H3K9me3 peptides. The efficiency declined at higher HP1 concentrations
(probably due to competitive inhibition by HP1 at concentrations resulting
in stoichiometric binding), but even in the presence of a significant excess
of the chromo domain, there was still considerable phosphorylation of the
peptide observed, as observed for all three HP1 isoforms (Figure 3.7A, C,
E).
In parallel, we examined with fluorescein-labelled H3K9me3
peptides whether phosphorylation of H3S10 would eject the HP1 chromo
domain from its binding site. Upon addition of CPC, the effect of serine
10 phosphorylation on HP1 CD association was monitored over time
by fluorescence anisotropy measurements. In keeping with the binary
switching hypothesis, phosphorylation of a H3K9me3 peptide by the CPC
in the test tube results in dynamic loss of HP1 CD binding, an observation
made with the CD of all three isoforms α, β, and γ (Figure 3.7B, D, F).
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Figure 3.7: In vitro reconstitution of release mechanism by "methyl-phos
switching": The HP1 chromo domain is released from H3K9me3 upon serine
10 phosphorylation by the CPC in vitro.
A, C, E: Phosphorylation of H3K9me3 peptides in the presence of HP1α chromo
domain (A), HP1β chromo domain (C) and HP1γ chromo domain (E). H3 peptides
(1-15, 1 µM) were incubated in in vitro radioactive kinase assays with [γ-32P]ATP
and CPC (immunoprecipitated from Xenopus egg extracts) in the presence of increasing concentrations of recombinant HP1 chromo domain (1 to 67.5 µM). Reactions were run on SDS-PAGE, stained with Coomassie (top) and analyzed by
autoradiography (bottom). Brackets and arrow heads indicate where the HP1 CD
and the peptide runs on the gel, respectively.
Reactions with a pre-phosphorylated peptide (H3K9me3S10ph) or in the presence of the Aurora B-inhibitor hesperadin confirm the specificity of the reaction.
Even in the presence of a large molar excess of the HP1 CD, significant phosphorylation is observed.
B, D, F: Fluorescence polarization measurement of HP1 release upon serine 10
phosphorylation. Different concentrations of recombinant HP1α chromo domain
(B), HP1β chromo domain (D), HP1γ chromo domain (F) were mixed with the indicated fluorescein-labelled H3K9me3 peptides (100 nM). CPC immunoprecipitated
from Xenopus egg extracts was added in the presence or absence of the Aurora B
inhibitor hesperadin (4 µM). By fluorescence polarization, the dissociation of the
HP1 CD from the peptide over time was recorded (end point after over night reaction shown; n= 3, error bars indicate s.d.).
In the presence of hesperadin (no serine 10 phosphorylation) the peptide remains
associated with the HP1β chromo domain (yellow plot). Without hesperadin (serine 10 becomes phosphorylated), the chromo domain dissociates from the peptide (blue plot), approaching the curve observed for the H3K9me3S10ph peptide
(red plot).
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Figure 3.8: Additional specificity controls for in vitro reconstitution of release
mechanism by "methyl-phos switching" (Controls for HP1β CD shown).

3.8

A: Control reaction carried out with H3K9me3S10A peptides, which cannot phosphorylated by the CPC. Addition of the CPC has no effect on the binding of the
HP1β chromo domain. (H3K9me3S10A peptides generally show about fivefold
reduced affinity for the HP1β chromo domain compared to H3K9me3 peptides.)
B: Mass spectrometric analysis (MALDI-TOF) of CPC reactions from Figure 3.7D
containing 50 µM of HP1β chromo domain. In the absence of the Aurora B inhibitor hesperadin, the H3K9me3 peptide (*) becomes completely phosphorylated to
H3K9me3S10ph (**). As expected, there is no effect on the H3K9me3S10A control
peptide.
C: Samples of the reactions analyzed in Figure 3.7D were run out on SDS-PAGE
and stained with Coomassie, proving that the HP1β chromo domain is not degraded in the course of the experiment. Bracket indicates position of HP1β chromo domain. Note: Identical controls as presented here for the HP1β CD were also
carried out for the reactions with all other isoforms, with very similar results.
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The release of the HP1 chromo domain from the H3K9me peptide is
dependent on the kinase activity of the CPC, since no such changes are
observed if Aurora B activity is inhibited with the small molecule inhibitor
hesperadine (Hauf et al., 2003; Figure 3.7B, D, F) or if an unphosphorylatable
H3K9me3S10A peptide is used (Figure 3.8A). Mass spectrometry confirmed
that the peptide was indeed phosphorylated specifically at serine 10 (Figure
3.8B). Aliquots of the reactions were subsequently run out on SDS-PAGE
gels, to exclude the trivial explanation that the HP1 CD had simply been
degraded during the incubation (Figure 3.8C).

"Methyl-phos switching" in the test tube with full-length HP1
Taking these observations made with the chromo domains of HP1 a step
further, we attempted to repeat the analysis with full-length HP1 proteins.
However, in pilot experiments we observed that full-length HP1 itself was
subject to in vitro phosphorylation by the CPC. While it is not clear whether
this curious observation actually reflects a real in vivo event, it of course
represents a problem for the analysis of the "methyl-phos switching"
mechanism in the test tube, because it makes it difficult, if not impossible to
specifically attribute dissociation of the effector protein to phosphorylation
of the H3 tail. Closer analysis of the in vitro phosphorylation of full-length
HP1 by the CPC revealed, however, that the phosphorylation was isoformspecific (Figure 3.9). Only full-length HP1α and HP1γ were phosphorylated,
while full-length HP1β was not. Thus, we could avoid the problem of HP1
in vitro phosphorylation by focusing our analysis to the β isoform of HP1.
Our experiments with full-length HP1β showed ejection by serine 10
phosphorylation very similar to the observations with the CDs (Figure 3.10).
This proves that the release of HP1 from H3K9me3 in our reductionist in
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vitro system is not just limited to the isolated chromo domain, but can also
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Figure 3.9: Isoform-specific phosphorylation of HP1 by the CPC in vitro.

3.9
Isoform-specific in vitro phosphorylation of HP1 by the CPC (radioactive
in vitro
kinase reaction followed by autoradiography). Recombinant full-length HP1α
and HP1γ are phosphorylated by the CPC. No phosphorylation is observed for
full-length HP1β. Bracket indicates position of full-length HP1 isoforms (additional bands are mostly degradation products), arrow head indicates position of
the control peptide.
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Figure 3.10: Full-length HP1β is released from H3K9me3 upon serine 10
phosphorylation by the CPC in vitro.
An experiment analogous to the one described in Figure 3.7 was3.10
carried out with
full-length HP1β (see Figure 3.7 for experimental details). Left: The radioactive
kinase assay shows that H3K9me3 peptides are phosphorylated even in the presence of high concentrations of full-length HP1β. Right: Fluorescence anisotropy
measurements indicate that, as the HP1 CDs, full-length HP1β dissociates from
H3K9me3 peptides upon serine 10 phosphorylation by the CPC.
All the controls depicted in Figure 3.8 were carried out for this experiment as
well, showing no effect of CPC treatment on the association of full-length HP1β
with H3K9me3S10A peptides (fluorescence anisotropy), specific phosphorylation
of serine 10 (mass spectrometry), and little degradation of the effector protein in
the course of the reaction (SDS-PAGE).

"Methyl-phos switching" in the test tube with MSK1
While our controls clearly show that Aurora B-dependent phosphorylation
of serine 10 is required for the release of HP1 in this reconstituted system,
they cannot exclude that there are additional effects caused by the
presence of other components in the test tube. In particular, it is possible
that the other complex members of the CPC, which are always present in
the reactions as well, also play a part.
99

Unfortunately, the very low specific activity of recombinant Aurora B
made it difficult to carry out similar experiments with the isolated kinase.
However, taking advantage of our identification of MSK1 as another kinase
capable of phosphorylating H3K9me3 peptides in vitro, we were able to
reproduce the CPC results with this kinase: MSK1 was capable of efficiently
phosphorylating H3K9me3 peptides in the presence of the HP1 chromo
domain (Figure 3.11A), and the phosphorylation resulted in the ejection of
the chromo domain from its binding site on the methylated H3 tail (Figure
3.11B). This proves that the release of the HP1-H3K9me3 interaction
by serine 10 phosphorylation does not require any of the other complex
members of the CPC, but that serine 10 phosphorylation is sufficient for
the release of CD binding in our reductionist in vitro system.

Reversibility of "methyl-phos switching" in the test tube
In the cell, the release of HP1 from its binding site is reversible, and the
protein reassociates with chromatin at the end of mitosis. To test the
assumption that this reversibility could be achieved by "methyl-phos
switching", we examined the reverse reaction and sought to find out if this
observation could be reproduced in our in vitro system. In these experiments,
removal of serine 10 phosphorylation from H3K9me3S10ph peptides by
PP1, a phosphatase known to dephosphorylate H3S10ph (Prigent and
Dimitrov, 2003), resulted in reassociation of the HP1β chromo domain to
the peptide (Figure 3.12). The effect can be abolished by inclusion of the
phosphatase inhibitor microcystin LR, showing that it indeed depends on
the dephosphorylation.
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Figure 3.11: Dissociation of the HP1β CD from H3K9me3 upon serine 10

3.11

phosphorylation by MSK1 in vitro.

A: H3K9me3 peptides are phosphorylated by MSK1 even in the presence of a
large excess of HP1β chromo domain (radioactive kinase experiment). In addition
to the analysis by SDS-PAGE and autoradiography, peptide phosphorylation was
quantified by filter binding assay and scintillation counting. While high concentrations of the HP1β chromo domain slow down the peptide phosphorylation,
there is still significant phosphorylation activity observed. Bracket, arrow head
and asterisk indicate positions of HP1β CD, peptide and MSK1, respectively.
B: Release of the HP1β CD from H3K9me3 peptides upon treatment with the serine 10 kinase MSK1 (fluorescence anisotropy). Phosphorylation of H3K9me3 peptides by MSK1 shifts the binding curve to the right, close to the curve observed
with a H3K9me3S10ph control peptide. This indicates dissociation of the chromo
domain from the peptide.
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Figure 3.12: Reassociation of the HP1β CD upon phosphatase
treatment of
3.12
H3K9me3S10ph peptides.
Dephosphorylation of a H3K9me3S10ph peptide results in restoration of the interaction with the HP1β chromo domain. Binding of the HP1β chromo domain
to a fluorescein-labelled H3K9me3S10ph peptide was measured by fluorescence
anisotropy. In the absence of the phosphatase inhibitor microcystin LR, the phosphatase (recombinant PP1, NEB) removes serine 10 phosphorylation (as determined by mass spectrometry, data not shown) and binding of the HP1β chromo
domain to the peptide is restored (blue plot). In the presence of the microcystin,
serine 10 phosphorylation is unaffected by phosphatase treatment and no reassociation is observed (red plot).

Taken together, the presented data demonstrate that in our reductionist
system enzymatic phosphorylation of serine 10 results in the release
of HP1 from methylated H3 peptides, while removal of S10ph causes
reassociation. Thus, these experiments unambiguously demonstrate the
operation of a "methyl-phos switching" mechanism for the dynamic and
reversible regulation of HP1 binding to the stable K9-methyl mark in the
test tube.
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H3S10 phosphorylation coincides with the release of HP1 in vivo
The described in vitro findings suggest that the "methyl-phos switching"
mechanism could account for the observations made in vivo and that
transient, reversible phosphorylation of serine 10 during mitosis might
also be the mechanism how the dynamic interaction between HP1 and
H3K9me3 over the cell cycle is achieved within the cell. To test this
hypothesis, we turned to a combination of inhhibition experiments and
microscopy.
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Figure 3.13: The mitotic release of HP1 coincides with the appearance of
H3K9me3S10ph in vivo.
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The
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H3K9me3S10ph epitope occurs at late G2, at the same time when the typical
dot-like staning pattern of HP1β starts to become diffuse and HP1β is released
from chromatin. Only at telophase, when the dual epitope is removed again, does
HP1 start to reassociate with chromatin. Similar observations were made in HeLa
cells and with the HP1 isoforms α and γ. DNA stained with DAPI. Figure courtesy
of Dr. Wolfgang Fischle.
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Taking advantage of the dual-epitope(H3K9me3S10ph)-specific
antiserum that he had generated, Dr. Fischle carried out a careful IF
analysis in cultured mammalian cells, comparing the time of dual epitope
appearance with the release of HP1. This analysis revealed a close temporal
correlation between the occurrence of the H3K9me3S10ph mark and the
dissociation of HP1 from chromatin at late G2 (Figure 3.13). Significant
H3K9me3S10ph staining is only observed in mitotic cells that have lost the
characteristic chromatin-associated HP1 localization pattern and instead
show diffuse HP1 staining throughout the cytoplasm. Thus, there is a
close link between the temporal and local occurrence of the dual epitope
in mitosis and the dissociation of HP1 from chromatin.
Inhibition of Aurora B kinase prevents the release of HP1 in vivo
The observed close correlation between S10 phosphorylation and HP1
dissociation prompted us to carry out a direct in vivo test to see if there was
a causal link between mitotic serine 10 phosphorylation and the release of
HP1 (experiments carried out by Dr. Fischle).
To this end, asynchronously growing HeLa cells were treated with
hesperadin and the effect of this inhibition on the mitotic dissociation of
HP1 was studied by immunofluorescence microscopy. We found that upon
inhibition of Aurora B, all three HP1 isoforms were retained on mitotic
chromosomes (Figure 3.14A).
Since these observations were dependent on stainings with HP1
antibodies, we reproduced the experiment with cells expressing GFPtagged HP1 isoforms. Similar to endogenous HP1, GFP-HP1 was retained
at chromatin upon hesperadin treatment (data not shown). Thus, our
experiments with GFP-HP1 confirm the findings with endogenous HP1 and
exclude the possibility that our in vivo observations are simply a peculiar
artifact of epitope masking.
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Figure 3.14: Retention of HP1 on chromatin upon inhibition of mitotic ser-

3.14

ine 10 phosphorylation in vivo (Figure courtesy of Dr. Wolfgang Fischle).
A: Upon inhibition of Aurora B kinase activity, endogenous HP1 isoforms are retained on mitotic chromatin. 10T1/2 cells were either mock treated or treated with
hesperadin (200 nM), and then analyzed by immunofluorescence microscopy with
the indicated antibodies. In cells treated with hesperadin, no H3K9me3S10ph
signal is observed and HP1 does not dissociate from chromatin at metaphase.
DNA stained with DAPI. Bar, 10 μm.
B: Retention of HP1 on mitotic chromatin upon knock-down of Aurora B kinase
by RNA interference. HeLa cells either mock treated (Control) or treated with Aurora B siRNAs (Aurora B RNAi) were analyzed by IF microscopy. Aurora B RNAi
resulted in loss of the dual epitope and failure of HP1β to dissociate from mitotic
chromatin. Staining for HP1α and HP1γ gave very similar results. DNA stained
with DAPI. Overlay generated from HP1β and DNA channels. Bar, 10 μm.
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Retention of HP1 on chromatin in vivo upon Aurora B inhibition
was also confirmed by biochemical fractionation experiments with HeLa
and 10T1/2 cells arrested in mitosis with nocodazole. Upon Aurora B
inhibition, we observed increased association of all three HP1 isoforms
with chromatin. At the same time, there was no change in the levels of
HP1, H3K9me3 or the acetylation of H3 at lysine 14 (data not shown).
Since all these observations depended on the use of hesperadin,
it was possible that our observations were just the result of unspecific
side-effects of this small molecule inhibitor. To exclude this possibility,
we examined the effect of Aurora B depletion by RNA interference on
HP1 dynamics in mitosis. In keeping with the results obtained from the
inhibition experiments, knock-down of Aurora B prevented the dissociation
of HP1 from chromatin during mitosis (Figure 3.14B), while not affecting
the localization of HP1 in interphase cells.
In sum, these in vivo experiments strongly suggest that serine 10
phosphorylation of H3 is a necessary step for the release of HP1 from
chromatin in mitosis.

HP1 binds to metaphase chromosomes lacking H3 serine 10
phosphorylation in Xenopus egg extracts
We realized that the tissue culture system offers only very limited
possibilities to manipulate experimental parameters in order to investigate
the molecular mechanism of mitotic HP1 release. An experimental system
that allows for detailed examination and highly controlled experimental
manipulation of cell cycle events are Xenopus egg extracts. Therefore, we
collaborated with Boo S. Tseng and Dr. Hironori Funabiki, experts in the
use of this cell-free system (who had actually already independently made
observations related to "methyl-phos switching" in Xenopus egg extracts).
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In keeping with our observations in tissue culture cells, Boo Tseng
and Dr. Funabiki demonstrated simultaneous occurrence of the dual mark
K9me3S10ph and release of GFP-tagged Xenopus HP1 from chromosomes
in egg extracts entering mitosis (data not shown).
Upon removal of Aurora B through immunodepletion of the CPC,
as expected H3 serine 10 phosphorylation was clearly diminished, while
the levels of H3K9me3 were unaffected. Most notably, however, binding of
HP1α to chromosomes was significantly increased in extracts depleted of
the CPC compared to control extracts. This retention of HP1 on chromatin
was dependent on the chromodomain-H3K9me3 interaction, since the
interaction could be competed with an H3K9me3 peptide (no effect of
unmodified H3 peptide) and since mutation of one of the caging amino
acids (W57A) drastically reduced the amount of bound GFP-xHP1α in ∆CPC
extracts. Thus, these data show clearly that HP1 cannot bind to metaphase
chromosomes when H3 is phosphorylated at serine 10, in the absence of
serine 10 phosphorylation, however, it associates through mechanisms
that depend on chromo domain-binding to H3K9me3.

Discussion
A novel mechanism how histone modifications control the
recruitment of effector proteins
With the described experiments, I have, together with my collaborators,
provided answers for two longstanding questions. Firstly, we have identified
a biological role for mitotic H3 serine 10 phosphorylation (H3S10ph), a
prominent mitotic histone mark with so far elusive biological function.
We have demonstrated that H3S10 phosphorylation plays a crucial role
in the regulation of the chromatin association of Heterochromatin protein
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1 (HP1), an effector protein with important functions in the formation
of heterochromatic structures that dissociates from chromatin during
mitosis.
Secondly, the experiments presented here led to the discovery of the
mechanism underlying the mitotic release of HP1 from chromatin. They
show that the reversible dissociation of HP1 from its binding site at histone
H3 during mitosis is achieved through histone phosphorylation.
Reconstitution of the release mechanism with purified components in
the test tube and subsequent inhibition studies in vivo clearly demonstrated
that Aurora B phosphorylation of H3 at serine 10 at the onset of mitosis
is crucial for the ejection of HP1 from mitotic chromatin. H3 serine 10
phosphorylation sterically and electrostatically interferes with binding of
HP1 to its binding site at methylated lysine 9 of histone H3, resulting in the
release of the effector protein. Thus, in this "methylation-phosphorylation
switching" mechanism, two histone modifications collaborate to control
association of an effector protein with chromatin (Figure 3.15). While the
actual binding site (the methylation mark) is stable, the dynamic histone
phosphorylation mark serves to regulate dynamic binding and release of
the effector protein.
"Methyl-phos switching" is a novel mechanism how two histone
modifications collaborate to bring about dynamic regulation of effector
binding, that defines a new class of cross-talk between histone modifications
in general (Fischle et al., 2003c; Fischle et al., 2003d). Our findings have
been confirmed by other investigators (see below), and it is becoming
increasingly clear that there are broader implications for this mechanism
within the field of chromatin and beyond.
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Figure 3.15: "Methyl-phos switching" controls HP1 dissociation
during mi3.15
tosis.
A "methyl-phos switching" mechanism controls the dynamic release of HP1 during mitosis. Model summarizing the mechanism of mitotic HP1 dissociation by
"methyl-phos switching", as it is established by the experiments described in
chapter 3 of my thesis.
HP1 is recruited to chromatin by methylated lysine 9 on the histone H3 tail.
During mitosis, H3 serine 10 is phosphorylated by the Chromosomal Passenger
Complex (CPC) with its kinase Aurora B. This sterically interferes with binding
of HP1’s chromo domain to H3K9me, resulting in HP1 dissociation. At the end of
mitosis, serine 10 phosphorylation is removed by phosphatases and HP1 binding to H3K9me is restored. Thus, serine 10 phosphorylation allows for a reversible release of HP1 from chromatin, even though its binding site at H3K9me3 is
stable.

In the following, I will briefly discuss different aspects of mitotic
"methyl-phos switching" of HP1, "methyl-phos switching" in other cellular
contexts and binary switching in general in light of the literature. In the
first part of this discussion, I will briefly address what the responsible
phosphatase might be and if there may be other supportive mechanisms
besides "methyl-phos switching" that contribute to the mitotic release
of HP1. In the second part of the discussion, I will go into the general
implications of our findings.
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Identity of the phosphatase responsible for the removal of H3S10ph
in vivo
Observations in vivo indicate that the mitotic dissociation of HP1 is a fully
reversible process. In our in vitro reconstitution system, the methylationphosphorylation switch could be readily reversed by phosphatase treatment,
and removal of serine 10 phosphorylation by phosphatase PP1 resulted in
full reassociation of the HP1 chromo domain with H3K9me3 (Figure 3.12).
The responsible phosphatase in vivo, however, is still unknown. Even so,
there are some interesting observations and worthwhile speculation.
One of the genes identified in PEV screens, Su(var)3-6, has been
shown to encode a catalytic subunit for type 1 serine-threonine protein
phosphatases (PP1; Baksa et al., 1993). Interestingly, mutation of this gene
leads not only to strong PEV suppression, but also to abnormal mitosis,
mitotic defects, and hyperploidy. Considering the role that HP1 "methylphos switching" plays in the mitotic dissociation of HP1 and (possibly) in
the definition of boundaries of heterochromatin (see below), this phenotype
comes very close to what would be expected for a phosphatase that is
involved in "methyl-phos switching" of HP1.
Potential contribution of other mechanisms to the mitotic release of
HP1 in vivo
The existence of the "methyl-phos switching" mechanism and its importance
for the mitotic dissociation of HP1 has been confirmed by multiple groups,
in vitro and in vivo, and in both mammalian cells and S. pombe (Chen et al.,
2008; Hirota et al., 2005; Kloc et al., 2008; Sabbattini et al., 2007; Terada,
2006).
In extreme reductionist systems (only H3 peptides and the HP1-CD)
"methyl-phos switching" is always sufficient for HP1 release (Fischle et al.,
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2005; Terada, 2006), allowing to study the mechanism without overlapping
other effects and thus establishing binary switching as a mechanism for
the regulation of effector protein association with histone marks in general.
However, in more complex systems there seem to be other effects that also
affect experimental observations. Already when full-length HP1 proteins
are used instead of the isolated chromo domain, "methyl-phos switching"
is not always sufficient. We have shown that full-length HP1β is released
from H3 peptides upon serine 10 phosphorylation, while Terada reports that
full-length HP1α does not dissociate in very similar experiments (in parallel
control experiments, the HP1α CD was ejected; Terada, 2006). Thus, there
are differences between isoforms, and additional binding mechanisms seem
to prevent the release of full-length HP1α after "methyl-phos switching".
This raises the question whether "methyl-phos switching", while clearly a
necessary step, is also sufficient for the release of HP1, particularly in an
in vivo context where HP1 undergoes may different interactions.
By Aurora B inhibition and depletion in various experimental systems,
in vivo experiments have clearly demonstrated the importance of "methylphos switching" for the release of HP1, for example in mammalian cells
(Fischle et al., 2005; Sabbattini et al., 2007; Terada, 2006), in Xenopus egg
extracts (Fischle et al., 2005) and in S. pombe (Kloc et al., 2008). Further
support came from a different approach, the overexpression of an exogenous
H3 protein with a S10A mutation in mammalian cells, which also led to
increased retention of HP1 at chromatin (Terada, 2006). However, these
experiments can only prove that "methyl-phos switching" is necessary for
the release of HP1, while they do not address whether it is sufficient.
When HP1 binding to full-length H3 or chromatin was tested in
the presence of cellular extracts, binding of HP1 in spite of serine 10
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phosphorylation of H3 has been reported. In pull-downs with recombinant
full-length HP1γ from acidic-soluble cellular extracts, for example, Fass
and colleagues found that serine 10 phosphorylation does not prevent H3
binding (Fass et al., 2002), suggesting that the reversal of the CD-H3K9me
interaction is not sufficient for the release of HP1 from chromatin in vivo.
Such a conclusion is also supported by an experimental observation made
by our collaborators Boo Shan Tseng and Dr. Hironori Funabiki. In Xenopus
egg extracts, exogenous HP1 with a mutation in the chromo domain still
showed partial retention on chromosomes (in extracts depleted of CPC),
even though mutation of the chromo domain abolishes H3K9me-dependent
binding of HP1, therefore mimicking the effect of complete "methyl-phos
switching" (Fischle et al., 2005).
HP1 is known to undergo various molecular interactions and bind to
chromatin by multiple different mechanisms in vivo. Considering the clear
evidence for a role of other interactions in stable chromatin association of
HP1 (see Introduction), it is very likely that there may be other interactions
besides the CD-H3K9me interaction that have to be reversed for the mitotic
release of HP1. It is therefore expected that other mechanisms besides
"methyl-phos switching" do play a part in the mitotic dissociation of HP1
from chromatin in vivo. Interestingly, there are indications in mammalian
cells that HP1 becomes multiply phosphorylated during mitosis (Minc
et al., 1999). While the sites of these phosphorylations had not been
mapped and little, if anything, was known about the function of these
mitotic phosphorylations, it is tempting to speculate that mitotic HP1
phosphorylation could provide a mechanism for the reversal of molecular
interactions of HP1 and thus contribute to the release of the protein during
mitosis.
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"Methyl-phos switching" of HP1 at H3 lysine 9/serine 10 outside of
mitosis
As shown in this chapter of my thesis, in the regulation of mitotic HP1
dissociation "methyl-phos switching" plays a central role. However, there are
other instances where there are indications that "methyl-phos switching"
may regulate HP1 behaviour.
In a recent publication by Sabbattini and colleagues (Sabbattini et
al., 2007), it was reported that H3 S10 phosphorylation by Aurora B in
postmitotic cells leads to delocalization of HP1β. While HP1β is localized
to regions of facultative heterochromatin in activated B cells, it becomes
displaced from facultative heterochromatin in an Aurora B-dependent
fashion during the differentiation process to terminally differentiated
postmitotic plasma cells. The displacement of HP1 may allow binding of
other chromatin proteins involved in transcriptional silencing to these
regions of the genome. The study thus establishes a non-mitotic role for
"methyl-phos switching" in differentiation.
Another instance, where "methyl-phos switching" of HP1 may play a
role, is meiosis. H3 serine 10 phosphorylation has been reported in meiosis
as well, and it is possible that HP1 might have to be released for accurate
progression of meiotic divisions (Kaszas and Cande, 2000; Wei et al., 1998;
Wei et al., 1999).
"Methyl-phos switching" of HP1 could also be involved in
transcriptional activation. It is well established that HP1 has, besides its
function in heterochromatin, also a role in the repression of euchromatic
genes (see Introduction, Section "Cellular Localization and Functions of
HP1"). This is reflected by the multiple interactions HP1 undergoes with
transcriptional repressors, such as TIF1α (Le Douarin et al., 1996), TIF1β/
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KAP1 (Nielsen et al., 1999), Rb (Nielsen et al., 2001), or E2F (Ogawa et
al., 2002). In keeping with this interpretation, it has been reported that
transcriptional activation of a silenced transgene array in human cells
involved the dissociation of associated HP1 proteins (Janicki et al., 2004).
Clearly, HP1-mediated gene repression is reversible, and mechanisms
must have evolved to overcome this form of gene silencing. Interestingly,
H3 serine 10 phosphorylation has also been observed in connection with
gene activation. During a process called immediate early gene response
which involves the rapid induction of gene expression and cell growth
upon treatment of quiescent mammalian cells with mitogens (Mahadevan
et al., 1991), a burst of H3 serine 10 phosphorylation is observed at
specific loci that are activated during this process (e.g. Chadee et al., 1999;
DeManno et al., 1999; Yamamoto et al., 2003). Several kinases involved
the phosphorylation or serine 10 during this process have been identified
(MSK1, RSK2, IKKα; Anest et al., 2003; Sassone-Corsi et al., 1999; Strelkov
and Davie, 2002).
Interestingly, in my experiments on HP1 "methyl-phos switching" in
vitro, the immediate early kinase MSK1 was capable of ejecting the HP1
chromo domain from its binding site at H3K9me3 (see Section "Methyl-phos
switching" in the test tube with MSK1"). Thus, while it is not clear at this
point if HP1 really participates in the regulation of immediate early genes,
it remains an interesting hypothesis to test if "methyl-phos switching" of
HP1 by serine 10 phosphorylation is indeed a step in the activation of
these genes.
"Methyl-phos switching" of HP1 may also be the key to explain another
curious observation in Drosophila cells. Reduced levels of the H3S10
kinase JIL-1 lead to spreading of HP1 and H3K9 methylation to ectopic
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locations along the arms of chromosomes (Zhang et al., 2006). A possible
explanation for this finding is that in a wild-type situation JIL-1 controls
HP1 association by "methyl-phos switching", preventing HP1 association
at specific target sites, blocking the spreading of heterochromatin, and
thus defining heterochromatic domains through "methyl-phos switching".
All in all, there are multiple pieces of evidence suggesting an
involvement of HP1 "methyl-phos switching" in biological processes outside
of mitosis.

"Methyl-phos switching" of HP1 at other sites
HP1 chromatin association is mediated by the interaction of the chromo
domain with H3K9me. However, lysine 9 and serine 10 of H3 are part a
sequence motif "ARKS", which is a typical "modification cassette" (Fischle et
al., 2003a), a sequence motif that is multiply posttranslationally modified.
A brief review of the predicted human proteome shows that there are
almost 70 proteins with an “ARKS” motif in the human genome (A. Basu,
personal communication), thus conferring to these proteins the ability to
undergo regulated molecular interactions with binding partners. At several
instances, it has been reported already that the "ARKS" motif or related
motifs are methylated at the lysine and/or phosphorylated at the serine
or threonine. Examples have been found in the H3 tail at K9 and K27,
in H1.4 at K26, in G9a at K165, and in the hinge of macroH2A at K157.
Intriguingly, HP1 itself contains a very similar "KRKS" motif (see Chapter
4 of this thesis). In several cases HP1 binding to these sites has been
reported (Daujat et al., 2005; Sampath et al., 2007).
The linker histone H1.4 contains an "ARKS" cassette (Figure 3.16,
top). Lysine 26 within this motif is methylated by the HMTase Ezh2 in
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vivo, and in reporter assays methylation of this site is necessary for Ezh2mediated transcriptional repression (Kuzmichev et al., 2004). In a recent
publication, Daujat et al. report that HP1 binds through its chromo domain
to H1K26me in vitro and in pull-downs from cellular extracts (Daujat et al.,
2005). It is tempting to speculate that H1K26 methylation may be one of the
suspected ways of H3K9me-independent recruitment of HP1 to chromatin
(see Introduction). However, it has also been found that the neighbouring
S27 is subject to phosphorylation (Garcia et al., 2004), and the interaction
of HP1 with H1.4K26me is abolished by simultaneous phosphorylation
of the neighbouring

serine 27, as shown in various pull-down and

competition experiments (Daujat et al., 2005). The observations raise the
intriguing possibility that release of HP1 from H1.4K26me by "methyl-phos
switching" may be the explanation for observed decondensation effects of
S27 phosphorylation (Roth and Allis, 1992).
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Figure 3.16: Examples of HP1 "methyl-phos switching" at sites other than

3.16

H3K9me3S10ph.

Top: Histone H1.4 contains a modification cassette "ARKS" that is methylated
at K26 and binds HP1. Phosphorylation of the neighbouring S27 abolishes HP1
association (Daujat et al., 2005). Bottom: The histone methyltransferase G9a
contains an "ARKT"motif that is methylated at K165 and recruits HP1. A phosphorylation of T166 right next to the methylated lysine prevents HP1 binding.
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Another case of possible HP1 "methyl-phos switching" is G9a, a histone
methyltransferase that methylates H3 at lysine 9 (Tachibana et al., 2001).
G9a contains an "ARKT" motif (Figure 3.16, bottom), and autocatalytic
methylation of lysine 165 within the G9a sequence generates a binding site
that HP1γ associates with in vivo (Sampath et al., 2007). In in vitro binding
assays, this interaction is reversed by phosphorylation of the adjacent
threonine 166. While the biological function of G9aK165 methylation and
the existence of T166ph in vivo still have to be established, this may turn
out to be another case of HP1 "methyl-phos switching" in the cell.
Thus, H3K9meS10ph is not the only site where "methyl-phos switching"
of HP1 is observed. Several other proteins, both in histones and in nonhistone proteins, have modification cassettes that give them the ability to
recruit HP1 in a manner that is regulated by "methyl-phos switching".

Binary switching as a general mechanism in the cell
From these examples, it is clear that "methyl-phos switching" is a versatile
mechanism that is used by the cell in many different contexts, for the
regulation of HP1 binding in mitosis, during differentiation, or during for
the definition of boundaries of heterochromatin, and for the association
with different histones and non-histone proteins alike.
However, the demonstration of binary switching has even broader
implications. Since various different histone marks serve as binding sites to
recruit effector proteins, it is obvious that the mechanism will not be limited
to HP1 and "methyl-phos" switching, but that various other proteins binding
to different types of modifiations may be regulated by this mechanism and
variations of the mechanism with other combinations of marks will occur,
such as "acetyl-phos", "methyl-acetyl", or even "methyl-methyl" switching.
117

M
P M

NH2-A R T K Q T A R K S ...

CHD

2

3

4

M
M

H3: NH2-A R T K Q T A R K S ...
2

3

4

M
M

M
M

NH2-A R T K Q T A R K S ...
2

3

4

Figure 3.17: Regulation of the chromatin association of the chromatin remodeller CHD by a "methyl-phos" and a "methyl-methyl" switch.

3.17

Example of a "methyl-phos" and "methyl-methyl" switch involving the chromatin
remodeller CHD. CHD binds to methylated lysine 4 in the H3 tail. Both phosphorylation of theronine 3 (top, "methyl-phos switch") and methylation of arginine 2
(bottom, "methyl-methyl switch) abolish association of CHD with H3K4me.

This is illustrated by the example of CHD (chromo-ATPase/helicaseDNA-binding), a nucleosome remodeling factor with two chromo domains
(Figure 3.17). Cooperating with each other in a tandem arrangement, these
two CDs bind to H3K4me, a hallmark modification of active chromatin
(Flanagan et al., 2005). The two neighbouring residues of H3, threonine 3
and arginine 2, have both been found to be modified in vivo as well. H3 T3
is phosphorylated during mitosis by the kinase haspin, a modification that
is required for proper chromosome alignment in metaphase (Polioudaki
et al., 2004). H3 R2 is the site of methylation by the methyltransferase
CARM1 and plays a role in transcriptional activation (Chen et al., 1999).
In fluorescence anisotropy experiments, it was found that the presence
of either additional modification (i.e. a dual epitope H3R2meK4me or
H3T3phK4me) significantly reduces binding of CHD to H3K4me (Flanagan
et al., 2005). Thus, binding of the chromatin remodeller CHD to H3K4me
is another case of binary switching, which in this case involves both a
"methyl-phos" and a "methyl-methyl switch" and may control recruitment
of the chromatin remodeller.
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Within the histone tails, there are many regions with a very high
density of clustered histone marks (see Figure 1.3 for an overview). This
is exemplified by the histone H3 tail (Figure 3.18). Within the first 30
amino acids of the H3 sequence, there are multiple regions of very densely
clustered histone marks found. For many of these sites, binding proteins
have been found, and thus it seems very likely that other cases will be
discovered in the future where chromatin effector proteins are regulated
by this mechanisms (Fischle et al., 2003a).
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Figure 3.18: High density and clustering of posttranslational modifications
3.18
in the histone H3 tail.
The histone H3 tail shows a very high density of posttranslational modification
sites, many of which cluster together. This suggests the existence of other binary
switches within the H3 tail. Red circle: (mono/di/tri-) methylation. Green square:
phosphorylation. Yellow star: acetylation.

While the recruitment of effector proteins by histone marks has
received a lot of attention in recent years, the regulation of protein
interactions by posttranslational modifications is a general principle that
has been studied intensely for years (Pawson, 1995; Seet et al., 2006).
Many of the principles observed with histones have also been found in
non-histone proteins. It is therefore likely that the mechanism of binary
switching will be found in many interactions between non-histone proteins
as well. Future research will tell how far beyond the field of chromatin
biology the consequences of this novel mechanistic principle will reach.
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Chapter 4
Regulation of HP1
through effector phosphorylation:
Phosphorylation of the HP1 hinge Region
Introduction
The recruitment of specific effector proteins by posttranslational histone
modifications represents a key mechanism for controlling chromatin
structure and function. The elusive mechanisms for how these effector
proteins are directed to chromatin and released, and how they fulfill
their functions in the dynamic environment of the nucleus, remain major
challenges for the field of chromatin biology.
Arguably one of the more famous of these effector proteins,
Heterochromatin Protein 1 (HP1) has over the last few years been the focus
of intense research. This has led to a number of key findings, and has not
only provided insights into the functions and mechanisms of action of
this important chromatin factor, but has also shaped our understanding
of chromatin in general. For example, as described in previous chapters,
the discovery that chromo domains are modules for methyl-lysine binding
provided a paradigm for how proteins can be recruited to modified histones
(Bannister et al., 2001; Jacobs et al., 2001; Lachner et al., 2001).
However, despite the progress made, a number of important
questions in HP1 biology remain unresolved, such as a full understanding
of the interplay of the different mechanisms involved in HP1 recruitment to
chromatin, the different roles of the three HP1 isoforms, the exact sites and
function of HP1 posttranslational modifications (especially in mammalian
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cells), or the mechanisms that regulate HP1’s multiple molecular
interactions. Addressing these questions will be of vital importance for
a full comprehension of the biological role of HP1 as well as for a deeper
understanding of the mechanisms that control chromatin structure and
function.
In Chapter 3, I presented data that finally provides the mechanism
of reversible HP1 dissociation from chromatin at the onset of mitosis. HP1
is released by a mechanism called methyl-phos switching, through which
the interaction of the HP1 CD with methyl-K9 H3 is reversibly abolished
by transient phosphorylation of the histone at serine 10. An essential step
in the ejection of HP1 from mitotic chromatin, this release mechanism
illustrates how HP1 and its dynamics during mitosis are controlled by
histone phosphorylation.
But histone phosphorylation may not be the only way how
posttranslational modifications control HP1 behaviour. Indeed, it has been
observed in various organisms that HP1 itself is subject to phosphorylation.
Highly intriguing changes in HP1 phosphorylation at specific stages of the
cell cycle suggest that phosphorylation may be a critical mechanism to
control the protein’s function, making HP1 phosphorylation an important
frontier that urgently needs to be addressed.
Studying the posttranslational modifications of HP1 may also be
of more general interest. Much has been learned in recent years about
the mechanisms of how histone modifications recruit effector proteins to
chromatin to bring about specific effects. However, far less attention has
been given to the possibility that the functions of effector proteins may also
be controlled by posttranslational modifications of the effector proteins
themselves. It is tempting to speculate that such a regulation on side of the
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effector proteins may exist as well, since it would allow the cell to modulate
the read-out of the histone code. Indeed, it has been observed that the
"modification cassettes" that are found in histone proteins are also present
in non-histone proteins (sequences closely related to the "ARKS" motif in
H3 are present, e.g., in the histone methyltransferase G9a or even in HP1;
see Chapter 3, Discussion, section "Methyl-phos switching at other sites").
Modulation of the read-out of histone marks by modification of effector
proteins would add yet another layer of complexity to the regulation of
chromatin structure and function. Phosphorylation of HP1 may be a good
model to address this fundamental question.
While carrying out in vitro kinase experiments for the reconstitution
of methylation-phosphorylation switching in the test tube (Chapter 3), I
made the observation that the Chromosomal Passenger Complex (CPC,
a mitotic kinase complex with important regulatory roles in mitotic
chromosome segregation and cell division) phosphorylates not only histone
H3, but also full-length HP1 in vitro. This phosphorylation is isoformspecific, since only HP1α and HP1γ are phosphorylated, while there is
no phosphorylation observed for HP1β (Figure 4.1). The finding appeared
immediately intriguing, because it is in keeping with an observation in
the published literature that had suggested mitotic phosphorylation of the
HP1 isoforms HP1α and HP1γ before.
In a paper published in 1999, E. Minc and colleagues for the first
time presented evidence that HP1 is phosphorylated in human cells (Minc
et al., 1999). When they immunoprecipitated HP1 from HeLa cells grown
in the presence of radioactive phosphate, they found that HP1α and HP1γ
were radioactively labelled in IPs from both interphase and mitotic extracts,
while no labelling was observed for HP1β. Following up on this finding,
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Figure 4.1: In vitro phosphorylation of HP1 by the Chromosomal Passenger
Complex.

4.1
Isoform-specific phosphorylation of HP1 by the Chromosomal Passenger Complex in vitro. Recombinant HP1α, HP1β and HP1γ were incubated with X. laevis
Chromosomal Passenger Complex (a gift from Boo Tseng, Funabiki lab) in radioactive in vitro kinase assays. Autoradiography shows that the isoforms HP1α and
HP1γ are phosphorylated in this reaction, while HP1β is not. Bracket indicates
position of full-legth HP1 isoforms on the gel. Faster migrating bands are probably degradation products.

they carried out 2D gel electrophoresis to analyze the number of charged
isoforms of HP1 (Figure 4.2). In mitosis, additional species with more
negative charge (either due to gain of negative charge or neutralization
of positive charge through posttranslational modification) appeared
for HP1α and HP1γ, suggesting that the proteins acquired additional
posttranslational modifications such as additional phosphorylations. It
was never confirmed whether these sites are indeed phosphorylations,
where the sites of modification lie within the HP1 sequence, or what the
biological function of such curious hyperphosphorylation of HP1 during
mitosis might be.
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Figure 4.2: Indications for in vivo phosphorylation of HP1 in the literature

4.2

(Figure from Minc et al., 1999).

HP1α and HP1γ may be hyperphosphorylated in mitosis in vivo. Total cell extracts
from interphase (I) and mitotic (M) HeLa cells were separated by 2D gel electrophoresis, followed by immunoblotting for the different HP1 isoforms. Plus/minus
signs indicate the orientation of the electrodes during the isoelectric focusing
step. The black circle marks the place on the membrane where the interphase
signal for HP1α was detected. The appearance of additional dots in the mitotic
samples suggests that HP1α and HP1γ are modified by a posttranslational modification that adds negative charge or reduces positive charge. Additional phosphorylations in mitosis could explain this observation.

In light of the findings reported by Minc and colleagues, several
lines of evidence suggested that my in vitro observations might reflect a
real in vivo event: (1) The observed in vitro phosphorylation showed the
same isoform-specificity as the metabolic labelling described by Minc et al.
(2) In the cell, the Chromosomal Passenger Complex is active specifically
in mitosis and could therefore indeed be responsible for the additional
charged HP1 species observed by Minc et al. in mitotic samples. And (3)
an interaction of HP1α and HP1γ with INCENP, a component of the CPC,
has been described in the published literature before (Ainsztein et al.,
1998). Therefore, I decided to follow up on my observation of HP1 in vitro
phosphorylation by the CPC.
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Focusing mostly on HP1α, in this chapter I summarize the
mapping of this phosphorylation to a conserved site in the hinge region,
confirmation and characterization of the mark in vivo, the identification of
the responsible kinase, and experiments to elucidate the biological function
of the mark. I also report the identification of a series of additional, novel
phosphorylations in the hinge regions of all three HP1 isoforms by mass
spectrometry, describe the tests I performed to ask if these modifications
contribute to the regulation of HP1α dynamics during mitosis, and end
with observations that suggest that the HP1α hinge phosphorylations may
play a role in the regulation of RNA binding to HP1.

Results
Mapping of HP1 in vitro phosphorylation by the CPC to a conserved
cassette in the hinge region
Through a combination of in vitro kinase assays, deletion/mutation
analysis and computer-based predictions, I succeeded in identifying the
sites of the observed in vitro phosphorylation of HP1α and HP1γ by the CPC
(Figure 4.3). The sites of modification are serine 92 in HP1α and serine 93
in HP1γ1. These serine residues fall within the hinge region of HP1 that
connects the chromo and chromoshadow domains. Recombinant Aurora
B kinase (without the other CPC components) showed slightly reduced site
specificity compared to the complex, but otherwise reproduced the results
obtained with the CPC (data not shown).
1

For a long time it has been unclear, where exactly translation of the mammalian
HP1γ open reading frame starts. By mass spectrometry, my collaborator Hillary
Montgomery (Hunt lab, University of Virginia) and I could confirm the exact
identity of the HP1γ N-terminus. In some other studies, a translation start ten
amino acids downstream had been assumed. Thus, what I refer to as HP1γ S93
by some other studies would refer to as HP1γ S83.
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Figure 4.3: Mapping of the site of HP1α and HP1γ in vitro phosphorylation
4.3
by the Chromosomal Passenger Complex.
Radioactive in vitro kinase assays. Phosphorylation of HP1α and HP1γ is completely abolished by mutation of serine 92 and serine 93, respectively. Inclusion
of hesperadin, a small molecule inhibitor of Aurora B kinase activity (Hauf et al.,
2003), completely prevents phosphorylation, indicating that phosphorylation is
indeed caused by Aurora B activity and not by another component that copurified with the CPC during immunoprecipitation from X. laevis egg extracts. Asterisk indicates full-length HP1α/γ.

In order to assess the sequence context and level of conservation
of the serines identified as phosphorylation sites, I generated a sequence
alignment of the human HP1 isoforms with the HP1 proteins of other
organisms. As shown in Figure 4.4, the overall sequence conservation
within the hinge region is rather low. HP1αS92ph/HP1γS93ph is part of
a highly conserved region right in the middle of the hinge sequence. This
sequence motif (KRKS) is found in HP1 proteins from mammals down
to flies. Similar, though not identical, sequence motifs are found in S.
pombe (SKRK, KSRK) and T. thermophila (RKS, KRS) (not shown in the
alignment).
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Figure 4.4: Sequence alignment of the HP1 hinge region.
4.4

Sequence alignment of the hinge regions of HP1 isoforms from different organisms (equivalent to human HP1α amino acids 72-114). Overall, the conservation
of the hinge region is not very high, with the exception of two conserved stretches
of basic amino acids in the middle and in the C-terminal part of the hinge. HP1α
S92 and HP1γ S93 (asterisk) are homologous residues and are part of a conserved
sequence motive KRK(S) (blue box). hHP1: human, mHP1: mouse, xHP1: X. laevis, dHP1: Drosophila melanogaster. Drosophila HP1b was not included, because
the ClustalW algorithm used did not align its KRKS motive to the cassette in the
other HP1s (compare to Figure 1.7).

In the human HP1β isoform, the serine is replaced with an
alanine (KRKA), which explains the isoform-specificity of the observed
phosphorylation. That the alanine is not always found in exactly the same
isoforms (in X. laevis, HP1α has an alanine, while HP1β and HP1γ have
serines; in flies KRKS is found in HP1a and HP1b, but not in HP1c) may
indicate that in distinct organisms biological functions may be distributed
differently between the isoforms.
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The KRKS motif resembles the Aurora B target site on histone
H3 (ARKS around lysine 9 and lysine 27). The ARKS sequence has the
characteristics of a "modification cassette" (Fischle et al., 2003a) that
includes sites of methylation, effector protein binding (HP1 and Polycomb,
respectively; see Chapter 1), phosphorylation, and methyl-phos switching
(see Chapter 3). Even in non-histone proteins, a closely related modification
cassette has been found to be a site of methylation, and simultaneous
phosphorylation of the neighbouring site leads to "methyl-phos switching"
(the ARKT motif in the methyltransferase G9a seems to function as a
"histone mimic", Sampath et al., 2007; see also Chapter 3, Discussion,
section "Methyl-phos switching at other sites"). This suggested to me that
the very similar, conserved KRKS motif might play an interesting role in
the biology of the HP1 hinge.

Specific antibody for HP1αS92ph
To examine the phosphorylation sites in vivo, I decided to rely on
modification-specific antibodies against the sites. An HP1αS92ph serum
was made available to me through the generosity of Dr. Raul Urrutia (Mayo
Clinic, Rochester, MN). This group had just carried out computer-based
phospho-site predictions of HP1 for various cellular kinases. On this basis,
they had generated several sera for predicted phospho-serines in the HP1
sequence, and two of these sera were against HP1αS92ph and HP1γS93ph.
To avoid direct competition, we decided to collaborate with a division of
labor such that I would focus on the HP1α phosphorylation, while they
would work on HP1γ.
As a first step, I characterized the HP1αS92ph serum and tested
its specificity in western blotting experiments with unmodified and in vitro
phosphorylated HP1 isoforms. As shown in Figure 4.5A, the serum ("Phos128

HP1α antibody") turned out to be quite specific for HP1αS92ph, with little
cross-reactivity to the other HP1 isoforms or unmodified HP1α.
The HP1αS92ph antibody was also tested in peptide competition
experiments with extracts of nocodazole-arrested HeLa cells (which carry
the HP1αS92 phosphorylation; see following section). Again, in these
experiments the antibody proved highly specific for its epitope (Figure
4.5B).

HP1αS92 phosphorylation is a mitotic mark in vivo
Taking advantage of the HP1αS92ph antibody, I set out to test whether the
S92 phosphorylation mark indeed also existed in vivo. Since I had observed
in vitro phosphorylation of serine 92 with a mitotic kinase complex (the
CPC), I decided to look for the signal in cells arrested in mitosis. These
western blotting experiments from cellular extracts confirmed the existence
of HP1α S92 phosphorylation in vivo and showed that HP1αS92ph is
specifically enriched in cells arrested in mitosis (Figure 4.6A).
Similar observations were made in immunofluorescence experiments
carried out with HeLa cells. In these experiments mitotic cells were stained
strongly, while for interphase cells only a very weak background staining
was observed (Figure 4.6B). That the observed IF signal was indeed specific
for the HP1αS92ph epitope was confirmed by IF peptide competition
experiments (Figure 4.6C).
To study the kinetics of the HP1αS92ph mark in more detail, I
carried out a time-course experiment with cells synchronized by doublethymidine block (Figure 4.6D). Consistent with my findings obtained with
nocodazole-arrested samples, the HP1αS92ph signal was specifically
observed in mitosis, showing similar kinetics as the mitotic marker H3
serine 10 phosphorylation.
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Figure 4.5: Characterization of the HP1αS92ph antibody 4.5
in immunoblotting.
A: Recombinant HP1 isoforms were incubated with recombinant Aurora B kinase
in the presence or absence of ATP. Immunoblotting of these samples shows that
the HP1αS92ph antibody ("Phos-HP1α" antibody) distinguishes with exquisite
specificity between the isoforms as well as between the phosphorylated and unphosphorylated form. Bracket indicates area where full-length recombinant HP1
proteins run.
B: Peptide competition experiment with Phos-HP1α antibody. The antibody
(1:2000) was preincubated with different peptides (2 µg/ml) and then used for
immunoblotting of HeLa total cell extracts (asynchronous cells or cells arrested in
mitosis with nocodazole). Only the phosphorylated HP1α peptide can compete the
signal. HP1α peptides: amino acids 83-101. H3 peptide: amino acids 1-20.
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Figure 4.6: HP1αS92 phosphorylation is a mitotic mark.
A: Whole cell extracts of HeLa cells (asynchronous or arrested in mitosis with nocodazole) were analyzed by western blotting. The mitotic marker H3S10ph confirms enrichment for mitotic cells upon nocodazole treatment. While HP1α levels
do not change, HP1α serine 92 phosphorylation is specifically observed in mitotic
cells.
B: Immunofluorescence microscopy of HeLa cells. The mitotic cell shows intense
HP1αS92ph staining, while the interphase cell next to it is not stained at all.
General HP1α staining confirms that this observation is not simply explained by
changes in the levels of HP1α or differences in antibody accessibility.
C: Peptide competition. The HP1αS92ph antibody (1:200) was preincubated with
different peptides (2 µg/ml) and then used for immunofluorescence staining of
HeLa cells. Competition with a phosphorylated HP1α peptide completely abolishes
the observed signal, while control peptides (unmodified HP1α peptide, H3S10ph
peptide with the very similar ARKS sequence) have no effect. HP1α peptides:
amino acids 83-101. H3 peptide: amino acids 1-20.
D: HeLa cells were synchronized by double-thymidine block. After removal of the
second S-phase block, samples were taken at regular intervals and whole cell extracts analyzed by immunoblotting. The Phos- HP1α signal comes up in mitosis
(around 12 h), at the same time as the mitotic marker H3 serine 10 phosphorylation. U: Unsynchronized cells; N: Nocodazole-arrested cells.
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Overall, these western blotting and IF experiments confirm that
HP1α serine 92 is indeed a site of phosphorylation in vivo, and that this
site is specifically phosphorylated in mitosis.

Detailed characterization of HP1αS92ph by immunofluorescence
microscopy
In order to take a closer look at the temporal correlation between HP1αS92ph
and the well characterized mitotic marker H3S10ph, I carried out an IF
costaining of HP1αS92ph and H3S10ph by (Figure 4.7A). This analysis
confirmed that there is a close temporal correlation in the appearance
of the two marks (both at late G2/early prophase). The staining of both
antibodies disappears slowly around the stage of cytokinesis (Figure 4.7A).
At first sight, the localization of the HP1αS92ph signal with its exclusion
from chromatin during mitosis looks very similar to stainings with general
HP1α antibodies (data not shown).
Closer inspection of immunofluorescence stainings, however, yielded
two intriguing observations (Figure 4.7B): The first is that the HP1αS92ph
antibody stains two dot-like structures that look in their cellular position
and their migration behaviour like spindle poles/centrosomes. The
second, that at telophase there are differences between the stainings of
the HP1αS92ph antibody and a general HP1α antibody (Millipore MAB
3584) (see below).

Presumed centrosomal staining
Dot-like structures suggestive of centrosomal staining had on occasion also
been observed in prophase (Figure 4.7A) or even interphase (Figure 4.6C),
even though these stainings were not very reproducible. To investigate
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Figure 4.7: Detailed characterization of the HP1αS92ph signal by immunofluorescence microscopy.
A: Immunofluorescence microscopy of HeLa cells after costaining for HP1αS92ph
and H3S10ph. The signal of the two antibodies appears with a very similar timing
in early prophase. HP1αS92ph then follows the movement of HP1α as it dissociates from chromatin. The signal becomes weaker as mitosis proceeds, but is still
visible untill cytokinesis.
B: Immunofluorescence microscopy of HeLa cells after staining with the indicated
antibodies. The HP1αS92ph antibody stains dot-like structures, most likely centrosomes, in metaphase as well as cytokinesis. In cytokinesis, the general HP1α
staining shows that most of HP1α has already reassociated with chromatin. However, HP1αS92ph staining is at this point still excluded from chromatin. Note
4.7

that the general HP1α and Phos-HP1α stainings depicted in this figure are not
co-stainings, but rather individual stainings.
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whether the spindle pole signal was the result of a small amount of highly
phosphorylated HP1α at the centrosomes or just a crossreactivity of the
HP1αS92ph antibody, I studied the effect of HP1α knock-down by RNAi on
the staining of HeLa cells (Figure 4.8).

HP1

Phos-HP1

DAPI

No RNAi

HP1 RNAi

Figure 4.8: Effect of HP1α RNAi on centrosomal staining of the Phos-HP1α
4.8

antibody.

Immunofluorescence microscopy with HP1αS92ph and HP1α antibodies after
transfection with HP1α or mock siRNAs. HP1α RNA interference clearly reduced
the levels of HP1α, as well as the Phos-HP1α signal in the cytoplasm/nucleus.
The dot-like structures seem less affected.

It is difficult to judge from these pictures to what extent the signal
of the dot-like structures is affected by the RNAi, because partial removal
of strong dot-like staining may be hard to detect and quantify, and the
effects were somewhat variable. My overall conclusion is, however, that
there is little if any effect of HP1α RNA interference on the dot-like staining.
Because, in addition to this finding, I had never observed myself nor seen
in the literature any reports of spindle pole/centrosome staining with any
general HP1α antibody, I concluded that the centrosomal staining may
be a crossreactivity and decided not to follow up on this observation any
further.
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HP1αS92ph labels a pool of HP1α that is still excluded from chromatin
at cytokinesis
The second curious observation made from the IF stainings of Figure 4.7B
are the differences between HP1αS92ph and general HP1α stainings at
the end of mitosis. In late telophase/cytokinesis, the majority of HP1α
is already back at its binding site at chromatin, as can be seen from the
staining with the general HP1α antibody. At the same time, however, the
(fading) Phos-HP1α signal is still seen largely in the cytoplasm, indicating
that HP1α molecules carrying the S92 phosphorylation mark have not yet
reassociated with chromatin. Thus, it seems that the Phos-HP1α antibody
marks a specific subpool of HP1α that has not yet re-engaged into a
molecular interaction with chromatin.
The observation was confirmed by costainings in several human
(HeLa, HeP2 cells; data not shown) as well as mouse cell lines (NIH3T3,
10T1/2; see Figure 4.9A). In addition to reproducing the exclusion of the
HP1αS92ph signal from chromatin at telophase/cytokinesis (see Figure
4.9B for blow-up), these experiments also confirmed that HP1α S92
phosphorylation exists in mouse cells and behaves exactly as in human cells.
(In peptide competitions, the general HP1α signal (Monoclonal Antibody
#3584 from Chemicon/Millipore) was unaffected by both unmodified
and phosphorylated HP1α peptides in immunofluorescence and western
blotting experiments (data not shown).)
That the S92 phosphorylation staining is excluded from chromatin
is of course just a correlation and does not prove any causal link between
this phosphorylation and the regulation of HP1α chromatin association. An
alternative explanation would be for example the existence of a chromatinassociated phosphatase that removes the phospho-mark as soon as HP1α
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Figure 4.9: Differences between HP1αS92ph and general HP1α stainings

telophase.
A: Detailed analysis of HP1αS92ph in mouse 10T1/2 fibroblast cells (IF). Kinetics and localization of the HP1αS92ph staining are very similar to the stainings
observed in human cells. (Note: The pronounced punctate staining of HP1α in
interphase cells is a known characteristic of mouse cells.)
B: Blow-up from panel A with increased settings for sensitivity and contrast. As
in human cells, Phos-HP1α labels in mouse cells specifically the pool of HP1α
that has not yet reassociated with chromatin at telophase/cytokinesis.
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comes close. However, it is tempting to speculate that the exclusion of
phosphorylated HP1α from chromatin may be indicative of a causal
relationship, that S92ph controls HP1α chromatin association and that
the phosphorylation has to be removed for stable reassociation of HP1α at
the end of mitosis.
Experiments that I carried out to follow up on this observation are
described below (Section "A role for HP1α serine 92 phosphorylation in
regulating HP1α chromatin association?"). However, before I go into detail
about these experiments, I will first present data in which I confirm that
Aurora B is indeed the kinase responsible for S92 phosphorylation in
vivo.

Aurora B is the kinase responsible for HP1α S92 phosphorylation in
vivo
As shown in Figure 4.7A, HP1α S92 phosphorylation and H3 S10
phosphorylation take place at about the same time in late G2/early
prophase, suggesting that Aurora B may be responsible not only for H3 S10,
but also for HP1α serine S92 phosphorylation. In addition, the sequence
context of HP1α serine 92 (KRKS) resembles known Aurora B target sites
(e.g. in H3S10: ARKS), and Aurora B efficiently phosphorylates HP1 in
vitro. Furthermore, HP1α (as well as HP1γ) has been reported to interact
with another component of the Chromosomal Passenger Complex, INCENP
(Ainsztein et al., 1998). Thus, I decided to directly test the hypothesis that
Aurora B is responsible for HP1α S92 phosphorylation in vivo.
To begin, I turned to immunofluorescence costaining to show that
Aurora B and HP1α indeed colocalized at the time of HP1α phosphorylation.
As expected for a chromosomal passenger protein, in prophase at the time
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when HP1αS92 phosphorylation occurs, Aurora B was found all over the
chromosomes, therefore significantly overlapping with the localization of
HP1α serine 92 phosphorylation (data not shown). Encouraged by this
correlative observation, I went ahead to test involvement of Aurora B in
mitotic HP1α phosphorylation in a more direct way.

Aurora B inhibition with hesperadin
To test directly whether Aurora B is indeed the kinase responsible for
mitotic HP1α phosphorylation in vivo, I carried out Aurora B inhibition
experiments with the small molecule inhibitor hesperadin (Hauf et al.,
2003). However, Aurora B activity is required for multiple important steps
in mitosis, and without it the spindle check-point does not function,
preventing mitotic arrest by chemicals commonly used for this purpose.
Since detection of HP1αS92ph in western blots requires enrichment for
mitotic cells, I was forced to adapt a more indirect approach (Hauf et al.,
2003).
HeLa cells were arrested in mitosis by treatment with nocodazole for
12 h. Then the arrested cells were treated with hesperadin. Simultaneously
with hesperadin, the proteasome inhibitor MG132 was added to the cells,
which precludes the degradation of anaphase inhibitor and thus prevents
cells from leaving metaphase. After a brief incubation of 15 min with
hesperadin/MG132, cells were harvested and tested by western blotting.
Generally, phosphatases are globally present and constitutively
active, while kinases are highly regulated in their localization and activity.
The phosphorylation of a specific site is determined by the balance between
these counteracting forces. Consequently, if Aurora B is the kinase
responsible for serine 92 phosphorylation, inhibition of this kinase should
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shift the phosphorylation/dephosphorylation balance in the arrested cells
towards the unphosphorylated form, resulting in a reduced HP1αS92ph
signal.
With control immunoblots I verified that my basic experimental
set-up was working (Figure 4.10). When I subsequently checked the
effect of the hesperadin/MG132 treatment on HP1αS92ph, I found that
the phosphorylation signal accumulated upon nocodazole arrest was
significantly reduced and brought down to levels observed in unsynchronized
cells. This strongly supports the hypothesis that Aurora B is indeed the
kinase responsible for HP1α S92 phosphorylation in vivo.
Hesperadin
& MG132:

- + - + +

Nocodazole:
HP1S92ph
HP1 gen.
Cyclin B1

*

H3S10phos
H3 general
Figure 4.10: Aurora B inhibition with the small molecule inhibitor hesperadin decreases HP1αS92 phosphorylation.
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HeLa cells were arrested in mitosis with nocodazole. Then they were either treated
with hesperadin/MG132 or vehicle. Asynchronously growing cells (no nocodazole
treatment) serve as control.
As expected, nocodazole arrest results in accumulation of the mitotic cyclin B1
(asterisk indicates a crossreacting band) as well as increased levels of H3S10ph
and HP1αS92ph. Blots with antibodies against general H3 and HP1α confirm
equal loading. Upon treatment with hesperadin/MG132, the cyclin B1 signal persists, proving that cells did not leave mitosis. Levels of H3S10ph and HP1αS92ph,
on the other hand, are reduced upon hesperadin/MG132-treatment.
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However, it should be noted that the described inhibition experiment
is based on a chemical compound, which might have unspecific effects
on other kinases. Indeed, off-target effects of hesperadin have already
been reported (e.g. on Aurora A, Hauf et al., 2003). I therefore decided
to complement the small molecule inhibition experiment with a second,
independent method.

Aurora B knock-down by RNA interference
To verify the observations made in the inhibition experiment through a
second approach that was independent of a chemical compound, I carried
out knock-down experiments of Aurora B by RNA interference.
Because Aurora B knock-down prevents the straightforward use of
nocodazole to arrest cells in mitotis (see above), I generated a synchronized
population of HeLa cells by double-thymidine block. Between the first and
second block, the cells were transfected with siRNAs targeted at the Aurora
B sequence. After the release of the second block and transition through
S phase, the synchronized cell population was harvested upon entry into
mitosis (as judged from cells deattaching and rounding up). Cell synchrony
and enrichment for mitotic cells in samples transfected with Aurora B and
mock siRNAs was confirmed by flow cytometry (Figure 4.11, left).
Western blotting shows that Aurora B RNAi resulted in almost
complete removal of the kinase, while Aurora A protein levels were
unaffected (Figure 4.11, right). When I examined how this specific removal
of Aurora B affected mitotic HP1α S92 phosphorylation, I found a significant
decrease in the levels of this mark. This strongly supports the hypothesis
that Aurora B is indeed the kinase responsible for phosphorylation of HP1α
serine 92 during mitosis in vivo.
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Figure 4.11: Aurora B RNAi decreases HP1αS92 phosphorylation.
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Left: Analysis of DNA content of cells synchronized by double-thymidine block.
Cells were stained with propidium iodide, analyzed by flow cytometry and the
data plotted as histograms. 2N: DNA content of diploid cell (before replication).
4N: doubled DNA content after replication.
a: In a control population of unsynchronized HeLa cells, most cells are in G1
phase (2N DNA content) and only few cells in S (between 2N and 4N) or G2 (at 4N).
b: Positive control: HeLa cells in mitosis (arrested in prophase with nocodazole)
uniformly have 4N DNA content. c: HeLa cells 2h after double-thymidine blot
proceed through S phase as a homogeneous population. d, e: Cells synchronized
by double-thymidine block, transfected with mock (d) or Aurora B siRNAs (e),
and harvested at mitosis. Most cells have 4N DNA content, indicating reasonably good cell synchrony. d) and e) are the samples used for analysis by western
blotting, see on the right. f: Synchronized HeLa cells prevented from proceeding
through mitosis by nocodazole block. Comparison of d and e with f shows that
a small number of cells in d and e had already progressed through mitosis and
reentered G1 at the time of harvesting. However, there is still significant enrichment for mitotic cells observed in d) and e).
Right: Western blots of synchronized HeLa cells treated with either Aurora B or
mock siRNAs, and harvested when the majority of cells were in mitosis (see left,
panels d and e). Aurora B RNAi efficiently reduces Aurora B protein levels, while
not affecting Aurora A. Even though HP1α protein levels are similar in both samples, HP1α serine 92 phosphorylation is significantly decreased in the sample
treated with Aurora B siRNAs.
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In sum, I have presented multiple experiments that all support the
interpretation that Aurora B is the kinase responsible for mitotic
phosphorylation of HP1α at serine 92. Colocalization of Aurora B and HP1α
at the time of phosphorylation, chemical inhibition, knock-down of Aurora
B by RNA interference, site-specific in vitro phosphorylation as well as
the published observation reporting an interaction of HP1α with another
member of the Chromosomal Passenger Complex, INCENP (Ainsztein et
al., 1998), all point in the same direction. While it cannot be ruled out
that there are other kinases that contribute to this phosphorylation at the
onset of mitosis, the simplest interpretation of my data is that Aurora B is
the main kinase responsible for HP1α serine 92 phosphorylation in vivo.

Hypothesis: Does HP1α serine 92 phosphorylation play a role in
regulating HP1α chromatin association?
The observation that HP1αS92ph specifically stains a subpopulation of
HP1α which has not yet reassociated with chromatin is highly intriguing,
because it raises the possibility that serine 92 phosphorylation may play a
role in the regulation of HP1α chromatin association.
As conclusively shown by the findings described in Chapter 3 of my
thesis, H3 serine 10 phosphorylation is essential for the mitotic release of
HP1 from chromatin, and other groups have confirmed this observation
(Hirota et al., 2005; Terada, 2006b). However, these different reports do
not fully agree as to whether H3 serine 10 phosphorylation is actually also
sufficient for HP1α dissociation. While in peptide binding assays reduced
binding of the chromo domains of all three HP1 isoforms and of full-length
HP1β to H3K9me3S10ph peptides was found (Fischle et al., 2005a; Hirota et
al., 2005), H3S10 phosphorylation seems not sufficient to prevent binding
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of full-length HP1α and HP1γ (Fass et al., 2002; Terada, 2006a). Differences
in the experimental systems cannot fully account for these conflicting
observations. One intriguing explanation to this conundrum is, however, a
possible contribution of other HP1 domains besides the chromo domain to
the association of full-length HP1α and HP1γ with chromatin. If in addition
to the chromo domain-H3K9me interaction other molecular interactions
contribute to stable association of HP1α and HP1γ with chromatin in vivo,
then reversal of chromo domain-binding by methyl-phos switching may
not be sufficient for the release of the full-length proteins.
This

interpretation

is

supported

by

observations

that

our

collaborators Boo Tseng and Dr. Hironori Funabiki made with Xenopus
egg extracts during the study of methyl-phos switching. While exogenous
full-length xHP1α was released from chromatin in the presence of CPC
and retained upon depletion of the CPC, a point mutation that abolished
the CD-H3K9me interaction displayed an intermediate effect and clearly
some binding in CPC-depleted extracts (Fischle et al., 2005b).
Contributions of additional interactions besides the CD-H3K9me to
HP1 chromatin interaction have been suggested repeatedly in the literature
(Dialynas et al., 2006; Eskeland et al., 2007; Muchardt et al., 2002; see
Chapter 1, Section "Molecular Mechanisms of HP1 Recruitment"). The
molecular mechanism for the reversal of such interaction(s) may well be
phosphorylation on the side of the effector protein HP1.
Given the phosphorylation of HP1α and HP1γ, it might seem surprising
that HP1β is not phosphorylated. However, considering the differences in
the interactions of the different isoforms, it is possible that HP1β does not
require Aurora B phosphorylation, because it simply does not undergo
the specific interaction that is reversed by HP1α/γ phosphorylation. Of
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interest in this context, in none of the publications reporting interaction of
full-length HP1 with H3 carrying serine 10 phosphorylations was retention
of HP1β reported. In our own experiments full-length HP1β was readily
released from H3K9me peptides upon S10 phosphorylation (Figure 3.7B).
Based on the observation that HP1αS92ph closely correlates with
HP1α release and specifically stains a subpopulation of HP1α which is
largely not associated with chromatin in immunofluorescence, and the
possible importance to release other HP1 interactions besides the CDH3K9me interaction as described above, I formulated the hypothesis that
HP1α S92 phosphorylation might play a role in the mitotic release of HP1α
from chromatin in vivo (Figure 4.12).
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Figure 4.12: Hypothesis: HP1α serine 92 phosphorylation is a necessary
step for the dissociation of HP1α from chromatin in vivo.
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This hypothesis assumes that stable HP1α binding to chromatin invovles, in addition to chromo domain binding to H3K9me, a second interaction mediated by
the hinge region (to an unknown chromatin component X). Efficient release of
HP1α from chromatin during mitosis is therefore a two-step process and involves
not only methyl-phos switching, but also HP1α serine 92 phosphorylation to reverse the hinge interaction. Stable reassociation of HP1α to chromatin at the end
of mitosis, on the other hand, requires the removal of HP1αS92ph.
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S92 phosphorylation correlates with increased extractability of
HP1α
Support for the hypothesis came from observations I made in biochemical
experiments. Following a protocol commonly used in the Allis lab to prepare
chromatin on a small scale, I extracted chromatin prepared from mitotic
HeLa cells with a low-salt buffer (Mendez and Stillman, 2000). When I
then compared the S92 phosphorylation of extracted and retained HP1α
by western blotting, I found that the level of HP1αS92 phosphorylation
correlates with the extractability of HP1α (Figure 4.13A).

A pool of HP1α associated with metaphase chromosomes is not
recognized by the Phos-HP1α antibody in IF experiments
A second observation in support of the hypothesis that serine 92
phosphorylation may play a role in HP1α chromatin association came
from immunofluorescence microscopy. In metaphase cells, I observed on
occasion a pool of HP1α that specifically localized to chromatin. However,
this pool of HP1α was only detected by general HP1α staining and not with
the Phos-HP1α antibody (Figure 4.13B).
One possible explanation for this finding is that some HP1α protein
is not phosphorylated and therefore remains chromatin-associated
throughout metaphase. This would be in keeping with the hypothesis that
HP1α serine 92 phosphorylation plays a role in the release of HP1α from
chromatin (for alternative explanations see below).
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Figure 4.13: Biochemical and IF experiments suggest that HP1α serine 92
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phosphorylation may indeed regulate HP1α chromatin association.
A: Mitotic HeLa cells were lysed with 0.2% NP40 and purified chromatin was
extracted with a buffer of low ionic strength ("low-salt buffer": 2 mM KCl/3 mM
EDTA/0.2 M EGTA). Serine 92 phosphorylation of extracted (S, soluble) and unextracted (I, insoluble) HP1α was compared by western blotting. Levels of phosphorylation are much higher in the extracted fraction. C: chromatin fraction before extraction; S: soluble in low-salt buffer; I: insoluble in low-salt buffer.
B: Immunofluorescence microscopy of HeLa cells. Staining with a general HP1α
antibody labels a pool of HP1α that is associated with the mitotic chromosomes
of metaphase cells. This pool of HP1α is not recognized by the Phos-HP1α antibody.
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Stable cell lines expressing HP1α with serine 92 point mutations
Encouraged by these findings, I decided to test the hypothesis that HP1α
phosphorylation at serine 92 might be involved in the control of HP1α
dissociation from chromatin directly. However, I did not have specific
knowledge of which interaction(s) might be stabilizing HP1α's chromatin
binding. In fact, the details of HP1 chromatin binding in vivo are exceedingly
complex, possibly requiring several steps of binding and stabilization
and multiple interactions (see Chapter 1). While it is clear that the CDH3K9me3 interaction is a particularly important interaction for binding
of HP1 to chromatin, HP1 chromatin association in vivo is not completely
understood. This made it impossible for me to set up an in vitro system
of which I could be sure that it fully reflected the in vivo situation. Thus,
I reasoned that the best way to test my hypothesis was the expression of
HP1α constructs with S92 mutations in cultured mammalian cells. If the
hypothesis in Figure 4.12 was correct, then an unphosphorylatable HP1α
should be retained at chromatin (at least in the most extreme scenario).
Similarly, an HP1α construct that mimics constitutive phosphorylation
should not reassociate properly with chromatin at the end of mitosis.
(Since the interaction controlled by S92 phosphorylation might be only of
a stabilizing nature, it was possible that the phenotype would be a little
less pronounced.)
To this end, I generated HeLa cell lines that stably expressed tagged
HP1α with either wt (wild-type) sequence or with a point mutation at
serine 92 (mutated to alanine to prevent phosphorylation; mutated to
glutamate to mimic constitutive phosphorylation). Originally, I developed
stable cell lines expressing HP1α fused with Green Fluorescent Protein
(GFP). However, with these cells I observed significant differences in the
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fractionation behaviour of wt GFP-HP1α and endogenous HP1α (data not
shown). Thus, I generated a second set of cell lines with a much smaller
FLAG-HA-FLAG tag. As a control for effects caused by the tag, I generated
two sets of cell lines with the constructs tagged on the N-terminal and the
C-terminal side of the protein, respectively.
In western blotting experiments, the cell lines for both N-terminally
(Figure 4.14) and C-terminally tagged (data not shown) HP1α were
characterized, proving expression of a protein of the expected size (Figure
4.14, left). Tagged HP1α is phosphorylated with the same efficiency as
endogenous HP1α (Figure 4.14, right), and in fractionation experiments
as well as peptide pull-down experiments with H3 peptides tagged HP1α
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Figure 4.14: Characterization of HeLa cell lines stably expressing FLAG-HAtagged HP1α.

4.14

Cell line expressing N-terminally FLAG-HA-tagged HP1α shown. Whole cell extracts of cell lines were analyzed by immunoblotting. Left: An additional band
of the expected size is detected in the HP1α western blot, showing the expression level of the tagged HP1α. Right: Upon nocodazole arrest, exogenous tagged
HP1α is phosphorylated to the same extent as endogenous HP1α (compare with
ratio of bands in HP1α blot). HP1α(N): HeLa cells stably expressing N-terminally FLAG-HA-tagged HP1α. wt: Unaltered HeLa control cells. Amidoblack shows
equal loading of the lanes. Similar results were obtained with the C-terminally
tagged constructs.
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No obvious effect of serine 92 mutation on HP1α localization
The effect of serine 92 mutation on the localization of HP1α was analyzed
by immunofluorescence microscopy after staining with an HA antibody.
Clearly, the tag did not alter the cellular localization of HP1α in these
experiments, because tagged wt HP1α (no mutation) showed the same
localization as observed before for endogenous wt HP1α (Figure 4.15, top
row).
Inter

Meta

Ana

Telo

HP1 (N)

HP1 S92A (N)

HP1 S92E (N)

Figure 4.15: No obvious effect of HP1α serine 92 mutations on HP1α local4.15

ization.

Immunofluorescence microscopy (anti-HA) of HeLa cell lines stably expressing
FLAG-HA-tagged HP1α constructs with and without serine 92 point mutations.
Typical stainings are shown. Point mutation of serine 92 does not have any clear
effect on HP1α localization or dynamics at the different stages of mitosis.
Stages of mitosis are indicated above the panels. (Since only mouse interphase
cells show clear heterochromatic dots, no such dots are observed in these HeLa
cell stainings.) HP1α (N): HP1α with wt sequence, N-terminally tagged; HP1α S92A
(N): HP1α with serine 92 mutated to alanine, N-terminally tagged; HP1α S92E (N):
HP1α with serine 92 mutated to glutamate, N-terminally tagged. Comparable observations were made with the C-terminally tagged constructs.
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If serine 92 phosphorylation was indeed essential for the regulation
of HP1α dissociation during mitosis, I reasoned that mutating this serine
should affect the localization of HP1α during mitosis. Mutation of serine 92
to alanine precludes phoshorylation and may therefore prevent the release
of HP1α from chromatin; mutation of serine 92 to glutamate, on the other
hand, might mimic constitutive phosphorylation (phosphomimic) and may
thus delay or even prevent stable reassociation of HP1α with chromatin
at the end of mitosis. However, my analyses failed to show any obvious
effects of the serine 92 point mutations on HP1α localization or dynamics
(Figure 4.15).
There are several possible explanations why these point mutations
of serine 92 do not have any clear effect on HP1α localization. S92ph could
be redundant with other phosphorylations or other covalent marks, or may
need to cooperate with additional modifications in order to bring about an
effect on HP1α's chromatin association (see below section "Redundancy /
Requirement for cooperation"). But it is of course also possible that serine
92 phosphorylation does indeed fulfill its function on its own, but that this
function is simply not the regulation of HP1 chromatin binding. Serine 92
phosphorylation could for example control a different molecular interaction
of HP1α that has to be released/established during mitosis, but that does
not affect the association of HP1 with chromatin.

Hypothesis: HP1α serine 92 phosphorylation regulates the HP1α's
association with a specific binding partner
If such an interaction exists, I reasoned that a yet unidentified binding
partner would display differential binding to unmodified versus S92phosphorylated HP1α. Based on this assumption, I set out to identify
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molecules that bound to the serine 92 region of HP1α if it was unmodified,
but were abrogated, if S92 was phosphorylated, or vice versa.

Peptide pull-downs to identify protein interactions controlled by HP1α serine
92 phosphorylation
My first approach to identify such phosphorylation-dependent binders
was by peptide pull-down (Wysocka, 2006). Protein modules binding in
dependence of a single modifications often recognize only a short sequence
stretch around the modification site (Seet et al., 2006); thus, a peptide
was generated that included the site of modification and about ten amino
acids upstream and downstream (HP1α residues 83-101). Phosphorylated/
unmodified HP1α peptides were immobilized on avidin-coated agarose
beads and incubated with cellular extracts. After washing steps, bound
proteins were eluted and run out on SDS-PAGE gels, to identify specific
bands after silver-staining. Since a binding protein might be a factor that
is only expressed at a certain time during the cell cycle, extracts from
both asynchronously growing and nocodazole-arrested HeLa cells were
used. To minimize the risk of peptide dephosphorylation by phosphatases
present in the extract, high concentrations of phosphatase inhibitors (25
mM NaF, 25 mM β-glycerolphosphate, 6 mM Orthovanadate, CalBiochem
Phosphatase Inhibitor Set (contains Cypermethrin, Dephosphatin, Okadaic
acid, and NIPP-1); these are levels known to protect endogenous HP1α
from dephosphorylation) were present at all times during the pull-down.
However, no phospho-specific bands were detected reproducibly in these
first pull-downs.
Several technical aspects of the experimental procedure could account
for this. Therefore, I repeated the experiment under various conditions,
152

such as different methods of extract preparation, using HeLa S3 suspension
cells (larger cell number results in higher extract concentration, in case
the binding partner was only a low-abundance protein) and lowering the
number and stringency of washing steps (to reduce the risk of washing off
a low-affinity interactor). To make sure even weak specific binders were
not missed in this complex protein mixture, whole gel lanes were analyzed
by mass spectrometry (carried out by the MS facility of the Max-PlanckInstitute for Biophysical Chemistry in Göttingen, Germany). Subsequently,
the complete lane was compared in its protein content and abundance
with control pull-downs.
To validate the approach, I also included a positive control by using
K9me3 and unmodified H3 peptides (Figure 4.16). As expected, in the
H3K9me3 pull-down all three HP1 isoforms HP1α, HP1β and HP1γ were
found. In contrast, no HP1 peptides were detected in the pull-down with
unmodified H3 peptide. Thus, the control pull-downs specifically enriched
for the expected modification-dependent interactors and verified the
approach.
Comparison of the proteins in pull-downs with HP1α S92ph and
unmodified HP1α peptides (see Figure 4.16 for example), however, did not
lead to the identification of any convincing and reproducible candidates.
Minor differences in the binding to the two peptides seemed either caused
by handling (different keratins), unspecific binding of abundant and sticky
cellular proteins (e.g. chaperonin, ribosomal proteins, actin, tubulin) or
could be excluded due to their cellular localization (e.g. mitochondrial
proteins).
Besides the possibility that S92 phosphorylation simply does not
regulate a protein interaction at all, there are several other possible reasons
why pull-down experiments may not have led to the identification of an
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interactor. It could be that the binding partner was not present in sufficient
abundance in the extracts used or that the affinity of the interaction is
very low. Indeed, interactions depending on a single posttranslational
modification have often been found to be rather weak (Fischle et al.,
2003b; Pawson, 1995; Ruthenburg et al., 2007). The low affinity may even
be a prerequisite for dynamic regulation, and in the context of the fulllength protein such interactions could be stabilized by additional contacts
with other partners. In this case a classical biochemical pull-down with
a peptide may simply not be sensitive enough for the identification of the
interaction partner.
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Figure 4.16: Peptide pull-down to identify phosphorylation-dependent
bind-

ers of HP1α.
Peptide pull-down carried out with a nuclear extract of unsynchronized HeLa S3
cells. (Similar experiments were completed with extracts from nocodazole-arrested cells.) Extracts were incubated with biotinylated peptides immobilized on avidin-coated agarose beads. After washes the beads were boiled in protein sample
buffer, and the mixture was run out on an SDS-gel and stained with Coomassie.
Lanes were subsequently cut into small pieces and subjected to analysis by mass
spectrometry. Lanes 3 and 4 show the control pull-down with unmodified and
K9-methylated H3 peptides. Some differences are so clear that they can even be
seen in the coomassie staining. All three HP1 isoforms were subsequently identified specifically in the H3 K9me3 lane (asterisk marks a band that is most likely
HP1γ). Lanes 5 and 6 show an example of an HP1α (83-101) peptide pull-down
(unmodified vs. S92ph). Only little protein binds to the HP1α peptides (compare
to lane 2), and banding patterns for the two pull-downs are virtually identical.
154

Phage display screen for interacting proteins regulated by HP1α serine 92
phosphorylation
To exclude that an interaction partner was missed due to these limitations
of the biochemical pull-down, I applied a complementary approach by
phage display screening, which I carried out (as some other experiments
described in this thesis) in the laboratory of Dr. Wolfgang Fischle at the
Max-Planck-Institute for Biophysical Chemistry in Göttingen (Germany).
Its multiple rounds of clonal enrichment (see Figure 4.17) make this
approach particularly suited for the identification of weak interactions
with rare binding partners.
To verify that the screen was working as expected, control peptdides
(unmodified H3 peptide and H3K9me3 peptide) were probed with a library
containing minute amounts of an HP1-expressing phage (diluted 1:106).
Within a few rounds of selection, the H3K9me3 peptide significantly
enriched for the HP1-expressing phage (Figure 4.18, left), proving that
this phage display screening protocol can indeed be used for efficient
and highly selective enrichment for specific binders of posttranslational
modifications.
The actual screen for binding proteins controlled by HP1α S92
phosphorylation was carried out with two different phage libraries (from
liver and brain tissue; Novagen), to increase the chances that a binding
protein was found in the library. For every peptide I worked in duplicates,
to estimate the reproducibility of the results. To my disappointment, the
screening with the HP1α peptides did not result in the enrichment of
any specific phages, as judged by a preliminary analysis by PCR (Figure
4.18, right). Any follow-up experiments would have involved a significant
investment in time and effort (screening of clones from last round of
selection; sequencing of fused mammalian cDNA sequence; verification of
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identified interactions). The preliminary analysis by PCR suggested that it
was unlikely that a binding partner would be identified in the end (even
though the positive control showed that the procedure was working in
general). I therefore decided to abandon the phage display screen.

Figure 4.17: Principle of phage display screening.
Principle of the phage display screen for factors specifically interacting
with
4.17
HP1αS92ph. An immobilized HP1αS92ph peptide (1) is incubated with a library
of phages expressing different cDNAs on their surface (2). After washing steps
(3), phages binding to the peptide are released (4) and the eluted phages amplified in bacteria (5). The resulting mixture of phages is used for a second round
of peptide binding (6). By successive rounds of binding and amplification phages
expressing specific binding proteins are enriched, even if the interaction is rather
weak and the binding protein present only at very low abundance in the original
library (7).
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Unmod.

---

K9me3

Unmod.

S92ph

*

H3 (1-20) peptides

HP1 (83-101)
peptides

Figure 4.18: Phage display screen to identify phosphorylation-dependent
4.18
binders of HP1α.

Phage mixtures eluted after different rounds of selection were analyzed by PCR
(with sequencing primers annealing on both sides of the insert within the phage
sequence). The appearance of specific bands indicates the enrichment for individual phages. For each peptide, selection rounds 1 to 5 are shown, separated by
a lane with DNA molecular weight marker.
Left: Control. For the H3K9me3 peptide, a strong band of the expected size (asterisk) is observed within few rounds of selection, proving fast and strong enrichment for phages expressing HP1. The unmodified H3 peptide shows no significant
enrichment besides the band that is also seen in the beads-only control.
Right: Actual screen. Neither with the unmodified HP1α peptide nor with the
HP1αS92ph peptide specific bands (besides the band seen in the beads-only control) are observed.

Redundancy / Requirement for cooperation
At this point, I pursued several different approaches (and variations of these)
in order to identify a phospho-dependent binding partner. Even though
I had tried to anticipate and work around limitations of some of these
approaches, there were of course still multiple trivial technical explanations
possible why the experiments undertaken had not succeeded.
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It cannot be excluded, for example, that the length of the HP1α peptide
used in these assays (19 aa) was simply not sufficient for stable binding,
even though modules binding in dependence of a single posttranslational
modification often recognize only a few amino acids around that mark (Seet
et al., 2006). I carried out pilot experiments by passing cellular extracts
over a recombinantly expressed HP1α hinge construct, but obtained
protein mixtures too complex to analyze, possibly because the hinge region
is not structured and therefore extremely sticky as an isolated domain. As
an alternative explanation, it was also possible that a phosphorylationdependent binding partner existed, but that it was not a protein, but
a nucleic acid and therefore not represented in the extracts/libraries I
used.
However, besides these possibilities, there was another explanation
for the failure to identify S92ph-dependent binding that seemed even more
likely: Serine 92 phosphorylation may not fulfill its function on its own,
but in concert with other modifications. This could even explain why no
phenotype was detected upon S92 mutation in vivo.
If there are indeed multiple sites of posttranslational modification
in mitosis and modification of some of these is already sufficient for HP1α
dissociation (i.e. there is redundancy among the modifications), this could
explain why S92A mutation does not prevent dissociation of HP1α. The
interplay of several sites of posttranslational modification could also be
the reason why S92E mutation has no detectable effect: If a threshold
number of sites have to be modified simultaneously to cause dissociation
of HP1α from chromatin (i.e. a "requirement for cooperation" of several
modifications), mutation of a single site to glutamate will not prevent
HP1α from reassociating at the end of mitosis. Thus, the existence of
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other modifications that collaborate with S92ph could explain the lack
of a phenotype for point mutations of serine 92 despite all the intriguing
correlative observations made.
As far as the type of posttranslational modification that may be
collaborating with S92 phosphorylation is concerned, it could in principle
be any kind. However, it seems particularly tempting to speculate about a
role of phosphorylation. Additional phosphorylation would further increase
the negative charge already introduced by S92ph, multiple kinases are
known to be active during mitosis, and E. Minc et al. had already made
observations suggesting that there may be more than one site of mitotic
HP1α phosphorylation (Minc et al., 1999).
Studying the role of HP1α S92 phosphorylation in the context of
such other mitotic phosphorylations is only possible, if these other
phosphorylations (or modifications) are known. Therefore, I decided that
it would be a worthwhile undertaking to examine the posttranslational
modification profile of HP1 in detail.

Purification of HP1
In order to identify and map the sites of mitotic HP1 phosphorylation/
modification, I decided to purify the protein from cultured cells and
determine the posttranslational modification profile by mass spectrometry
(MS). Besides novel modifications, the MS approach also promised to
confirm the existence of mitotic HP1α S92 phosphorylation in vivo through
a completely independent method (in addition to the antibody-based
methods I had already used), and might possibly even permit quantifying
the abundance of the S92ph mark in mitotic and interphase cells.
Three different approaches for the purification of HP1 were
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developed, which I briefly summarize below. In each of these cases, the
actual mass spectrometric analysis was carried out by my collaborator
Hillary Montgomery in the lab of Dr. Don Hunt at the University of Virginia
(Charlottesville, VA).
(1) Acid extraction and HPLC enrichment of endogenous HP1 followed by
analysis from SDS-PAGE gel
I isolated endogenous HP1 by acid extraction from highly enriched
mitotic HeLa cells (nocodazole treatment followed by mitotic shake-off,
resulting in about 95% enrichment for mitotic cells).

Upon further

separation by reversed phase HPLC (Figure 4.19A, left), HP1-containing
fractions were run out on an SDS-PAGE gel (Figure 4.19A, right), and
HP1 bands excised and analyzed by MS.
This approach led to the identification of three phosphorylations
(HP1βS89ph, HP1γS93ph and HP1γS95ph), but unfortunately no
convincing modification was identified for the isoform that I was most
interested in, HP1α. Peptide coverage for all HP1 isoforms was low due
to three technical aspects of the procedure: Firstly, acid extraction,
even though the method of choice for enrichment of histones, is not
very effective for the extraction of HP1, a finding that may be due to
differences in isoelectric point (mammalian HP1 has a much lower pI
than histones; note that this is in contrast to, e.g., Tetrahymena HP1,
which has a pI more similar to that of histone proteins). Secondly, the
approach requires proteolytic digestion and subsequent recovery of
peptides from gel bands, which is often inefficient. And thirdly, in-gel
digests are usually done with trypsin, and due to its richness in basic
amino acids especially the HP1 hinge is cut by trypsin into pieces too
small for most analyses.
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Figure 4.19: Purification of HP1 for analysis of modification profile by mass
spectrometry.
A: Approach 1: Enrichment for of endogenous HP1 isoforms by acid extraction,
RP-HPLC and gel electrophoresis.
Left: Proteins acid extracted from mitotic HeLa cells were separated by RP-HPLC
on an acetonitrile gradient. Fractions containing the HP1 isoforms were identified
by slot blotting (the three isoforms eluted together, area between red lines). It is
clear from the chromatogram that HP1 proteins are, in contrast to e.g. histones,
only minor components in the extract. Right: HPLC fractions containing HP1
proteins were united and run on an SDS-PAGE gel, to cut bands for MS analysis.
Asterisk: band containing (among other proteins) HP1α and HP1β. Arrow head:
band containing HP1γ.
B: Approach 2: Purification of endogenous HP1γ by cell fractionation and immunoprecipitation (HP1γ shown because HP1α runs exactly behind antibody band).
Left: HP1γ western blots after immunoprecipitation from the cytoplasmic fraction of mitotic HeLa cells. Most of the HP1γ in the fraction is precipitated in the
HP1γ IP, while the control IP shows that this is dependent on the HP1γ antibody.
I: Input. U: Unbound. B: Bound. Right: Coomassie-stained gel of the HP1γ IP
and control IPs (25% ot total IPs loaded). Compared to the amounts of antibody,
the levels of HP1γ (arrow head) in the IP are rather low . Note, though, that HP1
peptides were not analyzed from the gel, but rather directly from the beads after
limited proteolytic digest.
C: Approach 3: Purification of tagged, overexpressed HP1α from mitotic HeLa
cells by cell fractionation and immunoprecipitation from the cytoplasmic fraction.
Coomassie-stained gel (10% of total IP loaded). Arrow head: position of tagged
HP1α. Asterisks: antibody bands.
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(2) Cell fractionation and immunoprecipitation of endogenous HP1 followed
by analysis on the beads
To overcome these problems, I turned to a second approach for the
purification of HP1. For more efficient extraction of HP1, cultured cells
were subjected to biochemical fractionation (Wysocka et al., 2001), and
all proteins subsequently stripped off of DNA with a high-salt buffer.
The HP1 isoforms were further enriched by immunoprecipitation with
monoclonal HP1 antibodies (Figure 4.19B, left). HP1 was then digested
directly on the beads (not from the gel), and resulting peptides subjected
to MS.
Even though only partial digests were carried out and I had
verified saturation of the beads with HP1, a large excess of antibody was
detected in these MS samples (see Figure 4.19B, right), most likely due
to the procedure of antibody immobilization (I used anti-mouse beads to
immobilize anti-HP1 monoclonals, and some of the antibody may have
been bound in an inactivating fashion). MS analysis of HP1α against
such a background of antibody protein fragments turned out to be next
to impossible. Only upon inclusion of an additional enrichment step for
phospho-peptides by IMAC (immobilized metal affinity chromatography)
could novel HP1 modifications be identified.
The above altered approach resulted in the identification of
multiple phosphorylations for all three HP1 isoforms (see below). It
also led to the first proof by mass spectrometry for the existence of the
S92ph mark in vivo. However, inclusion of the IMAC step made any
quantification of the levels of phosphorylation impossible.
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(3) Cell fractionation, immunoprecipitation and on-beads analysis of
exogenous tagged HP1
To reduce the amount of antibody in the sample, I took advantage of my
cell lines expressing the three HP1 isoforms with a FLAG-HA tag and
switched to anti-FLAG agarose beads, while still pursuing an approach
of immunoprecipitation/on-beads analysis (Figure 4.19C). The samples
obtained by this procedure turned out to be very well suited for the
analysis by mass spectrometry and even allowed for quantification of
phosphorylation levels.
To investigate whether the phosphorylation levels changed in
the course of the cell cycle, I purified and analyzed HP1 from both
asynchronously growing and mitotically enriched (nocodazole-treated)
cell populations, and diverse fractions (cytoplasmic, nucleoplasmic,
chromatin-associated). Overall, the analysis led to the identification of
six phosphorylation sites on HP1α, one on HP1β and three on HP1γ (see
Figure 4.20 and Figure 4.21 for example mass spectra; see Figure 4.23
for summary of results). I will discuss these phosphorylations in detail
in the section below entitled "Most phosphorylations cluster within the
hinge region of HP1α".
Several other proteins were detected in the IPs that despite rigorous
washing steps co-immunoprecipitated with the tagged HP1α. Especially
the HP1α IPs were analyzed in depth, and we found that many of these
coprecipitating proteins were published interaction partners of HP1α,
such as HP1β, HP1γ, Su(var) 3-9, KAP-1, INCENP, CAF1 p150, Lamin B1,
Lamin B Receptor, Ki-67, BRG1, and NIPBL (see Table 4.1). In addition,
a few factors were detected that are members of complexes shown before
to interact with HP1, for example Dasra B/Borealin, CAF1 p60, or NSL1
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4.20

Figure 4.20: Tandem mass spectrum of a singly phosphorylated HP1α peptide (S92ph) (Figure courtesy of Hillary Montgomery).
Tandem mass spectrum (MS/MS) of a singly phosphorylated HP1α peptide
(S92ph), residues 87-108, fragmented by electron transfer dissociation (ETD).
The peptide was generated by an on-beads digest of exogenous HP1α with endoproteinase Glu-C. A fraction of the resulting peptide mixture was analyzed by online nanoflow high performance liquid chromatography micro-electrospray ionization tandem mass spectrometry (nHPLC-µESI MS/MS). The instrument cycled
through the acquisition of a full-scan mass spectrum (MS) and the top five most
abundant masses in this initial MS scan were sequentially chosen for tandem MS
(MS/MS) spectra (depicted in this Figure). Full sequence coverage was attained
for this +6 charged peptide, 442.40 m/z. The spectrum provides evidence that
the HP1α peptide is phosphorylated at serine 92. c’ and z’• fragment ions are denoted in blue and red, respectively. Doubly-charged fragment ions are denoted
with asterisks (*).
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4.21

Figure 4.21: Tandem mass spectrum of a doubly phosphorylated HP1α peptide (S85phS92ph) (Figure courtesy of Hillary Montgomery).
Tandem mass spectrum (MS/MS) of a doubly phosphorylated HP1α peptide
(S85phS92ph), residues 76-108, fragmented by electron transfer dissociation
(ETD). Full sequence coverage was attained for this +7 charged peptide, 572.10
m/z. The spectrum shows that this HP1α peptide is doubly phosphorylated, at
serine 85 and serine 92. c’ and z’• fragment ions are denoted in blue and red,
respectively. Doubly-charged fragment ions are denoted with asterisks (*).
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4.22
Figure 4.22: Tandem mass spectrum of an HP1γ peptide defining the
HP1γ

N-terminus (Figure courtesy of Hillary Montgomery).
Tandem mass spectrum (MS/MS) of the N-terminal peptide from HP1γ, residues
2-24, fragmented by electron transfer dissociation (ETD). Full sequence coverage
was attained for this +5 charged peptide, 522.10 m/z. The spectrum confirms the
existence of an N-acetylated peptide ASNKTTLQKMGKKQN… in vivo. This implies
that translation of HP1γ starts ten residues upstream of what is often assumed to
be the N-terminus of HP1γ. c’ and z’• fragment ions are denoted in blue and red,
respectively. Doubly-charged fragment ions are denoted with asterisks (*).
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Table 4.1: Known interaction partners of HP1 found in the HP1 IP
Identified interaction

Reference

HP1beta

Le Douarin et al., 1996

HP1gamma

Le Douarin et al., 1996
Aagaard et al., 1999

SUV39H1
Czvitkovich et al., 2001
KAP1

Le Douarin et al., 1996

INCENP

Ainsztein et al., 1998
Murzina et al., 1999

CAF1 p150
Ryan et al., 1999
BRG1

Nielsen et al., 2002

Lamin B1

Kourmouli et al., 2000

Lamin B receptor

Ye et al., 1997

Ki-67

Scholzen et al., 2002

NIPBL

Lechner et al., 2005

SUV39H1: Suppressor of varieagation 3-9 homolog 1. INCENP: Inner
centromere protein. CAF1: Chromatin assembly factor 1. BRG1: Brahmarelated gene 1 (also known as SWI/SNF-related matrix-associated actindependent regulator of chromatin). NIBPL: Nipped-B like protein.

Table 4.2: Proteins found in HP1 IP that are components of complexes
known to interact with HP1
Identified interaction
Dasra B/Borealin

Complex

Reference

Chromosomal Passenger

Sampath et al., 2004

Complex

Ainsztein et al., 1998

NSL1

Mis12 Complex

CAF1 p60

CAF1 Complex

Euskirchen, 2002
Obuse et al., 2004
Murzina et al., 1999

NSL1: NNF1 synthetic lethal. NNF1: Necessary for nuclear function 1. CAF1:
Chromatin assembly factor 1.
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(Table 4.2). Co-immunoprecipitation of these proteins can be considered
as further validation that the tagged HP1α protein indeed undergoes the
same interactions and behaves the same way as endogenous HP1α.
Of interest, from coimmunoprecipitated HP1γ, Hillary Montgomery
and I could obtain specific information about the HP1γ N-terminus (Figure
4.22), which settles a long-standing uncertainty about the exact translation
start site of the protein. Detection of a peptide ASNKTTLQKMGKKQN…
demonstrates that in Hela cells, translation of HP1γ starts (also) ten amino
acids upstream of what is often assumed as the protein's N-terminus
(MGKKQN…). We also found that the terminal methionine of HP1γ is
actually processed, and that the protein is N-acetylated.
In addition to known interaction partners of HP1α, a number of
other proteins were identified from these IPs. These include several
transcriptional regulators (BCLAF, ERH, TRAP3), proteins involved in sister
chromatid cohesion and cell division (Prohibitin 2, NDR1), and a protein
phosphatase (PP1) (see Table 4.3). These proteins co-purified with tagged
HP1α, but unfortunately there was no selection for phospho-dependent
binders in this pull-down.

Most phosphorylations cluster within the hinge region of HP1
Most of the identified phosphorylation sites map to the hinge region
of HP1 (Figure 4.23). This is intriguing, because it suggests that the
phosphorylations may indeed collaborate to bring about a hinge-mediated
effect, for example in the regulation of a molecular interaction. Thus, it
provides support for the hypothesis that redundancy among the different
HP1 phosphorylations may indeed be the reason why mutation of serine
92 to alanine has no observed phenotypic effects.
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Table 4.3: Potential novel interaction partners of HP1
Identified interaction

Reference

BCLAF

Kasof et al., 1999

ERH

Isomura et al., 1996

TRAP3

Fondell et al., 1996

Prohibitin 2

Coates et al., 1997

NDR1

Millward et al., 1995

PP1

Trinkle-Mulcahy and Lamond, 2006

BCLAF1: BCL2-associated transcription factor 1 (also known as Btf, . ERH:
Enhancer of rudimentary homolog. TRAP3: Thyroid hormone receptor
associated protein 3. NDR1: Nuclear Dbf2-related kinase (also known as Serinethreonine kinase 38). PP1: Protein phosphatase 1.
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Figure 4.23: Cartoon depiction of HP1 phosphorylation sites
identified by
4.23
mass spectrometry.
The phosphorylation sites identified by mass spectrometry are: S85, S87, S92,
S95, S97, and S110 in HP1α; S89 in HP1β; and S93, S95, and S176 in HP1γ.
Almost all phosphorylation sites fall within the hinge region of the HP1 proteins.
Yellow star: acetylation site identified in the HP1α chromo domain (K24). Mass
Spectrometry was carried out by my collaborator Hillary Montgomery (Hunt lab,
UVA)
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Because of the striking density of serine residues in this region, the
HP1 hinge has long been speculated to be phosphorylated (Badugu et al.,
2005). However, actual evidence for the existence of such phosphorylations
has been lacking so far. The mass spectrometry data generated by Hillary
Montgomery and me is the first time that definitive evidence is presented
for the existence of such a series of phosphorylations in the hinge region.
Compared to the other two domains of HP1, the hinge region has received
much less attention. The discovery of these posttranslational modifications
of the hinge may therefore contribute to our understanding of this
understudied domain of HP1.

Conservation of phosphorylation sites
Sequence conservation of the serines identified as phosphorylation sites
was assessed from an alignment of the human HP1 isoforms with the HP1
proteins of other organisms (Figure 4.24). Outside of the conserved blocks
of basic amino acids, the hinge regions of most HP1s have a high density
of serines, glutamic acid and aspartic acid; however, the exact order of
the serines and acidic residues is not conserved between organisms. But
despite this low conservation at the level of the exact amino acid sequence,
the composition and character of this region is well preserved across the
different species.
The conservation of the basic and acidic (i.e. charged) character of
these clusters makes it reasonable to assume that a molecular interaction
mediated by these patches of positively and/or negatively charged amino
acids could be conserved across different organisms. And if the target
sequence for the kinase(s) responsible for the observed phosphorylations
(besides serine 92) is defined simply by an acidic sequence context, it is
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well possible that the phosphorylations as well as the responsible kinase(s)
are conserved between different species.

hHP1
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K AKEAE---PKAKTESTKRKA------GSDDIKAKR RRE-S NDIA
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identical

similar
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Figure 4.24: Alignment of the hinge regions of HP1 proteins
4.24from different species indicating the position of the newly identified phosphorylation
sites.
Low sequence conservation between the conserved blocks of basic amino acids
makes it difficult to obtain a meaningful alignment. However, the character of
these sequence stretches seems very well preserved between species. Identified
phosphorylation sites in green. hHP1: human, mHP1: mouse, xHP1: Xenopus
laevis, dHP1: Drosophila melanogaster HP1.

Higher levels of phosphorylation in mitosis
The IPs of tagged exogenously expressed HP1α allowed me to obtain
quantitative data for several of the phosphorylation sites from both
asynchronous and mitotic samples. Comparing the phosphorylation
levels (see Table 4.4) clearly reveals that there is a significant increase of
phosphorylation during mitosis at several of these sites. It seems possible
that I have identified the sites for which indications had been found
before by the Buendia lab (Minc et al., 1999). While the levels of mitotic
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Table 4.4: Relative phosphorylation levels obtained by MS

phosphorylation found in the quantitative MS analysis may not seem high,
I assume that the values measured are artificially low due to technical
aspects of the experimental procedure (such as incomplete enrichment
for mitotic cells or phosphatase activity during extended incubations and
handling). This is supported by other observations that I lay out in more
detail in the Discussion at the end of this chapter.
In summary, our mass spectrometry analysis of HP1α posttranslational
modifications revealed that the protein is multiply phosphorylated. The
sites of phosphorylation specifically cluster in the hinge region in an area
with a high density of serines and acidic amino acids between blocks of
basic residues, a characteristic that is conserved between species. The
levels of phosphorylation at most of these sites are specifically upregulated
during mitosis.

Hypothesis: Multiple HP1α hinge phosphorylations collaborate to
control the mitotic release of HP1α from chromatin
Having identified this series of novel phosphorylations in the HP1α
hinge, I was now in a position to reevaluate the hypothesis that HP1α
phosphorylation may play a role in the release of HP1α, this time taking the
potential collaboration of multiple phosphorylations into consideration. For
this purpose I generated stable HeLa cell lines expressing HP1α constructs
in which all the sites of mitotic HP1α phosphorylation were mutated to
alanine (six sites, see Figure 4.23; because I made the cell lines before
our MS approach finally succeeded, the construct included an additional
seventh mutation, S103A). To control for unwanted effects of the tag, two
versions of this HP1α "aStA" construct (for "all Serines to Alanine") were
generated, one with an N- and one with a C-terminal FLAG-HA-tag.
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By immunofluorescence microscopy I examined if there was any
effect of the mutations on the localization or dynamics of HP1α in mitosis. If
there was indeed a role of the hinge phosphorylations in the mitotic release
of HP1α, then simultaneous mutation of all mapped phosphorylation sites
should affect the dissociation of HP1α from chromatin despite redundancy
among the phosphorylation sites. However, even simultaneous mutation
of all serines in the HP1α hinge to alanine did not have any detectable
effect on the localization of the protein, neither in interphase nor at any
stage of mitosis (data not shown).
At first sight, this seems to reject the hypothesis that HP1α hinge
phosphorylation might play any role in the control of mitotic HP1 dissociation
from chromatin. However, upon more careful reflection, it became clear
that even after ruling out redundancy of phosphorylations as a potential
problem, there was still another major aspect of the experimental system
that could significantly complicate the experimental read-out, namely HP1
dimerization.
As described in the Introduction, it has been known that, through its
chromoshadow domain, HP1α can both homodimerize and heterodimerize
with HP1β and HP1γ (Platero et al., 1995; Smothers and Henikoff, 2000).
The interaction is strong enough to be observed in pull-downs with
recombinant components (Ye et al., 1997), and it is known that the different
HP1 isoforms affect each other in their localization in vivo (Dialynas et al.,
2007).
In the tissue culture system that I was using for the analysis of
the hinge mutations, endogenous unmutated HP1α, HP1β and HP1γ were
still present in addition to the exogenous, mutated HP1α I was testing.
Thus, it was possible that interaction with the endogenous, unmutated
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HP1 isoforms had a significant impact on HP1 dynamics in mitosis and
"masked" the effects of the mutations.

Analysis of HP1α aStA localization in cells devoid of endogenous
HP1α, HP1β and HP1γ
Point mutations abolishing HP1 dimerization have been published by
others before (e.g. HP1αI165E/HP1β161E, Brasher et al., 2000). However,
these mutations also affect other interactions of the HP1 CSD (some of
which actually depend on HP1 dimerization), and have been reported to
significantly reduce chromatin association of HP1 and change its localization
(Thiru et al., 2004). Thus, I reasoned that my best experimental option
was a cell system in which the endogenous HP1 proteins were absent.
Genetic knock-outs in mammalian cells have never been reported for any
of the HP1 isoforms in the literature. Similarly, it is unlikely that a stable
simultaneous knock-down of all three isoforms will be able to survive for
extended periods of time, because knock-down of two of the three isoforms
by RNA leads already to failure to segregate chromosomes faithfully during
cell division (Obuse et al., 2004). Thus, I reasoned that the best way to do
this experiment was by triple knock-down through simultaneous transient
transfection of siRNAs against all three endogenous HP1 isoforms.
To make sure that only the endogenous HP1α was knocked down
and not my mutated construct, I generated dsRNA oligos directed against
the 5' untranslated region of the gene (a gift from Dr. Wolfgang Fischle,
Goettingen; see Figure 4.25A). With fluorescent RNA oligos and flow
cytometric analysis I optimized the transfection conditions until I reached
efficiencies of >95% (data not shown). Even though successful transfection
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Figure 4.25: Localization of HP1α hinge mutations after knock-down of endogenous HP1 isoforms by RNAi.
A: Strategy of specific RNAi against endogenous HP1α. HP1α siRNAs were targeted against the 5' untranslated region of the HP1α gene, which is not present
in the mRNA of the exogenous HP1α construct that carries the phosphorylation
site mutations.
B: Immunoblots of cells at time of analysis by IF. Specific and almost complete
knock-down of all three endogenous HP1 proteins is observed. Exogenous, tagged
HP1α is unaffected by the RNAi. That there are sometimes traces of signal left
after RNAi may be because of the small fraction of cells that were not transfected
with the respective siRNA.
Asterisk: Exogenous HP1α. (Extended periods of culture led to a reduction in the
expression levels of N-terminally tagged HP1α. The specific effects of the RNAi on
the HP1 protein levels are therefore clearer in the C-terminally tagged cell lines.)
N: N-terminally tagged HP1α without mutations. N-aStA: N-terminally tagged
HP1α with all S in hinge mutated to A. C: C-terminally tagged HP1α without mutations. C-aStA: C-terminally tagged HP1α with all S in hinge mutated to A.
C: Immunofluorescence microscopy (anti-HA) of HeLa cell lines stably expressing
HA-tagged HP1α constructs, either with wt sequence or with all serines in the
hinge mutated to alanine, with or without triple knock-down of endogenous HP1
isoforms (stainings shown are representative of what was commonly observed).
No clear differences are seen at any of the cell cycle stages.
HP1α (N): HP1α with wt sequence, N-terminally tagged; HP1α "all S to A" (N): HP1α
with all serines in the hinge region mutated to alanine, N-terminally tagged
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of individual cells cannot be tracked during the final experiment, these
extremely high transfection efficiencies assure that 80-90% of cells will
receive all three oligos.
For the actual experiment, cells were transfected with either HP1α/
β/γ siRNAs or random sequence siRNA. The day after the transfection, cells
were split into two fractions and either seeded on cover slips for analysis
by IF, or replated for biochemical analysis of the knock-down. Cells were
harvested 3.5 d after transfection, according to pilot experiments the time
of lowest protein levels (data not shown).
Immunoblotting proved efficient knock-down of all three endogenous
HP1 isoforms, while the levels of exogenous HP1α protein were unaffected
(Figure 4.25B). However, even with endogenous HP1 isoforms largely
absent, I did not discover any clear differences in the localization of wt and
mutated HP1α in my analysis of immunofluorescence stainings (Figure
4.25C).
Theoretically, it is possible that the efficiency of the knock-down was
simply not efficient such that the remaining traces of endogenous HP1
isoforms were still sufficient to prevent an effect of the mutations. However,
this scenario seemed not very likely. Despite a number of observations
pointing in that direction, despite pursuing diverse experimental
approaches, mutating all serine residues in the HP1α hinge, and even
knocking down all endogenous HP1 isoforms simultaneously, I did not
find any clear evidence to support the hypothesis that phosphorylation
of the HP1α hinge controls the mitotic release of HP1α from chromatin.
Of course my experiments do not completely rule out such a possibility.
However, I decided that at this point that further follow-up experiments on
the hypothesis were not justified and that it would be the best for me to
reconsider other hypotheses.
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Hypothesis: HP1α hinge phosphorylation regulates reassociation of
HP1α with chromatin in metaphase
Alternatively, HP1α hinge phosphorylation may be the key to explain a
curious experimental observation of HP1 biology that I also pointed out
in the Introduction to this thesis: After the global release of HP1 from
chromatin at the onset of mitosis, a small fraction of HP1α (and, possibly,
also of HP1β and HP1γ) reassociates with the centromeric regions of the
chromosomes in metaphase (Hayakawa et al., 2003; Minc et al., 1999).
Hayakawa and colleagues mapped the region of HP1α that is required for
the reassociation with centromeres during metaphase. They found that
the above reassociation is independent of the chromo domain and rather
mediated by a region comprising the C-terminal part of the hinge and the
chromoshadow domain (aa 101-180).
Only a fraction of HP1α reassociates, and it has thus already been
suggested that posttranslational modification might be the mechanism how
this reassociation of HP1α is controlled (see Figure 4.26). While most of
the identified phosphorylation sites lie just outside of this mapped binding
region, due to tertiary structure effects or simply the immediate proximity
to the binding region the addition of a series of negative charges to the HP1α
hinge could prevent the interaction that causes this reassociation of HP1α
with the metaphase chromatin. This interpretation is supported by previous
observations, where serine 92 phosphorylation seems exclusive with the
binding of a pool of HP1α to metaphase chromosomes (Figure 4.13B). This
suggests HP1α hinge phosphorylation as the molecular mechanisms to
keep the majority of HP1α from reassociating with metaphase chromatin.
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Figure 4.26: Hypothesis: HP1α hinge phosphorylation regulates
4.26reassociation of HP1α with chromosomes in metaphase.
Schematic overview of the hypothesis: After HP1α is globally released from chromatin by methyl-phos switching (and possibly other mechanisms), a fraction of
HP1α reasociates with centromeric chromatin through chromo domain-independent mechanisms. This reassociation may be controlled by HP1α hinge phosphorylation. Only the pool of HP1α that happens to remain unphosphorylated
may be able to rebind, while HP1α hinge phosphorylation prevents the molecular
interactions for reassociation with metaphase chromosomes.

For better visualization of the small pool of chromatin-bound HP1α
against the large background of HP1α in the cytoplasm at metaphase,
an alternative protocol of fixation and extraction for immunofluorescence
microscopy was adapted (Figure 4.27A; Dormann et al., 2006). This protocol
was then used to compare the reassociated, chromatin-bound pool of two
HP1α constructs, one with all hinge phosphorylation sites mutated to
alanine, the other to glutamate.
No differences in the staining intensity were observed (Figure 4.27B)
suggesting that HP1α reassociation with chromatin is not significantly
altered by phosphorylation of the identified sites within the HP1α hinge.
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Figure 4.27: Mutation of phosphorylation sites in the HP1α 4.27
hinge has no
obvious effect on HP1α reassociation with metaphase chromosomes.
A: IF of HeLa cells stably expressing HA-tagged HP1α. Comparison of different
Fixation-Extraction procedures. If mitotic cells are fixed first and then extracted
(top), the excess of HP1α in the cytoplasm is seen. However, if the order is changed
and cells are extracted first and then fixed (bottom), all the unbound HP1α in the
cytoplasm is removed and the small pool of HP1α bound to metaphase chromatin
becomes visible.
B: Immunofluorescence microscopy (anti-HA) of HeLa cells stably expressing
tagged HP1α mutants. Cells were first extracted and then fixed. As commonly
observed, no difference in the HP1α pool associated with metaphase chromatin
is observed.
HP1α "all S to A" (C): HP1α with all serines in the hinge mutated to alanin and
C-terminal FLAG-HA tag. HP1α "all S to E" (C): HP1α with all serines in the hinge
mutated to glutamate and C-terminal FLAG-HA tag.
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Cell cycle FACS
In all the described IF experiments, mutated HP1α had shown the same
cellular localization at the different stages of mitosis as wt HP1α. In light
these observations, a direct involvement of HP1α hinge phosphorylation
in the regulation of HP1's chromatin dissociation or reassociation seems
unlikely. However, cells analyzed in IF experiments are "hand-picked" for
being in specific mitotic stages. It is therefore possible that eventually the
localization changes are the same for wt and mutant HP1α, but the kinetics of
these localization changes are actually different. Cells expressing mutated
HP1α constructs may simply take longer for their progression through
mitosis. Interestingly, mutation/deletion of HP1 is connected to lagging
chromosomes and delayed mitosis in several organisms (mostly of course
because heterochromatin integrity is important for centromere function;
Ekwall et al., 1995; Kellum and Alberts, 1995; Obuse et al., 2004).
To investigate whether mutations in the HP1α hinge region caused
such delays in mitosis, I carried out cell cycle FACS analysis of HeLa cells
expressing either wt or mutated HP1α. If the time for transition through
one of the steps of mitosis was extended, the fraction of cells in mitosis
would increase. However, my analysis of the flow cytometry data led only to
the discovery of minor differences between the individual samples (Figure
4.28). Since these differences showed no systematic pattern, they seemed
rather caused by random fluctuations or by the fact that these stable cell
lines that had been grown independently for a while, leading to minor
differences in their growth characteristics.
To exclude that the presence of the endogenous wild-type copy of
HP1α prevented the detection of a clear effect, I repeated the experiment
with cells in which the endogenous HP1α protein had been knocked down
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by RNAi. However, once again all the measurements fell within a rather
narrow range (data not shown), indicating that even in the absence of
endogenous HP1α there was no significant effect of the mutations on the
progression of mitosis.

4.28
Figure 4.28: Effect of HP1α hinge mutations on cell cycle progression.

Distribution of cell cycle stages of HeLa cell lines stably expressing various HP1α
constructs. Upon RNase digestion and propidium iodide staining, the DNA content of asynchronously growing cultures was determined by flow cytometry, followed by modelling of the culture's cell cycle distribution (Watson Pragmatic
model, FloJo software package).
The cell cycle distribution of the different cell lines is very similar.
N: N-terminally tagged HP1α without mutations. N-aStA: N-terminally tagged
HP1α with all S in hinge mutated to A. N-aStE: N-terminally tagged HP1α with all
S in hinge mutated to E. C: C-terminally tagged HP1α without mutations. C-aStA:
C-terminally tagged HP1α with all S in hinge mutated to A. C-aStE: C-terminally
tagged HP1α with all S in hinge mutated to E. N w/ Noco: Control cells (N-terminally tagged HP1α without mutations) arrested in mitosis with nocodazole.
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Hypothesis:

HP1α

hinge

phosphorylation

regulates

molecular

interactions of the hinge region
My thesis data suggest that hinge phosphorylation controls neither mitotic
HP1α dissociation from chromatin nor reassociation of a pool of HP1α
with chromatin in metaphase. Mutations of the phosphorylation sites also
do not affect progression through mitosis. However, the fact that these
phosphorylations in the HP1α hinge specifically occur in mitosis still
suggests that they may play a regulatory role at this phase of the cell
cycle.
It is unlikely that the phosphorylations fulfill their function by affecting
HP1α structure, because the hinge region is most likely unstructured (Ball
et al., 1997). There is also no indication that mitotic HP1α phosphorylation
affects protein stability; neither in the published literature, nor in any of
my experiments with synchronized cell populations or nocodazole arrested
cultures were changes in HP1α protein levels ever observed.
The identified modifications all cluster within a narrow region of the
HP1α hinge, adding a significant amount of negative charge to a rather
small patch of sequence. This suggests that HP1α hinge phosphorylation
may control a molecular interaction with a binding partner that associates
with this region of HP1α (Figure 4.29).
As outlined in the Introduction of my thesis, several molecules
have been described to bind to the hinge region of HP1α and are therefore
candidates: histone H1 (Hale et al., 2006), the chromosomal passenger
protein INCENP (Ainsztein et al., 1998), and RNA (Muchardt et al., 2002).
Since all these published reports included in vitro binding experiments, I
decided to test through direct in vitro interaction assays, whether any of
these interactions was affected by phosphorylation of the HP1α hinge.
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Figure 4.29: Hypothesis: HP1α hinge phosphorylation controls a molecular
interaction that has no connection to HP1 chromatin association.
Hypothesis: At the same time when methyl-phos switching releases HP1 chromatin association at the onset of mitosis, HP1α hinge phosphorylation reverses (or
establishes) a different molecular interaction with an unrelated molecule X.

Experiments to test if HP1α hinge phosphorylation controls HP1α's
interaction with histone H1
In 2006, the lab of Rafael Herrera (Baylor College, Houston)
reported a specific interaction of HP1α with H1b, a histone H1 isoform
predominantly found in heterochromatin (Hale et al., 2006; Th'ng et al.,
2005). The interaction was mapped to the HP1α hinge, and it was shown
that phosphorylation of H1b by CDK2 during interphase interrupts the
interaction, possibly to allow disassembly of higher order chromatin
structures for better access to the chromatin template (Roth and Allis,
1992). Since already phosphorylation of a single site in the H1b C-terminal
domain was sufficient to abolish the interaction, it is tempting to speculate
that phosphorylations on the HP1α hinge may have a similar effect.
In order to address the question in the most direct way, I relied on in
vitro binding experiments with recombinant proteins. However, although I
tried this experiment under various conditions (H1b purified under different
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(denaturing and nondenaturing) conditions, various salt concentrations,
presence/absence of BSA), I could never reproduce the reported specific in
vitro binding of H1b to the HP1α isoform or the specificity of binding to the
hinge region (data not shown).
My difficulties to repeat these experiments are mirrored by similar
observations made by other labs, who also have only seen unspecific
binding of H1b (Fischle, 2008). It cannot be ruled out that some minor
difference between our experimental procedures (e.g. different tags)
unexpectedly cause these conflicting observations. However, because
multiple approaches by multiple labs had not been able to reproduce the
reported results, I decided that it was advisable not to spend more time on
the interaction of H1b with HP1α.

Experiments to test if HP1α hinge phosphorylation controls HP1α's
interaction with RNA
The second molecular interaction of HP1α that I decided to examine was the
interaction with RNA. Prompted by observations by Maison et al. (Maison
et al., 2002), C. Muchardt and colleagues showed in 2002 in a series of
experiments (overlay assays and electrophoretic mobility-shift assays) that
HP1α and HP1γ bind RNA (Muchardt et al., 2002). While their in vitro
experiments were carried out with a random bacterial RNA, competition
demonstrated specificity with respect to the kind of RNA (competition by
mammalian nuclear RNA; no competition by AU- or GC-rich oligomers,
tRNA, or DNA). However, neither the nature nor the sequence of RNAs
bound by HP1α in vivo has been studied so far.
Muchardt and colleagues mapped the RNA binding activity in vitro
to residues 86 to 108 of HP1α (Muchardt et al., 2002), corresponding to
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the C-terminal half of the hinge, which is rich in basic amino acid (and
includes the KRKS sequence motif and most of the phosphorylation sites
that I identified within the HP1α hinge). Mutation of three adjoining
lysine residues within this sequence (K103, K104, and K105) to alanine
completely abolished RNA binding of HP1α. If the removal of three positive
charges by mutation entirely prevents RNA binding, then it seems quite
possible that the addition of multiple negative charges to the same region
by phosphorylation may have a similar effect. Thus, I hypothesized that
the HP1α hinge phosphorylations may have a function in the regulation of
RNA binding.
Further encouragement came from observations that I made while
purifying recombinant HP1α domains. After affinity purification of HP1α
hinge constructs (wt and with all serines in the hinge mutated to glutamate)
from E. coli cells, I took a UV-Vis spectrum of the purified protein. To my
surprise, the spectrum of the wt hinge had a significant peak at 260 nm
(Figure 4.30A, left) that was not present in the spectrum of the mutated
hinge construct (Figure 4.30A, right). Since the two samples had been
prepared in parallel and undergone exactly the same manipulation, this
suggested that a bacterial nucleic acid may be binding to and copurifying
with the wt HP1α hinge, while it did not associate with the mutated
hinge.
To verify the presence of the nucleic acid and learn more about
its nature, I treated aliquots of the dialyzed protein mixture with DNase
and RNase, respectively. Ethidium bromide staining after agarose gel
electrophoresis revealed that the 260 nm peak was caused by RNA (Figure
4.30B).
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Figure 4.30: HP1α hinge phosphorylation may regulate the interaction of
HP1α with RNA.
A: UV-Vis spectra of bacterially expressed His-HP1α hinge (wt or with serines in
hinge mutated to glutamate) after elution from Ni-NTA and dialysis. A peak at
260 nm (arrow) indicates that a nucleic acid copurifies with the wt HP1α hinge.
No such peak is observed in the spectrum of the mutated HP1α hinge.
B: The copurifying nucleic acid is RNA. Upon heat denaturing (5 min at 95º C),
aliquots of the elution from panel A were treated with either DNase or RNase A.
Only RNase treatmemt removes the nucleic acid.
C: Electrophoretic mobility shift assay to compare RNA binding of different HP1α
wt and mutant domains (autoradiography). As expexted, the control chromo domain construct does not bind the RNA probe and leaves the RNA in the unshifted
position (marked by an asterisk). While the wt HP1α hinge binds to and shifts the
RNA, the mutated HP1α hinge does not. (The signal that is seen in all lanes at the
top of the gel indicates that a fraction of the labelled RNA had aggregated.)
189

This suggests that (possibly due to the absence of its normal target
RNAs) the wt HP1α hinge associates by means of its RNA-binding capacity
with bacterial RNA. Mutation of the HP1α hinge (all serines in the hinge were
mutated to glutamate, introducing negative charges and thus mimicking
constitutive phosphorylation), on the other hand, seems to abolish the
ability of the HP1α hinge to bind RNA. Obviously, no conclusion can be
drawn from this experiment about the size or nature of RNAs bound by
HP1α in mammalian cells, because in this experiment nucleic acids were
sheared during cell disruption and the interaction with bacterial RNAs is
artifcial anyway. Nevertheless, the observation is completely in line with
the exciting hypothesis that phosphorylation of the HP1α hinge region
might indeed regulate the binding of RNA to HP1α.
As discussed above, so far little is known about the connection
between HP1α and RNA in vivo. In particular, no RNAs that may bind
HP1α in vivo have been identified yet. This makes it very difficult to design
experiments that directly test the effect of HP1α hinge phosphorylation on
RNA binding in the cell. Muchardt and colleagues used an in vitro method,
electrophoretic mobility-shift assays (EMSAs), to learn more about the
interaction they had observed in overlay assays (Muchardt et al., 2002).
Therefore, I decided to apply the same technique and subject the hypothesis
that HP1α hinge phosphorylation has an effect on HP1α's RNA binding to
a first test by EMSA.
To obtain recombinant protein for use in the EMSA, I took HP1α hinge
protein affinity purified from bacteria and then added an ion exchange
chromatography step to separate the protein component from the bacterial
RNA (data not shown). As RNA probe for these assays, a Drosophila mRNA
sequence (500 nt of the cyclin E gene) was used. In pilot experiments, I had
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established that this RNA probe reproduced the domain-specific binding
to HP1α described by Muchardt and colleagues (collaboration with Dr. E.
Bernstein, then a postdoc in the Allis lab; data not shown).
When I tested binding of the probe RNA to wt and mutated HP1α
domains, I observed a striking difference. The unmutated wt hinge bound
to and shifted the RNA probe. The mutated HP1α hinge (phospho-sites
replaced by glutamate), however, did not shift the probe at all (Figure
4.30C). While these experiments still are preliminary and have to be
repeated and extended, they are fully in keeping with the interpretation
that phosphorylation of the HP1α hinge region regulates the binding of
RNA to HP1α.

Discussion
Novel phosphorylations of HP1
In this chapter of my thesis, I have described the identification of a series of
phosphorylation sites of HP1. Phosphorylation at these sites is specifically
upregulated in mitosis, and most of them cluster in a short sequence
stretch of the hinge region, a domain of HP1 that so far has received
very little attention compared to the other domains of HP1. For one site,
HP1αS92ph, which is conserved between different species, I carried out a
detailed analysis with a modification-specific antibody and identified the
Chromosomal Passenger Complex as the responsible kinase in vivo.
Intrigued by curious correlations (Figures 3.5, 3.6, 3.9), I tested various
hypotheses about the function of these HP1 phosphorylations, ranging
from an involvement in the mitotic release of HP1α and a regulatory role in
the reassociation of a subpool of HP1α with metaphase centromeres to a
function in mitotic progression or the regulation of molecular interactions
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of HP1α, but no obvious effects were observed. In the last section, I present
experimental observations that suggest HP1α hinge phosphorylation may
regulate the interaction of the HP1α hinge with RNA.
The findings presented in this chapter of my thesis for the first time
identify specific phosphorylation sites of human HP1 (actually, while I was
working on this study, two other, non-mitotic phosphorylations of HP1
have been identified by other groups, see Chapter 5, General Discussion).
In 1999, Minc and colleagues had published observations made
from radioactive labelling experiments and western blotting after 2D gel
electrophoresis that allowed some predictions about the number of human
HP1 phosphorylations (Minc et al., 1999; see Figure 4.2). To what extent do
my findings match with the number of phosphorylation sites and changes
through the cell cycle suggested by the data of Minc and colleagues (Minc
et al., 1999)?
The most detailed analysis Hillary Montgomery and I carried out with
the HP1α isoform. For this isoform Minc and colleagues have indications
for low phosphorylation in interphase and hyperphosphoylation in
mitosis. This is fully in keeping with my findings (from their data, less
phosphorylation sites are expected in mitosis, but it is possible that
the two additional charged forms observed by Minc et al. are caused by
multiple sites, or that some of the phosphorylations in their experiment
were lost during handling). While my MS data on HP1γ is not as detailed,
it is also in line with the predictions (several phosphorylations). A major
discrepancy seems to exist, however, for HP1β, since I observed that HP1β
is phosphorylated (at S89), while Minc et al. claim that it was not (Minc
et al., 1999). Interestingly, MS data indicates that HP1β S89 is highly
phosphorylated, and to the same extent in both mitocic and unsynchronized
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samples (about 90%). Thus, it seems possible that the one spot in the 2D gel
of Minc and colleagues is caused by this phosphorylated species. Note that
Minc and colleagues claim that HP1β was not radioactively labelled, but do
not show the data, while they show this data for HP1α and HP1γ. This may
indicate that the HP1β labelling was ambiguous. Thus, it seems that my
mass spectrometry findings are overall in reasonably good agreement with
what was expected based on radioactive labelling and 2D gel electrophersis
by Minc and colleagues.
While the MS data generated by Hillary Montgomery and me
clearly shows an increase in phosphorylation during mitosis, the
levels in mitosis still are not very high, never reaching more than 30%
(see Table 4.4). However, for three reasons I suspect that the levels of
mitotic phosphorylation within the cell may be significantly higher than
suggested by our MS quantification. (1) The enrichment for mitotic cells
was not perfect. MS quantification was done from mitotic samples that
had not been further enriched by mitotic shake-off (to reduce the time
of handling), resulting in only about 75% enrichment for mitotic cells.
(2) Despite the use of phosphatase inhibitors there was probably some
loss of phosphorylation during the fractionation and immunoprecipitation
procedure. (3) In the samples obtained by approach 1 (higher enrichment
for mitotic cells, all steps under denaturing conditions), it was possible
to obtain quantitative data for one phosphorylation site, HP1γS93ph.
This serine is the homologous HP1γ site to HP1αS92ph, and it was found
phosphorylated to more than 70%. Unfortunately, no data for HP1αS92
could be obtained from this approach. However, these data suggests that in
vivo the homologous site HP1αS92 may have high mitotic phosphorylation
levels as well. The longer incubation times required for approach 3 (the
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approach used to purify HP1 for quantification of phosphorylation by MS,
which includes a cell fractionation step; see Section "Purification of HP1")
and the lower enrichment for mitotic cells in the starting material may
result in significantly underestimated levels of phosphorylation, possibly
at all sites.

Intriguing new experimental directions
The findings presented in this chapter open up interesting new experimental
directions. I identified Aurora B as the kinase responsible for HP1α S92
phosphorylation in vivo, but it has not beem addressed yet which kinases
are responsible for the other HP1 phosphorylations. Computational kinase
prediction suggests enzymes with a known cell cycle dependence as possible
kinases for HP1α hinge phosphorylation sites. For example, casein kinase
2 (Litchfield, 2003) was predicted for S85, S87, S97, and S110 in HP1α.
And S85 and S97 are predicted targets for the mitotic kinase PLK (Pololike kinase; Nigg, 1998). Thus, it will be very interesting to follow up on
this question in the future.
The identification of serine 89 of HP1β as a phosphorylation site with
high levels of phosphorylation (about 80%) in both interphase and mitosis
raises the question what the biological function of this modification may
be.
Besides phosphorylation, acetylation was discovered as another type
of HP1 posttranslational modification: HP1α was found to be acetylated at
lysine 24 (Figure 4.23). The levels of acetylation were rather low (<5%), and
even though this site is close to the aromatic cage, there is no direct indication
from the crystal structure that acetylation at this site will affect H3K9me
binding of the chromo domain. However, considering that these samples
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were prepared without deacetylase inhibitors and that K24 is solventexposed, it is possible that K24 acetylation could regulate interactions of
the chromo domain other than the CD-H3K9me interaction.
In our mass spectrometry analysis of tagged HP1α, several copurifying
proteins were identified (see Table 4.3). Since the purification conditions
were stringent, it is possible that these proteins might be novel interactors
of HP1α.
Together with the reagents that I have generated (tagged HP1 cell
lines, point mutants, recombinant HP1 constructs etc.), these data may be
promising as a starting point for some graduate student in the future in
the quest to expand our knowledge about HP1, the role of its modifications
and the factors it interacts with.
Hinge phosphorylation may regulate RNA binding to HP1α
In vitro observations that I made during the purification of mutated HP1
hinge constructs from bacterial cells and by electrophoretic mobility-shift
assay suggest the intriguing possibility that HP1α hinge phosphorylation
may be important for the regulation of the interaction of HP1 with RNA.
Clearly, these data on HP1 phosphorylation and RNA binding are still of
a preliminary character. They have to be repeated and extended in vitro,
for example by a further characterization of the in vitro interaction by
competition experiments. Several observations in the literature suggest
an involvement of RNA in HP1-dependent heterochromatin, thus making
the observation that HP1 phosphorylation may regulate RNA binding a
very interesting alley of research to pursue further. In the next chapter of
my thesis (General Discussion) I will suggest experiments to confirm my
observation, outline possible follow-up experiments, and speculate on the
biological role of this interaction and its regulation by phosphorylation.
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Chapter 5
General Discussion
In my thesis studies, I have focused my attention on two different ways
how phosphorylation regulates Heterochromatin Protein 1, an important
chromatin effector protein and key factor in the formation of heterochromatin
in eukaryotic cells (Figure 5.1): on the one hand, I discovered together
with my collaborators that phosphorylation of histone H3, the histone that
recruits HP1 to chromatin, is an essential step in the reversible ejection of
HP1 from chromatin at the onset of mitosis. On the other hand, I identified
several novel phosphorylations of HP1 itself, showed that these sites in
the HP1 hinge region are hyperphosphorylated specifically in mitosis, and
present observations suggesting that these mitotic phosphorylations may
control HP1α's association with RNA.
In this chapter, I strive to briefly summarize the experimental findings
presented in my thesis and then discuss important aspects in light of the
literature. In addition, I will outline possible future directions, and suggest
models that put my findings in a larger biological context.

"Methyl-phos switching"
Release of HP1 from chromatin by phosphorylation of histone H3:
"Methyl-phos switching"
Heterochromatin Protein 1 (HP1) is recruited to chromatin by binding to
methylated lysine 9 of histone H3 (H3K9me) through its chromo domain,
probably further stabilized by additional interactions. At the onset of
mitosis, the bulk of the protein is released from its binding site to be
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dispersed all throughout the cytoplasm (Hayakawa et al., 2003; Kellum
et al., 1995; Minc et al., 1999), even though the H3K9me persists, an
observation that was a long-standing conundrum in the field prior to this
work.
RNA
P P

PP P

P

HP1 phosphorylation
Methyl-phos
switch

HP1
M

M P

Figure 5.1: Regulation of HP1α by phosphorylation on two different levels.

5.1 levels. PhosDuring mitosis, HP1 is regulated by phosphorylation on two different
phorylation of histone H3 at serine 10 by Aurora B kinase results in the reversible
release of the CD-H3K9me interaction by methyl-phos switching and (possibly in
combination with other mechanisms) to dissociation of HP1 from chromatin. Simultaneously, phosphorylation of HP1α itself by Aurora B and other, currently
unknown kinases in its hinge domain abolishes the interaction with an RNA component (shown in green) that remains to be further characterized.

In experiments that I carried out in collaboration with Dr. Wolfgang
Fischle, then a postdoctoral fellow in the Allis laboratory (now a faculty
member at Max-Planck-Institute of Biophysical Chemistry, Göttingen), and
with colleagues from the Funabiki lab, Boo Shan Tseng and Dr. Hironori
Funabiki, I showed that the release of HP1 depends on phosphorylation of
histone H3 at serine 10, a site that is phosphorylated by the Chromosomal
Passenger Complex at the onset of mitosis. Serine 10 phosphorylation
in immediate proximity to HP1’s binding site at methyl-K9 sterically and
electrostatically interferes with binding of the chromo domain and therefore
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ejects the chromo domain from the histone mark. Removal of serine 10
phosphorylation at the end of mitosis, on the other hand, allows HP1 to
reassociate with H3. In addition to providing important insight into the
mechanism of mitotic HP1 release, these findings also identify a biological
function for mitotic H3 serine 10 phosphorylation, a histone mark with so
far elusive biological role (Nowak and Corces, 2004).
The data presented in my thesis is the first evidence for the existence
of a novel "binary methylation-phosphorylation switch" mechanism, that
controls the recruitment of effector proteins to chromatin through two
collaborating histone marks (see Figure 3.12A). Even though the actual
binding site of HP1, the methylation mark H3K9me, remains unchanged,
addition or removal of the H3S10 phosphorylation mark results in a
dynamic regulation of HP1 binding to chromatin.
Our findings close an important gap in the understanding of HP1
behaviour. As outlined in detail in the Discussion section of chapter 3,
they also have wide implications: "methyl-phos switching" is not limited
to the mitotic release of HP1, but has also been observed for HP1 in other
cellular contexts. Furthermore, examples of binary switching have been
found in non-histone proteins as well, and with other combinations of
modifications, such as "methyl-methyl switches" (see Chapter 3, Section
"Discussion"). Thus, binary switching appears to be a mechanism that is
employed by the cell in many different contexts. It will be very interesting
to see in the next years where else this regulatory principle is used.
However, our findings also immediately open up a whole array of
follow-up questions. Why does the cell use this peculiar mechanism to
regulate the reversible dissociation of HP1? Is "methyl-phos switching"
sufficient for the dissociation of HP1 from chromatin in vivo? And why
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must HP1 be released from chromatin during mitosis? In the following, I
will discuss these questions and speculate in light of the literature.

Why does the cell use a "methyl-phos switching" mechanism for the
mitotic release of HP1?
It has been observed on many occasions, that binding of effector proteins
to chromatin is often a dynamic and reversible process (Festenstein et
al., 2003; McNally et al., 2000; Phair et al., 2004). Generally, effectors are
recruited to chromatin by their interaction with specific histone marks
(which are established by "writer" enzymes). The release of effector proteins
appears to be accomplished by a number of different mechanisms. Besides
binary switching, these include removal of the histone mark by enzymes
(Lan et al., 2008; Yang and Seto, 2008), clipping of histone tails by proteases
(Allis et al., 1980; Duncan et al., 2008, or even replacement of the modified
histone as a whole (Ahmad and Henikoff, 2002). This of course raises
the question why the mitotic release of HP1 proteins is accomplished by
"methyl-phos switching" rather than by any of the other mechanisms. A
closer look at "methyl-phos switching" reveals that this mechanism has
certain characteristics that set it apart from all the other mechanisms.
In general, kinase function in the cell often controls rapid changes
in protein-protein interactions, for example in the recruitment of adaptor
proteins in signal transduction pathways (Seet et al., 2006), the control
of enzymatic activity via conformational changes (Johnson et al., 1996),
or the disassembly of the lamin network underlying the nuclear envelope
during mitotic prophase (Moir et al., 1995). Considering the rapid and
extensive changes that chromatin has to undergo to enable faithful
progression through mitosis, a kinase reaction might be the best way for
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the cell to achieve a fast global release of the HP1 effectors in a highly
regulated manner. Phosphorylation and dephosphorylation are quite
thermodynamically favorable and the kinetics of both enyzme classes are
quite rapid relative to other ways to establish or remove posttranslational
modifications.
Compared to the other mechanisms, "methyl-phos switching"
provides specificity to a mechanism designed to release an effector protein.
Since it interferes exclusively with the association of proteins binding
in the immediate vicinity of the phosphorylation site, effector proteins
associated with other regions of the histone remain completely unaffected.
This is in stark contrast to, e.g., tail clipping or histone exchange. While
these mechanisms allow to exchange the complete modification profile of
a histone in a single step, this comes of course at the price of specificity:
many different histone marks and all the interaction partners associated
with them are removed at once.
"Methyl-phos switching" is energy-efficient as well. With mechanisms
such as tail clipping or histone replacement, re-establishing HP1 association
with chromatin comes at a significant engery cost for the cell, because
it requires complete synthesis of a new histone and specific methylation
of the newly synthesized H3. Reassociation mediated by "methyl-phos
switching", in contrast, requires only a single kinase reaction and thus
allows dynamic regulation of chromatin read-out at minimal energetic cost
for the cell.
"Methyl-phos switching" also fully preserves the epigenetic information
encoded in the methyl-marks. Enzymatic removal of modifications through
demethylation, in contrast, would erase the "epigenetic memory" of the
H3K9 methyl-mark (Trojer and Reinberg, 2006).
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In sum, it seems that the different mechanisms to release effector
proteins all have their distinct characteristics that make them particularly
suited for specific situations. Clipping of histone tails and histone
replacement exchange a whole set of modifications at once and thus allow
to completely change the character of a histone in a single step. While this
may be quite helpful in certain cellular contexts, for example changes of
expression profile during differentiation (Duncan et al., 2008), it comes
with a significant energy investment and with the loss of the epigenetic
information of the histone marks. Enzymatic removal of the histone mark
is quick, specific and energy-efficient, but it also erases the epigenetic
information deposited in the histone marks. "Methyl-phos switching", on
the other hand, is fast, energy-efficient and at the same time preserves the
epigenetic information stored in the methylation marks. Thus, it seems
perfectly suited for the task of transiently and reversibly releasing the
effector protein HP1 during mitosis.

Potential contribution of other mechanisms to the mitotic release of
HP1 in vivo
It is clear at this point that "methyl-phos switching" is an essential step
in the release of HP1 from chromatin. However, as described in more
detail in the Discussion section of chapter 3, it is still an open question
whether "methyl-phos switching" is actually sufficient for HP1 dissociation
in mitosis.
In in vitro binding experiments with the HP1 chromo domain and
H3 peptides, H3 phosphorylation is always sufficient for HP1 release.
Experiments with full-length HP1 isoforms, however, have led to different
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observations with the individual HP1 isoforms, and even to contradicting
results (Fischle et al., 2005; Hirota et al., 2005; Terada, 2006). In binding
experiments in the presence of cellular extracts, retention of HP1 upon
abolishment of the chromo domain-H3K9me interaction has been observed
as well (Fass et al., 2002; Fischle et al., 2005).
In vivo experiments so far could only confirm that "methyl-phos
switching" is necessary for HP1 release in the cell (Fischle et al., 2005; Kloc
et al., 2008; Sabbattini et al., 2007; Terada, 2006), but have not addressed
the question whether it is also sufficient. Testing this question in vivo is not
straightforward. Because there are multiple genes for H3 in mammalian cells
(Marzluff et al., 2002), it is difficult to do an overexpression experiment with
an H3 construct with a S10E mutation: if such an overexpression partially
releases HP1, it is hard to tell if the residual chromatin-bound HP1 is all
due to HP1 association with simultaneously present wild-type copies of
H3, or if some of it is still associated with the mutated H3 through chromo
domain-independent mechanisms. Moreover, observations with chromo
domain mutants (which do not localize to heterochromatin at all in vivo,
Platero et al., 1995; Stewart et al., 2005; Thiru et al., 2004) suggest that
there may be a sequential order of the different interactions that mediate
stable chromatin association of HP1. It seems initial contact is made by the
CD and methylated K9. This may increase the local concentration of the
protein, and then a subsequent "locking" step by additional interactions
stabilizes HP1 binding to heterochromatic sites (Singh and Georgatos,
2002). Thus, constitutive disruption of the CD-H3K9me by mutation of
serine 10 may actually prevent CD-independent mechanisms from being
established in the first place.
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This difficulty is exemplified by a recent publication reporting that
phosphorylation in the chromo domain of HP1β by CK2 (casein kinase
2) is a necessary step in the release of HP1β from chromatin at sites of
UV-induced DNA damage (Ayoub et al., 2008). Mutation of the site of
phosphorylation, threonine 51, to glutamate abolished the interaction of
HP1β with chromatin. However, since the T51E mutant does not bind to
H3K9me (as shown by in vitro binding experiments), it is not clear whether
additional mechanisms of binding could be established at all. The system
may be used, however for an interesting test: if overexpression of casein
kinase 2 leads to the release of HP1, this would be an indication that
reversal of the CD-H3K9me3 interaction may indeed be sufficient for HP1
release in vivo.
An alternative approach that may at least allow to estimate the
severity of the contribution of other mechanisms besides "methyl-phos
switching" may be to take advantage of Xenopus egg extracts and their
options to manipulate experimental parameters in a cellular context that
approximates the in vivo situation. In this system, the release of HP1 from
interphase extracts could be tested with an H3S10 kinase other than
Aurora B (judging from my in vitro data, MSK1 may be a good starting
point; Figure 3.11). While still phosphorylating H3S10 efficiently, MSK1
is not very likely to phosphorylate, besides H3 serine 10, exactly the same
targets as the CPC, and it does not initiate and control diverse regulatory
events in mitosis. The level of retention of HP1 at chromatin may thus
permit to estimate the contribution of mechanisms other than "methylphos switching".
Otherwise, directly testing the sufficiency of "methyl-phos switching"
for the release of HP1 inside the living cell may require an artificial system
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that allows recruitment of a (non-mitotic) H3S10 kinase to a heterochromatic
locus bound by HP1. While such a system may be difficult to set up, it
should allow to give a final answer to the still open question whether other
mechanisms besides "methyl-phos switching" are required for the release
of HP1 from chromatin at the onset of mitosis.

Why does HP1 have to be removed from chromatin during mitosis?
In the course of my thesis work, my collaborators and I have studied the
mechanisms underlying the localization changes as well as the striking
alterations in posttranslational modifications that HP1 undergoes during
mitosis. Despite progress made, however, the overarching biological
question remains – what is the biological function of HP1 release from
chromatin during mitosis?

A challenging question to address experimentally
Experimentally, it is extremely challenging to address this question
directly. One obvious way to get insight into this question is to prevent HP1
dissociation by inhibiting/depleting Aurora B and studying the effects on
the mitotic cell. As shown by us and others, Aurora B inhibition/depletion
causes retention of HP1 (Fischle et al., 2005; Hirota et al., 2005; Sabbattini
et al., 2007; Terada, 2006). At the same time, it leads to a number of
unusual observations about chromosome structure and behaviour, such
as reduced cohesin dissociation from chromosome arms, a less pronounced
primary constriction at centromeres, "fuzzy" appearance of chromosomes
in hypotonic buffers, and syntelic attachment of the kinetochores of sister
chromatids to microtubules of the same spindle pole (Giménez-Abián et
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al., 2004; Hauf et al., 2003; Hirota et al., 2005). Eventually, it results in
chromosomal defects and polyploidy (Hauf et al., 2003).
However, it is well established that Aurora B is not just a histone H3
kinase, but also has important functions (besides HP1 phosphorylation)
at the spindle checkpoint and during cytokinesis with functions in
metaphase chromosome alignment, sister chromatid resolution, spindle
checkpoint signaling, bipolar spindle assembly, and cytokinesis (Ditchfield
et al., 2003; Hauf et al., 2003; Lampson and Kapoor, 2005). Thus, it is
impossible to differentiate whether the observed defects are indeed caused
by the failure of HP1 to dissociate from chromatin, lack of mitotic H3S10
phosphorylation (which may have other functions in addition to HP1
"methyl-phos switching"), or the inability of Aurora B to phosphorylate
other important mitotic targets.
One possible approach to see what the effects of HP1 retention are,
while not abolishing Aurora B activity, would be to replace the endogenous
H3 with an H3 that cannot be phosphorylated at serine 10, for example by
a S to A mutation. However, this is quite difficult to do in mammalian cells,
because mammals have a high copy number of H3 genes (twelve; Marzluff
et al., 2002). The only established experimental systems that contain an
HP1-like protein and have a low complexity of histone genes and thus
may allow such a study are S. pombe or Neurospora. Indeed, in S. pombe
the phenotype of H3S10 mutation has already been described as having
mitotic defects (Mellone et al., 2003).
However, this is hard to interpret due to a second caveat: H3S10A
does not only prevent phosphorylation, but also causes by itself already a
significant reduction in the affinity of the HP1 chromo domain for H3K9me
(by almost a factor of 10; Fischle, 2005; Hirota et al., 2005). This is not
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surprising, considering the stabilizing contribution of the hydrogen bonds
that serine 10 undergoes with residues of the HP1 CD (see Figure 3.2B).
It is therefore questionable whether HP1 would bind to H3S10A at all in
vivo (presumed that H3S10A is indeed subject to methylation in vivo, an
assumption that has not been tested yet). These doubts are further fueled
by the observation that GFP-Swi6 is mislocalized upon H3S10A mutation
in S. pombe (Mellone et al., 2003), and if indeed differences were observed,
it would be hard to tell if these were not simply due to effects of H3S10A
mutation on HP1 recruitment.
A second, alternative approach to get insight into the biological
function of mitotic HP1 dissociation would be to design an HP1 protein with
mutations in the chromo domain that make it "immune" to phosphorylation
of serine 10 (i.e. HP1 mutants that bind to H3K9me3S10ph equally well
as to H3K9me3). Due to the multiple effects of serine 10 phosphorylation
on the interaction of the CD with the methylated H3 tail (steric hindrance,
electrostatic repulsion, and loss of hydrogen bonds; see Figure 3.2B), it
is clear that this would be extremely difficult to achieve. Several such
mutations have been tested (Fischle et al., 2005). However, neither chromo
domain mutants designed to reduce the steric hindrance by the phosphate
group (E53A, E53G) nor mutants engineered to relieve the electrostatic
repulsion (E53Q, E53K) showed any increase in binding to H3K9meS10ph
peptides in vitro. Rather, these mutants showed significant loss of affinity
for H3K9me3 peptides, as expected owing to the loss of the hydrogen
bonds with serine 10. Thus, it will be a real challenge to engineer such a
switching-resistant HP1.
If experimental findings identify in the future other mechanisms
involved in the mitotic release of HP1, this may open new roads to study
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this question: While Aurora B kinase has various different functions
in mitosis, these potential other mechanisms might be easier to inhibit
specifically without side-effects on many other steps in mitosis.

Hypotheses on the biological function of HP1 release in mitosis
A direct experimental approach to this challenging question may therefore
require years of research. However, in the following I will speculate
about possible reasons why HP1 has to be released from chromatin
during mitosis. Three steps during mitosis come particularly to mind: (1)
condensin-mediated chromatin condensation, (2) removal of cohesin from
chromosome arms, and (3) proper resolution/segregation of chromatids.
During prophase of the cell cycle, the chromosomes are highly
compacted, in preparation of the spatial rearrangements involved in
chromosome alignment and segregation. The mechanism of this chromatin
condenstion at the onset of mitosis seems to be distinct from that of HP1mediated heterochromatin formation. It is possible that HP1 proteins need
to be released from chromatin, in order to permit mitotic chromosome
compaction by other factors (Figure 5.2).

HP1

Condensin

Figure 5.2: HP1 dissociation might be required for full mitotic chromatin
condensation (Possible biological function of mitotic HP1 dissociation from
chromatin) Figure adapted from Dormann et al., 2006.

5.2

Left: In a cell that progresses through M phase, HP1 is released at the onset of
mitosis. This process allows condensin to access chromatin, therefore promoting
mitotic chromatin condensation. Right: If HP1 does not dissociate, condensin
cannot get full access to chromatin and mitotic chromatin condensation is inhibited.
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One of the components involved in mitotic chromosome compaction
it condensin, a multisubunit complex formed by the association of two
SMC subunits (Structural Maintenance of Chromosomes, members of a
large family of ATPases with key function in higher-order chromosome
organization and dynamics (Yokomori, 2003)) with three non-SMC subunits
(Kimura and Hirano, 1997). Condensin’s exact mechanism of action is
not fully understood at this point. However, it is clear that the complex
binds to DNA and induces positive supercoiling (Bazett-Jones et al., 2002;
Kimura and Hirano, 1997; Kimura et al., 1999; Stray et al., 2005; Stray and
Lindsley, 2003), which probably contributes to chromosome compaction.
It is tempting to speculate that the presence of HP1 (or the chromatin
condensation mediated by HP1) would prevent access of condensin to DNA
and thus interfere with mitotic chromosome condensation. In keeping
with this model, it has been observed in S. pombe that in cells defective
in CPC function condensin does not localize to mitotic chromosomes and
chromosome condensation is impaired (Morishita et al., 2001). Similarly, in
human cells Aurora B depletion results in loss of centromeric localization
of condensin (Ono et al., 2004). Thus, from a biological point of view
dissociation of HP1 through binary switching may be essential for mitotic
chromosome condensation through condensin.
A second hypothesis is that the release of HP1 may be required for
the removal of cohesin from chromosome arms (Figure 5.3). Biorientation
of chromosomes on the mitotic spindle requires cohesion between sister
chromatids (Losada, 2007). This cohesion is accomplished by cohesin, a
multisubunit complex related to condensin, that forms a ring-like structure
around the sister chromatids (Gruber et al., 2003). Separation of sister
chromatids is dependent on the removal of cohesin from chromosomes,
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which in vertebrates is a two-step process (Losada, 2007). Originally
localized all over the chromosomes, at prophase the bulk of cohesin is
removed from chromosome arms. This removal depends on the mitotic
kinases Plk1 and Aurora B, and on the phosphorylation of one of the
cohesin subunits (Giménez-Abián et al., 2004; Losada et al., 2002; Sumara
et al., 2002). Only little cohesin persists on chromosomes, mostly at the
centromeric regions (Hoque and Ishikawa, 2001; Waizenegger et al., 2000),
where it is protected from removal through the protein Sgo1/MEI-S332
and the phosphatase PP2A (Kitajima et al., 2004; Salic et al., 2004; Sgo1
recruitment depends on centromeric HP1, Yamagishi et al., 2008). This
remaining cohesin is then removed at the metaphase-anaphase transition
by cleavage through separase, enabling the separation of sister chromatids
(Hauf et al., 2001; Waizenegger et al., 2000).
HP1/Cohesin

HP1/Cohesin

Figure 5.3: Dissociation of HP1 may be required for the release of condensin
from chromosome arms (Possible biological function of mitotic
5.3 HP1 dissociation from chromatin) Figure adapted from Dormann et al., 2006.
Left: HP1 release at the onset of mitosis also removes cohesin, which is associated with HP1, from chromosome arms. This allows for proper segregation of
chromatids into the two daughter cells. Right: If HP1 is not released, cohesin remains associated with the chromosome arms. The chromatids cannot separate,
which may lead to missegregation of chromosomes.

The exact function of Aurora B in the prophase dissociation of
cohesin is currently unknown. However, it seems possible that HP1
is involved in this dissociation. In S. pombe, cohesin binds to the HP1
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homolog Swi6, an interaction that is necessary for cohesin localization to
the heterochromatic structures of the pericentric regions and that seems
to be conserved in mammalian cells (Nonaka et al., 2002). Moreover, HP1
dissociation from chromatin and the release of cohesin occur with a very
similar timing during prophase. Thus, it seems quite possible that cohesin
removal from chromosome arms at prophase could be accomplished by
Aurora B through the ejection of HP1 by "methyl-phos switching", making
the biological function of HP1 release to help resolve the arm regions of
sister chromatids from each other.
A third possibility is that HP1 proteins may have to dissociate from
mitotic chromosomes to facilitate separation of chromatids (Figure 5.4).
HP1 is assumed to mediate chromatin condensation by crosslinking K9methylated nucleosomes through its ability to dimerize and interact with
other chromatin components (Figure 1.9A). If such crosslinking occurs
between different chromatids, it may not be possible to segregate sister
chromatids to opposing poles of the spindle during anaphase. In this
scenario, if HP1 is not removed before anaphase, the consequence might
be segregation defects such as lagging chromosomes, chromosome bridges,
and aneuploidy. Thus, according to this model, the biological function
of mitotic HP1 release of HP1 might be to reverse crosslinks between
individual chromatids to allow for the proper resolution and segregation of
chromosomes. In keeping with this interpretation, Interestingly, Terada,
while overexpressing an H3 construct with a S10A mutation in mammalian
cells, observed lagging chromosomes and chromatin bridges (Terada,
2006). It is impossible to differentiate whether these effects are due to the
retention of HP1 or reduced levels of K9 methylation and/or HP1 binding
to this H3 mutant in the first place (see above). However, the observations
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would match the phenotype expected for problems with chromosome
separation due to the failure to remove HP1 crosslinking of chromatids.
HP1

Figure 5.4: HP1 release may be necessary for proper resolution/segregation
of chromatids (Possible biological function of mitotic HP1 dissociation
from
5.4
chromatin) Figure adapted from Dormann et al., 2006.
Left: If HP1 is released at the onset of mitosis, the pulling forces exerted by the
spindle microtubuli segregate the chromatids into the two daughter cells (as indicated by the green arrow heads). Right: If HP1 is not removed, different chromatids (in this case sister chromatids) may remain attached to each other via HP1
cross-linking. This entangling inhibits proper resolution of chromatids and may
lead to defective chromosome segregation.

HP1 phosphorylation
HP1 isoforms are subject to phoshporylation
Prompted by experimental observations made during the study of HP1
"methyl-phos switching" in the test tube, in the second part of my thesis I
have focused on a potential involvement of posttranslational modifications
of HP1 itself during mitosis. Together with my collaborators, I have mapped
a set of in vivo phosphorylation sites of all three human HP1 isoforms, shown
that most of these sites map to the HP1 hinge region (see Figure 4.23), and
found evidence that HP1α and HP1γ are specifically phosphorylated in
mitosis (the levels of the observed HP1β phosphorylation were equally high
in interphase and mitosis, see Chapter 3, Section "Discussion"). One site
that is part of a highly conserved sequence motif ("KRKS"), HP1αS92ph, I
characterized in detail and present data that implicates Aurora B as the
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responsible kinase in vivo. While testing specific candidates for an effect
of HP1α hinge phosphorylation on their association with HP1, I made in
vitro observations that suggest that HP1α hinge phosphorylation may be
regulating the association of HP1α with RNA.
The sites of phosphorylation presented in my thesis is among the
first sites identified in mammalian HP1 proteins. While this work was in
progress, reports on two individual modifications on the two other HP1
isoforms have been published.
The Urrutia lab describes a role for HP1γ serine 93 phosphorylation
(or, assuming a different translation start site, serine 83 phosphorylation)
in interphase (Lomberk et al., 2006). According to their interpretation,
phosphorylation of this site by PKA leads to exclusively euchromatic
localization of HP1γ, interaction with the DNA repair factor Ku70 (but in the
absence of the other complex members that Ku70 usually associates with),
and impaired silencing activity. Another study reported phosphorylation
of HP1γS93 (but not HP1α and HP1β) in cells entering senescence, where
the modification is required for efficient incorporation of HP1γ into SAHF
(senescence-associated heterochromatin foci), domains of facultative
heterochromatin that repress proliferation-promoting genes (Zhang et al.,
2007). Ayoub and colleagues have recently implicated phosphorylation of
HP1β at threonine 51 by casein kinase 2 in the mobilization of HP1β after
DNA damage (Ayoub et al., 2008; see above).
HP1γS93ph is homologous to HP1αS92ph, the site of Aurora B
phosphorylation that I characterized in more detail in my thesis. However,
as opposed to these studies, I do not observe any localization effects upon
HP1αS92 mutation, HP1α is known to interact with Ku70 already in
an unphosphorylated state (Song et al., 2001), and I studied the events
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connected to HP1αS92 phosphorylation specifically in mitosis, which was
not investigated in these studies (similar to HP1αS92, HP1γS93, is also
upregulated in mitosis, even though that was not part of the study by
Lomberk and colleagues; my own observations in western blotting and
IF experiments with an antibody kindly provided by the Urrutia lab).
Nevertheless, these papers illustrate the potential of HP1 modifications to
control HP1 interactions and functions.

No effect of HP1 phosphorylation on localization dynamics in
mitosis
In my thesis work, I tested the hypothesis that HP1α hinge phosphorylation
may be involved in the different localization changes observed for HP1α
during mitosis, but did not observe any effect. Is it possible that the HP1α
hinge region nevertheless plays, besides regulating RNA association, a role
in HP1α release in vivo, and that this role was missed due to shortcomings
of the experimental approaches taken to address those questions?
My experiments designed to test different hypotheses about the
function of HP1α hinge mutations in vivo were largely based on mutation
of the identified phosphorylation sites. Serine to glutamate mutations were
used, for example, for testing a role of HP1 hinge phosphorylation in HP1α's
reassociation at metaphase; if HP1α hinge phosphorylation regulated this
reassociation of HP1α with metaphase centromeres, increased/decreased
binding of mutated constructs was expected. Glutamate is known to be a
good mimic for the negative charge effect of the phosphoryl-group, but it
is structurally different (planar instead of tetrahydric). Therefore it may
not always function as a mimic for phospho-serine, and problems like this
could of course prevent the observation of effects in experimental tests
based on such mutations.
213

However, mechanisms that may besides "methyl-phos switching" be
involved in the regulation of HP1 localization changes during mitosis will
likely depend on additional interaction partners of HP1. The identity of
these interactors is currently unknown, and they may actually not have
been identified at all. Thus, there is little alternative for systematic testing
of such hypotheses but in vivo. While far from perfect, glutamate and
alanine are probably still the best mimics for constitutively phosphorylated/
not phosphorylatable serine available (aspartate is clearly smaller than
phospho-serine).
Considering that HP1 chromatin binding can be guided by different
mechanisms, it is possible that only a small subpopulation of HP1
associated with a few loci is affected by HP1α

hinge phosphorylation

(see also below, Section "Speculations on the biological function of the
HP1-RNA interaction and of HP1α hinge phosphorylation"). In such a
scenario, effects of the mutations at these sites may have been missed
in my immunofluorescence analysis. Indeed, this cannot be completely
excluded, and it may be worth reconsidering some of my experiments in a
more detailed way (different extraction/fixation procedures, chromosome
spreads; alternatively even ChIP or examination of different cell types).
However, considering the detailed analysis that I have carried out already,
it does not seem worthwhile to continue along this path, unless additional
evidence for such an involvement of HP1 phosphorylation in HP1 localization
should emerge.
Furthermore, the analysis presented in this thesis was carried out with
fixed cells and therefore looks only at single time-points in the release/
reassociation process. The release and reassociation of HP1, however, is
a dynamic process, and it is possible that HP1 phosphorylation affects
the dynamics of this process rather than the final outcome. Elegant stud214

ies have already examined the dynamics of HP1 in living cells in other
context (during the activation of a silenced locus; Janicki et al., 2004),
and it may be worth it to carry out similar experiments to analyze the effect of HP1 phosphorylation mutations on the dynamics of HP1 in living
cells.

Possible existence of other HP1 binders regulated by HP1 hinge
phosphorylation
In vitro experiments presented in this thesis implicate HP1 phosphorylation
in the control of RNA binding to the HP1α hinge. This exciting finding
opens new doors for potentially interesting follow-up experiments and
allows for some intriguing hypotheses (see below). However, it should be
noted that this observation does not exclude that there may be other,
additional interactions besides RNA binding that may be regulated by the
same mechanism.
One protein that may be interesting to test in the future for
phosphorylation-dependent binding to HP1 may be the CPC component
INCENP, because there is literature suggesting that it binds to the HP1
hinge region. Even though it has been demonstrated that the interaction
with HP1α is not required for INCENP localization or localization changes
during mitosis (Ainsztein et al., 1998) and vice versa (Terada, 2006), it is
possible that this interaction affects for example the enzymatic activity
of the CPC on partners associated with HP1 (such as histone H3) by
positioning the complex in a favourable position. The ability of HP1 to
fulfill such a function might be modulated by HP1 phosphorylation.
It is also possible that so far unknown HP1 binders are regulated
through HP1 hinge phosphorylation. My experiments indicate that unbiased
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pull-down experiments to identify such factors may not be straightforward
with the isolated hinge domain (see Chapter 4, Section "Reduncancy /
Requirement for Cooperation"), but with careful optimization this may also
be a promising approach in the future.

Reasons for exclusion of HP1αS92ph signal from chromatin at
telophase
Originally, my interest in the role of HP1 phosphorylation in the regulation
of HP1α localization during mitosis was raised by IF experiments with the
HP1αS92ph antibody, when I made the observation that the signal of an
HP1S92ph antibody is excluded from chromatin, while with a general HP1α
antibody staining is observed (Figures 4.7B, 4.9BC, 4.13B). According my
mutation analysis, HP1α hinge phosphorylation has no effect on HP1α
localization in mitosis. How can the IF observations then be explained?
One possibility is that the S92ph epitope is masked by a molecular
interaction that HP1α undergoes when it reassociates with chromatin.
Alternatively, a chromatin-associated phosphatase could remove the
phosphorylation as soon as HP1 binds to chromatin. Notably, in a
fractionation experiment (Figure 4.13A) I observed by western blotting
that HP1α from a fraction loosely associated with chromatin showed
significantly higher levels of S92 phosphorylation than HP1α that was
tightly associated with chromatin. This might point to the latter of the two
possible explanations, a chromatin-associated phosphatase.

HP1 and RNA binding / Nature of the bound RNA(s)
In chapter 4 of my thesis, I have presented in vitro observations suggesting
that HP1α hinge phosphorylation may control the association of HP1α
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with RNA (Figure 4.30). These observations were made with recombinant
HP1α hinge constructs, that associated with bacterial RNA in the case of
the wild-type hinge sequence, but did not associate in the case of a hinge
sequence with S to E mutations at the phosphorylation sites. The effect
was reproduced in an electrophoretic mobility-shift assay (EMSA) with a
Drosophila mRNA sequence as probe. The conditions under which these
observations were made are certainly quite artificial and raise the question
whether this is indeed a real interaction or rather an in vitro artifact.
A first evaluation of this question may come from a closer look at
what is known in the literature about the interaction of HP1 with RNA.
There are reports by several groups that suggest such a connection., and
findings demonstrating a direct interaction of HP1 with RNA have been
published in mammals (Muchardt et al., 2002) and in S. pombe (Motamedi
et al., 2008). In addition, observations that could readily be explained by
direct RNA binding of HP1 were made in both Drosophila (Piacentini et al.,
2003) and mammals (Maison et al., 2002).
The first real in vivo evidence for a direct interaction of HP1 with
RNA has been reported only very recently from RNA immunoprecipitation
experiments with Swi6, the HP1 homolog in fission yeast (Motamedi et al.,
2008). These experiments demonstrated that Swi6 specifically binds to
noncoding cenRNAs (transcripts generated from the centromeric regions
of the S. pombe chromosome). While an indirect involvement of RNA in the
formation of Swi6-dependent heterochromatin is well established (Swi6 is
essential for an RNAi-dependent silencing loop which requires transcription
though noncoding heterochromatin to be sustained, see Introduction),
this is the first occasion that direct RNA binding is demonstrated in S.
pombe. As a model, Motamedi and colleagues suggest that Swi6 association
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with cen transcripts may tether nascent heterochromatic transcripts to
heterochromatin and allow RNAi complexes to assemble on the transcript.
It should be noted that detection of the transcripts was carried by RT-PCR
and only two transcripts were tested (cen and actin mRNA, which does
not associate with Swi6). Thus, no conclusion can be drawn from these
experiments whether there are other RNAs that may associate with Swi6.
In mammalian cells, there are also observations indicating a direct
association of HP1 with RNA, even though these experiments have not
been done in genuine in vivo systems. In 2002, Maison et al. noted in
work with mouse cells that RNase treatment during immunofluorescence
experiments destroys the architecture of heterochromatic domains and
specifically releases HP1α, a finding that could be reproduced in overlay
assays (Maison et al., 2002). Adding back RNA reversed all observed effect.
Maison and colleagues showed that there is some specificity with respect
to the species of RNA: only RNase A, and not RNase H (cleaves dsRNA and
DNA-RNA duplices) disrupts the heterochromatic structures and releases
HP1, and restoration of heterochromatic architecture and HP1α foci is
observed upon adding back total and especially nuclear RNA, while there
is little effect with tRNA and bacterial mRNA.
Prompted by similar observations in overlay assays, Muchardt and
colleagues showed that HP1α and HP1γ can bind RNA directly in vitro
and mapped this binding to the C-terminal part of the HP1α hinge region
(Muchardt et al., 2002). By competition experiments with different nucleic
acids in EMSAs, they carried out a preliminary characterization of the
RNA interaction that allow some conclusions about the specificity of HP1's
RNA-binding in this experimental system.
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It is unlikely that HP1 recognizes a complex RNA sequence motive,
because Muchardt and colleagues were able to carry out their EMSAs with a
random bacterial mRNA probe. On the other hand, binding is also not simply
dictated by attractive electrostatic forces either, because the interaction is
not competed by ssDNA, dsDNA, AU- or GC-rich RNA oligomers or tRNA.
Ribosomal RNA and especially total nuclear RNA, in contrast, compete
the interaction with the bacterial probe RNA efficiently. This suggests that
there is either some promiscuity with regard to the sequence specificity
of the HP1 hinge region, or the hinge recognizes a rather short sequence
or small structural RNA motif that is found rather often in a complex
sequence. It should be noted, though, that these in vitro observations do
not categorically exclude binding of only one specific RNA by HP1α in vivo.
The chromatin proteins MOF and MSL-3, for example, show no or little
binding specificity in their RNA binding in vitro, although they have a very
specific physiological target, roX RNA (Akhtar et al., 2000).
The RNA-binding region of HP1 was mapped by EMSA and overlay
assay to residues 86-108 of HP1α (the C-terminal part of the hinge region).
The region has no clear homology to known RNA-binding modules, despite a
high density of basic amino acids. However, RNA binding of sequences with
similar composition has been demonstrated in several ribosomal proteins
and retroviral virulence factors, such as HIV TAT (Brodersen et al., 2002;
Weiss and Narayana, 1998). An interacting domain of this size is not capable
of contacting more than 6 to 10 nucleotides at once (Ruthenburg, 2009),
which would explain the low sequence specificity of HP1 RNA binding.
The RNA binding domain includes most of the phosphorylation sites that I
have identified in the HP1α hinge. Interestingly, Muchardt and colleagues
demonstrated that simultaneous mutation of only three conserved lysines
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within the RNA binding region (K104/105/106A) abolishes RNA binding.
Thus, it seems feasible that introduction of a few negative charges by
phosphorylation of the RNA interacting domain may have a similar effect.
In addition to the reports in S. pombe and in mammals, a connection
between HP1 and RNA has been suggested in one other context. In
Drosophila, HP1a is recruited to the very actively transcribed sites of
developmental and heat shock-induced chromosomal puffs (Piacentini et
al., 2003). The association of HP1a with these puffs is functionally relevant
(reduced expression of HP1a results in decreased levels of transcripts at
these sites, overexpression of dHP1a in elevated levels) and RNA-dependent
(RNase treatment and induction of puffs without transcription). HP1 binds
specifically to coding regions of the actively transcribed hsp70 gene (rather
than to promoters). It has not been investigated so far whether there is
indeed a direct association of HP1 with RNA at these sites, and if so, what
the nature of this RNA may be. Since these findings in Drosophila implicate
HP1 with euchromatic RNA (as opposed to heterochromatic RNAs as in
the reports in S. pombe and mammals), HP1’s RNA binding may be more
complex and possibly directed towards different kinds of RNA (Kellum,
2003).
All in all, my experimental observations are in agreement with
published findings on HP1 interaction with RNA, and it seems quite possible
that HP1α hinge phosphorylation may indeed regulate the interaction of
HP1α with RNA in vivo. However, my preliminary observations and the
very limited data in the literature do not yet allow to draw any definite
conclusions to this important question.
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Next experimental steps
To expand on my preliminary finding that HP1 phosphorylation regulates
RNA binding in vitro, the first follow-up step will have to be a rigorous
confirmation of this experimental observation will be required. The EMSA
could be repeated with new preparations of labeled RNA (hopefully without
any aggregation), full-length HP1α constructs could be tested, and the
in vitro interaction could be further characterized, e.g. by the use of
different salt concentrations that would permit a qualitative evaluation
of the interaction’s affinity. Competition with different RNA species could
be carried out to verify if my HP1 hinge constructs reproduce the results
published for RNA binding of full-length HP1 before (Muchardt et al.,
2002).
As helpful as further examination of the interaction of HP1 with RNA
in the test tube may be, it will not get beyond the basic limitations of the in
vitro system. It is hard to exclude that observations made in such a system
are simply general effects of changes in charge that are amplified by the
artificial conditions of the test tube, while no such effect exists under in
vivo conditions. Thus, for meaningful data it will be necessary to study the
HP1α-RNA interaction in vivo.
A quick way to show that HP1 hinge phosphorylation indeed
affects RNA binding of HP1α in vivo would be by purification of HP1 from
tissue culture cells and autoradiographic analysis of copurifying RNAs
after radioactive labelling. From cell lines expressing tagged wt HP1α or
HP1α with S to A and S to E mutations, HP1 could be purified e.g by
immunoprecipitation/pull-down. Coprecipitating RNA could be labelled by
polynucleotide kinase end-labelling with

32

P-ATP (assuming free 5’-OH),

and then analyzed by gel electrophoresis and autoradiography. Differences
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in the RNA binding of the constructs should be visible as variations in the
banding pattern between the different constructs.
However, it is unclear how interpretable such a pull-down experiment
would be. Considering that HP1 undergoes dozens of different interactions
and is part of large heterochromatic complexes (see Chapter 1, Introduction),
the mixture of copurifying RNAs may simply be too complex to allow any
meaningful evaluation from an autoradiograph. Some improvement might
be achieved by the use of crosslinking methods such as CLIP (Crosslinking and immunoprecipitation, see below) to allow for more rigorous
purification.
By far the most insight into the interaction of HP1α with RNA, the role
of RNA in HP1 biology, and the part that HP1α hinge phosphorylation plays
in this context, will however come from identification of RNAs associated
with HP1α in vivo. While the exact experimental approach would depend
on the type and the size of the RNA associating with HP1 (e.g. non-coding
RNA, mRNA, small RNAs), Various protocols for this different purposes
have already been developed by others (e.g. Pfeffer et al., 2005; Rinn et
al., 2007). CLIP (Cross-linking and IP), a method specifically developed for
the highly specific purification of RNAs binding to protein in intact cells
(Ule et al., 2003), could be used. By a UV cross-linking step, specifically
interacting RNA is bound covalently to protein and can be purified by
harsh purification steps, such as denaturing purification or transfer to
nitrocellulose, which discards of free RNA (Ule et al., 2005). After removal
of HP1 protein by proteinase K digest, linker RNA can be ligated to the
5’ and 3’ ends, and the RNAs amplified by RT-PCR with DNA primers
complimentary to the RNA linkers. Sequence analysis could be carried out
either by microarray analysis or by Solexa sequencing.
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Purification and identification of protein-associated RNAs profits
immensely from a negative control that allows to distinguish specific
interactions from unspecific ones. Since my in vitro data indicates that
HP1α hinge phosphorylation abolishes RNA binding to HP1, the hinge
phosphorylation may offer a highly useful handle for the identification of
HP1-binding RNAs in vivo (cell lines expressing HP1α constructs with S to
E mutations in the hinge could be used as negative control and compared
to either wt or S to A constructs).
The experimental work and technical expertise required to
successfully identify HP1-associated RNAs through this approach is of
course significant. Therefore, I have recently entered into a collaboration
with Dr. Emily Bernstein, a former colleague in the Allis lab (now a faculty
member at Mount Sinai School of Medicine, New York). Dr. Bernstein is an
expert in RNA biology, and we are optimistic that our collaboration will soon
provide experimental validation whether my in vitro observations reflect
real in vivo behavior of HP1. Successful identification of HP1-associated
RNAs in mammalian cells will undoubtedly contribute significantly to
our understanding of this highly interesting chromosomal protein and its
function in the cell.

Hypotheses on the biological function of the HP1-RNA interaction
and of HP1α hinge phosphorylation
The fundamental biological question underlying these future experiments
is of course, what the role of the RNA interaction may be and why the RNA
has to be released during mitosis. As pointed out before, a very limited
amount of data is available on the connection between HP1 and RNA,
making models speculative by necessity. Even so, I want to propose three
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hypotheses what the role of RNA may be in HP1 biology and how the
regulation by HP1 hinge phosphorylation would fit into these scenarios.

1) RNA could play the role of "molecular glue" that stabilizes heterochromatic
structures.
The currently favored model of HP1-mediated heterochromatin
formation involves recruitment of HP1 by H3K9me and condensation
of heterochromatic domains by crosslinking through HP1 dimerization
of the chromoshadow domain (Jenuwein and Allis, 2001). Due to
the diverse molecular interactions that HP1 undergoes, it has been
suggested that HP1-mediated heterochromatin formation may be
enhanced by additional factors that, through interactions with HP1
and possibly each other, contribute to the formation of a tightly packed
dense heterochromatic structure (Craig, 2005; Dillon and Festenstein,
2002). According to my model, RNA fulfills such a function (Figure
5.5). By interacting with the hinge regions of multiple HP1 molecules,
RNA assists HP1 crosslinking in the formation of densely packed
heterochromatic regions and further stabilizes the heterochromatic
architecture.
The role of HP1α hinge phosphorylation in this model may be
a contribution to the disassembly of large heterochromatic complexes
during mitosis, at the time when HP1 is released by "methylphos switching" (and, possibly, other mechanisms). HP1 hinge
phosphorylation reverses the RNA-HP1 interaction, helping to break
down large heterochromatic complexes and to set HP1 molecules free
for reassociation with chromatin at the end of mitosis. Removal of HP1
hinge phosphorylation after mitosis (possibly by a chromatin-associated
phosphatase) would then reestablish RNA binding.
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Figure 5.5: RNA as "molecular glue" to stabilize 5.5
and compact HP1-dependent heterochromatic structures (Hypothetical model for the biological role
of the HP1α-RNA interaction)
According to this model, RNA may have a role in stabilization and compaction
of heterochromatic domains. Through the interaction of its chromo domain with
H3K9me (and likely, other interactions), HP1 is recruited to chromatin. Dimerization of HP1 molecules through their chromoshadow domain leads to crosslinking
of nucleosomes and significant compaction of the domain. Filling in the spaces
of this meshwork, RNA may bind to the hinge regions of several HP1 molecules
simultaneously. Like a "molecular glue", this further stabilizes and compacts the
heterochromatic structure.

This model is in keeping with several observations made by me
and others. In 2002 the Almouzni lab showed that an RNA component
is required for the maintenance of mouse pericentric heterochromatin
organization (Maison et al., 2002). Recently, it has been demonstrated
that in S. Pombe Swi6/HP1 directly associates with centromeric
transcripts (Motamedi et al., 2008), giving further credence that such a
model may indeed be possible in vivo.
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In my own experiments, I observed during a fractionation
procedure that (S92-) phosphorylated HP1α could be easily stripped
off of chromatin, while unphosphorylated HP1α was part of much
more stable chromatin structures (Figure 4.13A). That HP1α hinge
phosphorylation had no effect on HP1 localization would be explained in
this model by the fact that RNA compacts heterochromatic structures,
but is not directly involved in HP1 chromatin binding.
To test this model, one could analyze the complexes that HP1
is part of during mitosis and how they are affected by HP1 hinge
phosphorylation or mutation of the phosphorylation sites. Alternatively,
a more detailed analysis of the composition and architecture of
heterochromatic domains (and, possibly, how these are affected by
mutations of the HP1α hinge) may be a possible approach.
2) The interaction of HP1 with RNA could mediate the association of HP1
with euchromatic regions within the genome. Most likely in collaboration
with other interactions, interaction with mRNA recruits HP1 to these
sites, where the protein plays a role in the promotion of gene expression
(Figure 5.6).
This model is in agreement with my experimental findings and
several observations in the published HP1 literature. The association
of HP1 with euchromatic sites within the genome has been observed
in Drosophila and mammalian cells by various experimental methods
(Cryderman et al., 2005; de Wit et al., 2007; Johansson et al., 2007;
Piacentini et al., 2003; Vakoc et al., 2005; see Introduction).
Association of HP1 with such sites seems to be RNA-dependent, as
suggested by the observation that HP1 association with heat-shock and
developmentally induced puffs (highly expressed regions in Drosophila
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polytene chromosomes) is only observed in the presence of RNA
(Piacentini et al., 2003). High-resolution mapping of HP1a binding sites
in Drosophila HP1a shows that HP1 localizes specifically to transcribed
regions of actively expressed genes, and is excluded from the promoter
(de Wit et al., 2007; Johansson et al., 2007). This raises the possibility
that HP1 may actually be binding to the transcribed mRNA. However, it
is clear that there must be contributions of other mechanisms, because
HP1 associates only with few of the many actively transcribed loci in
the genome.

X
M

HP1
M

mRNA
M

Y

RNA Pol. II

DNA template

Figure 5.6: RNA binding of HP1 recruits HP1 to euchromatic loci (Hypothetical model for the biological role of the HP1α-RNA interaction)

5.6

RNA binding of HP1 could recruit HP1 to euchromatic loci. Besides abundant association with heterochromatic regions, HP1 is also found at a few euchromatic
sites (top). According to this model, the association of HP1 with these euchromatic regions is mediated by HP1 binding to mRNA (in green), most likely in collaboration with other interactions (not shown in this cartoon). At the locus, HP1
promotes gene expression by unknown mechanism (such as a role in mRNA stabilization), and may also recruit other factors (X, Y; shown in purple) to the site.
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The function of HP1 at these sites is currently not understood,
but the protein seems to positively regulate gene expression (loss of
HP1 results in reduced, overexpression in increased gene expression at
such sites, Cryderman et al., 2005; correlation of HP1 binding with gene
expression, de Wit et al., 2007). On a molecular level, it may be that HP1
promotes transcription at these sites through a role in transcriptional
elongation or even in mRNA stabilization (Kellum, 2003).
According to my proposed model, HP1 is recruited to these sites by
an interaction with RNA. During mitosis, the protein has to be released
from the sites of active transcription, possibly because transcription
has to be shut down to allow full condensation of the chromosomes.
In the model, the dissociation of HP1 from these sites is accomplished
by phosphorylation of HP1 in the hinge region, which abolishes RNA
binding.
Upon S to A mutation or S to E mutation of the HP1 phosphorylation
sites, HP1 is retained or released, respectively. But since there are only
few of such HP1-binding euchromatic loci, this effect is not readily
observed in my immunofluorescence assay, because there is a huge
excess of heterochromatic HP1 that at the same time dissociates from
chromatin by "methyl-phos switching" and this larger population
dominates IF observations.
In this model, only the small subpool of HP1 at euchromatic sites
depends on HP1 phosphorylation for its release in mitosis. However,
my data indicates that there is a significant amount of phosphorylated
HP1 present in mitotic cells. This could be explained by the existence of
additional functions of HP1 phosphorylation Alternatively, it is possible
that the "collateral" phosphorylation of the other pool of HP1 does not
hurt the cell and is therefore not selected against.
228

First hints whether such a model would be feasible at all could
come from the identification of the RNA(s) associated with HP1. As a
more direct test of the model, ChIP experiments at known euchromatic
binding sites of HP1 could be carried out. By comparing the association
of HP1 constructs with wt sequence and with mutated phosphorylation
sites, it should be possible to verify whether HP1 binding to these sites
is regulated by HP1α hinge phosphorylation.
3) HP1 binding to RNA could be important in regions of constitutive
heterochromatin

for

tethering

nascent

RNA

transcripts

to

heterochromatin.
This hypothesis was recently formulated by Motamedi and
colleagues (Motamedi et al., 2008) and is based on their observation of an
in vivo interaction of Swi6 (the S. pombe homolog of HP1) with noncoding
cen transcripts (transcripts originating from baseline transcription of the
silenced centromeric repeat regions) in fission yeast. The model (Figure
5.7) suggests that Swi6/HP1 tethers these nascent heterochromatic
RNA transcripts to chromatin. The stable association of the transcripts
with the sites of RNA synthesis is required for the subsequent assembly
of the RNAi complexes RITS (RNA-induced transcriptional gene
silencing complex) and RDRC/Dcr1 (RNA-dependent RNA polymerase
complex/Dicer 1) on the RNA (Motamedi et al., 2008), which facilitates
efficient processing of the transcripts to double-stranded siRNAs, a
step that is required for H3 lysine 9 methylation and heterochromatic
silencing (Grewal and Jia, 2007; Volpe et al., 2002). In keeping with the
hypothesis, in the absence of Swi6, the levels of centromeric siRNAs
are dramatically reduced (Motamedi et al., 2008), and localization of
RITS and RDRC to cen transcripts (Motamedi et al., 2008), and Rdp1
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to cen DNA (Sugiyama et al., 2005) is decreased compared to wild-type
cells, demonstrating that Swi6 is required for the efficient association
of RITS, RDRC and Dicer with their target transcripts at centromers.

siRNAs
Dcr1

dsRNA
RDRC

HP1
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M

RNA
RNA Pol. II
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DNA

Figure 5.7: HP1 tethers nascent heterochromatic RNA transcripts to the

5.7

heterochromatic locus (Hypothetical model for the biological role of the
HP1α-RNA interaction)
HP1 could bind nascent heterochromatic RNA transcripts and tether them to the
heterochromatic locus. This enables assembly of RNA processing complexes on
the RNA that are required for heterochromatin formation/maintenance. According to this model, HP1 associates with heterochromatin through the chromo domain – H3K9me interaction. Through the hinge region, HP1 associates with RNA
transcripts (in dark green) that are generated at low levels, and thus stably tethers them to the site. This permits assembly of machinery required for processing
of the transcript, such as the RNA-dependent RNA polymerase complex (RDRC,
in yellow) that generates double-stranded RNA (dsRNA), Dicer (in blue) that cuts
the dsRNA into siRNAs (short interfering RNAs), or RITS (in purple) that contains
siRNAs and is required for establishing/maintaining H3K9 methylation at centric
regions. Figure adapted from Motamedi et al., 2004.

It is possible that the interaction of Swi6 with cen RNA has to
be released during mitosis, for example because the heterochromatic
complexes associated with RNA processing would impede the efficient
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interaction of Swi6 with cohesin (Nonaka et al., 2002). Such an ejection
of cen RNA from Swi6 binding could conceivably be regulated by Swi6
phosphorylation.
It should be noted, though, that at the moment it is not yet
established if Swi6 indeed binds cen RNA through its hinge domain,
nor has it been investigated in detail to which extent the pathways
of heterochromatin nucleation/maintenance are conserved in higher
organisms.
All in all, little is known about the connection between HP1 biology and
RNA. As outlined above there are some very intriguing possibilities, and
my finding that RNA binding to HP1 is regulated by HP1 phosphorylation
may open the door for some exciting further discoveries in the future.

Conclusion
In my Ph.D. project I have explored the ways how phosphorylation
regulates Heterochromatin Protein 1, an important chromatin effector
protein. As I have shown, phosphorylation controls HP1 function on two
different levels: On one level, phosphorylation of histone H3 regulates
HP1 chromatin release during mitosis through binary switching, and the
discovery of this mechanism leads the way to a better understanding not
only of the mechanisms that control HP1 chromatin association, but also
of many other molecular interactions in chromatin biology and beyond,
that are regulated by similar mechanisms. On the other level, mitotic
phosphorylation of HP1 itself in its hinge domain appears to control the
association of HP1 with RNA. My observations open up new experimental
directions that may lead to a better understanding of the role and regulation
of RNA in the biology of Heterochromatin Protein 1.
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The recruitment of effectors by posttranslational modifications of
histone proteins is one of the key mechanisms to control chromatin structure
and function. The findings presented in my thesis illustrate, however, that
there are additional levels of complexity that involve an intricate interplay
between multiple histone modifications, as well as modulation of effector
function by posttranslational modification of the effectors themselves.
Exploring these layers of regulatory complexity will surely be challenging,
but the therapeutic potential of chromatin, especially for the treatment of
cancer, indicates that the effort will be well-invested.
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